



HAL
open science

The Specificities of Elite Female Athletes: A Multidisciplinary Approach

Carole Castanier, Valérie Bougault, Caroline Teulier, Christelle Jaffré,
Sandrine Schiano-Lomoriello, Nancy Vibarel-Rebot, Aude Villemain, Nathalie
Rieth, Christine Le-Scanff, Corinne Buisson, et al.

► **To cite this version:**

Carole Castanier, Valérie Bougault, Caroline Teulier, Christelle Jaffré, Sandrine Schiano-Lomoriello, et al.. The Specificities of Elite Female Athletes: A Multidisciplinary Approach. *Life*, 2021, 11 (7), pp.622. 10.3390/life11070622 . hal-04026774

HAL Id: hal-04026774

<https://hal.science/hal-04026774v1>





Submitted on 13 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Review

The Specificities of Elite Female Athletes: A Multidisciplinary Approach

Carole Castanier ^{1,2}, Valérie Bougault ³, Caroline Teulier ^{1,2}, Christelle Jaffré ⁴, Sandrine Schiano-Lomoriello ^{1,2}, Nancy Vibarel-Rebot ^{1,2}, Aude Villemain ^{1,2}, Nathalie Rieth ^{1,2}, Christine Le-Scanff ^{1,2}, Corinne Buisson ⁵ and Katia Collomp ^{1,2,5,*}

¹ CIAMS, Université Paris-Saclay, 91405 Orsay, France; carole.castanier@universite-paris-saclay.fr (C.C.); caroline.teulier@universite-paris-saclay.fr (C.T.); sandrine.schiano-lomoriello@univ-orleans.fr (S.S.-L.); nancy.rebot@univ-orleans.fr (N.V.-R.); aude.villemain@univ-orleans.fr (A.V.); nathalie.rieth@univ-orleans.fr (N.R.); christine.le-scanff@universite-paris-saclay.fr (C.L.-S.)

² CIAMS, Université d'Orléans, 45067 Orléans, France

³ LAMHESS, Université Côte d'Azur, 06205 Nice, France; valerie.bougault@univ-cotedazur.fr

⁴ B3OA, Université de Paris, 75010 Paris, France; christelle.jaffre@u-picardie.fr

⁵ Département des Analyses, AFLD, 92290 Chatenay-Malabry, France; c.buisson@afl.d.fr

* Correspondence: katia.collomp@univ-orleans.fr; Tel.: +33-238-417-178

Abstract: Female athletes have garnered considerable attention in the last few years as more and more women participate in sports events. However, despite the well-known repercussions of female sex hormones, few studies have investigated the specificities of elite female athletes. In this review, we present the current but still limited data on how normal menstrual phases, altered menstrual phases, and hormonal contraception affect both physical and cognitive performances in these elite athletes. To examine the implicated mechanisms, as well as the potential performances and health risks in this population, we then take a broader multidisciplinary approach and report on the causal/reciprocal relationships between hormonal status and mental and physical health in young (18–40 years) healthy females, both trained and untrained. We thus cover the research on both physiological and psychological variables, as well as on the Athlete Biological Passport used for anti-doping purposes. We consider the fairly frequent discrepancies and summarize the current knowledge in this new field of interest. Last, we conclude with some practical guidelines for eliciting improvements in physical and cognitive performance while minimizing the health risks for female athletes.

Keywords: menstrual phase; amenorrhea; hormonal contraception; performance; health; Athlete Biological Passport



Citation: Castanier, C.; Bougault, V.; Teulier, C.; Jaffré, C.; Schiano-Lomoriello, S.; Vibarel-Rebot, N.; Villemain, A.; Rieth, N.; Le-Scanff, C.; Buisson, C.; et al. The Specificities of Elite Female Athletes: A Multidisciplinary Approach. *Life* **2021**, *11*, 622. <https://doi.org/10.3390/life11070622>

Academic Editor: Angus Hunter

Received: 29 April 2021

Accepted: 23 June 2021

Published: 26 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The impact of intensive physical practice on women has attracted substantial attention in recent years. Yet, as women have been performing at the international level for just half a century in most sports disciplines, knowledge specifically on the elite female athlete has lagged behind that on elite male athletes. Indeed, one might say that in this sense, there is no real equality between women and men in sport [1]. A notable point in this regard is that the physiological (i.e., medical, dental, nutritional, and biological) and psychological monitoring of high-level athletes was established for male athletes and simply extrapolated to female athletes. More importantly, these extrapolations were made without serious questioning of the validity of this transfer [2], and the effects of the menstrual cycle phases, amenorrhea, the intake of oral estroprogestative or progestin-only pills, and intrauterine devices on female athletes are almost never taken into account. This is surprising, given their likely impacts not only on the physiological and psychological stress status of athletes but also on responses and adaptations to exercise [3].

The specificity of the female athlete is linked in part to the menstrual cycle (MC), with cycle length varying from one woman to another, although generally between 22 and

32 days (28 days on average). The first day of the cycle is the beginning of menstruation (day 1). The follicular phase (F) is the first phase of the normal menstrual cycle (NMC) before ovulation (from day 1 to around day 14, in the middle of the cycle), and the luteal phase (L) is the phase after ovulation until the first day of the next menstruation. The cycle is described by the fluctuation of the ovarian hormones: estrogens and progesterone. The estrogen leader, estradiol (E2), increases in both F and L, thus showing two peaks in concentration: one at the end of F (LaF), with a peak at the peri-ovulatory time (PeO), and one in the mid-luteal phase (MiL). Progesterone (PG) increases only once with a peak in L concomitant with the second E2 peak. The gonadotropins produced by the pituitary gland, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), peak during the ovulation phase, with during the late luteal phase (LaL) and the menstrual period (early follicular phase, EaF), levels of E2 and PG at their lowest. The menstrual cycle often appears to be disrupted in high-level athletes. First, even with regular cycles, female athletes can have prolonged F with shortened or absent L, secondary to a deficit in LH that induces insufficient PG production [4]. Moreover, a significant number of these athletes show disorders ranging from oligomenorrhea to amenorrhea (AM). Oligomenorrhea is defined as long and/or irregular MCs or cycles longer than 32 days [5], whereas AM is the absence of menstrual periods. Their prevalence in the general population is about 2 to 5% but increases among athletes, especially AM, ranging from 3.4% to 70%, with the highest prevalence observed in sports where the fat mass is very low, such as dancing and long-distance running [6–8]. The origin of AM, which is directly linked to a high workload and/or insufficient food intake, is probably multifactorial, with other main factors being (i) excessive secretion of endorphins, inducing a high opioid tone inhibiting the hypothalamic-pituitary-gonadal axis with subsequent inhibition of LH, FSH, E2, and PG secretion; (ii) insufficient fat mass to prevent the transformation of androgens to estrogens with a parallel decrease in leptin; and (iii) excessive secretion of prolactin (PRL).

Between 20 and 70% of elite female athletes use hormonal contraception, with a significant variation depending on the country (Australia, Denmark, Norway, Sweden, United States) and the sports discipline (football, basketball, track and field . . .) [7,9–11]. A large majority (68–75%) of these athletes take second-generation combined estrogen-progestin oral contraceptives (COCs), rather than progestin-only contraceptives (20–30%) [7,10,11]. The mono-, bi-, and triphasic COCs contain ethinylestradiol as the estrogen at concentrations between 20 and 50 µg per pill and, most of the time, levonorgestrel or norgestrel as the progestin at concentrations of 50 to 150 µg and 500 µg, respectively. They are taken for 21 days followed by 7 days off to reproduce the MC, but without the E2 and PG peaks and thus with more stabilized hormone levels. COCs are known to significantly decrease both free and total blood testosterone (TES) [12]. Progestin-only contraception is used continuously, either in tablet form or with an intrauterine device (IUD), and the main progestins are levonorgestrel and desogestrel. A significant number of elite athletes use hormonal contraception primarily to regulate their MC (24%), particularly those with a history of menstrual disturbances [9]. Moreover, a majority of COC users report having deliberately manipulated timing, frequency, and amount of menstrual bleeding, with a prevalence of 60–77% among competitive athletes, who most often cited special events and holidays, convenience, and sports competition as the reasons [7,11,13]. Non-COC users and, to a lesser degree, COC users report negative side effects during their MC, primarily in LaL with premenstrual syndrome (PMS) and during menstruation with dysmenorrhea, defined as pain during days 1–2 of menstruation.

Recent reviews [14,15] have examined the impact of MC and COC administration on physical performances in women ranging from sedentary to elite and from young to premenopausal, but the intention of this review is to focus on the specificities of the elite female athlete from a multidisciplinary perspective. We first present the current but still limited data on the effects of MC, AM, COC, and other hormonal contraceptives on both the physical and cognitive performances of these elite athletes. To highlight the mechanisms, as well as the potential performances and health risks in this population, we

then take a multidisciplinary approach and present the causal/reciprocal relationships between hormonal status and mental and physical health in young (18–40 years) healthy females, both trained and untrained. We thus cover the research on food intake, body composition, bone and ligament; the central nervous system (CNS) and neuromuscular and muscular responses, from decision-making to motor achievement; cardiorespiratory, gastrointestinal, urinary, endocrine, metabolic, and immune responses; and the Athlete Biological Passport (ABP) used for anti-doping purposes. We consider the fairly frequent discrepancies in the study results and summarize the current knowledge in this new field of interest, underlining the potential effects of hormonal status on both biological and psychological functioning and assessing the implications of these effects. Last, we conclude with some practical guidelines and perspectives for eliciting maximal improvements in physical and cognitive performances in female athletes while minimizing the health risks.

2. Hormonal Status and Performance in Elite Female Athletes

2.1. Hormonal Status and Physical Performance

A recent systematic study [14] explored the responses of sedentary to highly trained NMC women, without addressing the effect of age, and showed that exercise performance tended toward but was not significantly reduced during EaF compared to other MC phases. However, we cannot extrapolate the performance results obtained in this large cohort that included sedentary, active healthy or leisure sports women, and elite athletes, and thus we will only target this specific population.

2.1.1. Elite NMC Athletes

- Short intense exercise

Knee flexion and extension peak torque, passive knee joint position sense, and postural control [16] assessed in collegiate female athletes were similar between mid-follicular (MiF), PeO, and MiL. Sprinting performance in trained female students involved in multiple sprint and power events [17] were not different in MiF, PeO, and MiL, with the same metabolic responses, i.e., blood lactate, blood pH, and plasma ammonia. In parallel, no MC effect on jumping or sprint performance was found in high-level female soccer players [18,19] in EaF, LaF, and L. The same muscle strength, force, velocity, and anaerobic performance during a Wingate anaerobic test in female kickboxing athletes and judokas were also reported across MC [20–22]. However, the number of throws in the first 15-s period of a specific judo test in judokas was better in L [21], whereas a study [23] showed significant decreases in peak torque production of the extensors and flexors across isokinetic exercises in EaF vs. other MC phases in well-trained females.

- Incremental maximal test and endurance exercise

No modification in performance between MC phases at VO_2 max and peak treadmill velocity was found in endurance athletes, with tests performed either in EaF, LaF, EaL, and LaL [24] or in MiF and MiL [25]. On the field, the same results were obtained in elite soccer players by Tounsi et al. [19] but not by Julian et al. [18], who reported a reduction in performance in MiL during the Yo-Yo test. Last, Kishali et al. [26], using a questionnaire, estimated that physical performance was not affected during MC for most female athletes even in EaF, with decreased menstruation pain during training and competition.

2.1.2. Elite AM Athletes

The direct impact of AM on performance in elite athletes has almost never been investigated with, to our knowledge, only two direct studies. Vanheest et al. [27] examined the impact of ovarian suppression on the performances of junior elite female swimmers and showed that AM athletes with an energy deficit had a regression in their 400-meter swim velocity over 12 weeks compared to NMC athletes who showed an improvement. In parallel, they reported that E2, PG, triiodothyronine (T3), insulin-like growth factor (IGF-1), and energy status markers were highly correlated with sports performance. Simi-

larly, Tornberg et al. [28] found lower neuromuscular performance in AM vs. NMC elite endurance athletes, with AM athletes showing longer reaction times and decreased knee muscle strength and endurance. This lower neuromuscular performance was positively correlated with lower fat-free mass, glucose, E2, and T3, and negatively correlated with cortisol levels. In an indirect manner, Ackerman et al. [29] assessed the responses to an on-line questionnaire completed by 1000 female athletes from 15 to 30 years old and reported that athletes with low energy availability were more likely to be classified as having an increased risk of menstrual dysfunction combined with low performance. Indeed, athletes with low vs. adequate energy availability were 2.1 and 1.5 times more likely to report increased recovery time and decreased endurance, respectively, whereas decreased muscle strength, which is difficult to quantify via self-report, was not queried.

2.1.3. Elite COC Athletes

- Short intense exercise

Studies with monophasic [23,30] or triphasic [31] COCs have reported no change in anaerobic speed or isokinetic strength in highly active women or university athletes, whatever the progestin used. In parallel, Rechichi et al. [32] showed similar anaerobic power and repeat sprint ability in team-sport athletes at three time points of a single COC cycle, i.e., consumption, early and late in the withdrawal phase [32]. In the same way, swimming performance during a 200-m time trial was not affected within a monophasic COC cycle in competitive swimmers and water polo players at the same three time points of the COC cycle [33], in addition to unchanged body composition, peak heart rate, and blood glucose. However, peak blood lactate was significantly lower and mean pH higher late in the withdrawal phase, coupled with higher endogenous E2 levels and an increase in pH, possibly because of an increase in fluid retention, plasma volume, and cellular alkalosis. Yet, other data were discrepant. Redman et al. [34] reported in female rowers during the COC cycle an improved peak power output and anaerobic capacity with low estrogen and progestin, coupled with higher plasma glucose concentrations and lower plasma triglyceride concentrations at rest and during exercise. In the abovementioned study, Rechichi et al. [32] nevertheless reported decreased performance late in the COC withdrawal phase for reactive strength, which was interpreted as a negative impact of endogenous estrogen on neuromuscular timing and muscle activation time.

- Incremental maximal test and endurance exercise

No change in aerobic performance was found in trained runners with a monophasic [35] or a triphasic [31] COC despite a 4.7% decrease in absolute and relative VO_2max and an increase in fat mass with COC vs. EaF [31]. Rickenlund et al. [36] reported that endurance athletes after 10 months of monophasic COC use a significant increase in weight and fat mass only in athletes with previous oligo-/AM, associated with a decrease in ovarian androgens and increased bone mineral density (BMD), with the largest increase in the athletes with low BMD at baseline. Despite the significant changes in body composition, no significant impact on physical performance was recorded. Last, Rechichi et al. [37] found with a monophasic COC no difference in endurance performance in female cyclists/triathletes despite greater ventilation, oxygen equivalent, and blood lactate values during hormonal vs. withdrawal phase. In contrast, Sunderland et al. [38] examined the impact of COC use on the performance of high-intensity intermittent running in the heat in well-trained athletes twice within the COC cycle. Heart rate (HR), perceived exertion, sweat rate, plasma lactate, and ammonia did not differ, but the rectal temperature was higher, and performance was improved at days 15–28 vs. days 1–14.

2.2. Hormonal Status and Cognitive Performance

2.2.1. Elite NMC Athletes

Burrows et al. [24] found no modification in negative and positive affect and irritability in female runners between EaF, LaF, EaL, and LaL. In contrast, Cockerill et al. [39] used

the profile of mood state (POMS) questionnaire in elite NMC runners vs. inactive women 5 days before and 14 days after menstruation and reported that all athletes were less tense, depressed, tired, confused, and angry and more vigorous in PeO than in LaL, but with lower difference than non-trained subjects. It is interesting to note that the lower-intensity-training runners appeared to benefit psychologically, while high-intensity training had an adverse effect on mood. Moreover, PMS appeared to cause marked negative mood swings. Other studies indirectly investigated changes in self-reported physical fitness, performance, and side effects across MC, using various questionnaires given to the athletes, and all reported consistent results [11,26,40–43]. Indeed, 50% to 80% of the elite athletes claimed they were affected by PMS in the week prior to menstruation, and about 80% of them by menstruation. Most perceived their worst performance as being close to bleeding and scored highest for perceived fitness and performance in the phase following bleeding [43]. Forster et al. [44,45] showed that female soccer players with PMS had increased anxiety and pro-inflammatory cytokines compared to athletes without PMS and that this was combined pre-game with, respectively, greater tension in F and greater depression in L. Findlay et al. [46] conducted semi-structured interviews with elite female rugby players and focused on MC-related issues such as symptoms, the perceived impact of menstruation on different aspects of daily living and performance, methods of dealing with menstruation-related concerns, and available support and comfortability. Almost all athletes (93%) reported MC-related symptoms, with high inter-individual responses. As in the studies of Bruinvels et al. [41,42], one-third perceived heavy menstrual bleeding, and two-thirds reported symptoms that impaired their performances and self-medicating to alleviate the symptoms. Bruinvels et al. [42] therefore proposed a novel menstrual symptom index (MSi) to quantify their frequency.

2.2.2. Elite AM Athletes

The abovementioned study of Cockerill et al. [39] included AM athletes, and the data of the POMS used with a 21-day interval showed little variation between the two periods. In a comparison of elite AM and NMC athletes, Ackerman et al. [29] showed that athletes with increased risk of menstrual dysfunction were more likely to have impaired judgment, decreased coordination, decreased concentration, irritability, and depression, coupled with altered memory performance [47], this last effect probably mediated by the lack of E2, as estrogen replacement improves verbal memory and executive control in this population [48].

2.2.3. Elite COC Athletes

Brown et al. [40] found that the decision to actively control the MC was often triggered by a desire to reduce the effect on competition, to lessen anxieties about meeting the required weight, or to reduce the distractions to manage during competition. Oxfeld et al. [7] studied self-perceived physical and emotional symptoms related to COCs in elite female athletes and reported that their use did not abolish dysmenorrhea but may have reduced emotion-related side effects. For their part, Martin et al. [11] reported that the most common side effects after hormonal contraception were weight gain and mood swings, both of which can affect performance. It can also be noted that negative side effects are more common with progestin-only vs. COC users, especially with the IUD.

3. Possible Mechanisms: Performance and Health Risks

3.1. Food Intake, Body Composition, Bone, and Ligament

3.1.1. Food Intake and Body Composition

- NMC women

Some studies have shown significant variations of appetite and energy intake in healthy women across their MC [49,50], in part explained by the influence of E2 and PG on gastric emptying and the secretion of gastrointestinal hormones such as glucagon-like-peptide-1 (GLP-1) and cholecystokinin (CCK) [49]. Food intake thus may be higher during L than F in lean women [51,52], with an increase in macronutrient intake, especially sweet

foods, in LaL [53,54], but the changes remain poorly understood. Female athletes have distinct nutritional needs based on their sport, exercise intensity, and season [55], with disordered eating observed in athletes from several sports, especially esthetic ones [56], limiting understanding of the impact of MC on food intake. No difference in body mass or composition, determined by dual-energy absorptiometry (DXA) [57] or bioelectrical impedance [58], was found in well-trained NMC women across MC in most studies, with one study shows, however, an increase in body mass in L vs. F in the more hydrated and slim women [59].

- AM women

Classically, disordered eating, menstrual dysfunction, and low bone mass have been grouped under the term female athlete triad (FAT). This concept was recently renamed: relative energy deficiency in sport (RED-S), as proposed by the International Olympic Committee (IOC). The use of this much broader term is linked to the observation that the main problem seems to be the lack of available energy, with consequences affecting several systems, as a “spectrum” of occurring irregularities [60]. All papers have reported significantly lower fat mass in AM vs. NMC athletes, coupled with decreased fat-free mass in most of them [28,61–65].

- COC women

Nutritional choices do not seem to be adjusted to the use of COC [66], but the current data are insufficient to conclude on whether COC is associated with changes in dietary behavior. In addition, COC use was reported not to alter [58,67] or to increase body and fat mass [30,68], generally limited to athletes with previous oligo-/AM [36].

3.1.2. Bone Health and Ligament Injury Risk

The constant bone remodeling occurs under the control of mechanical loading, cytokines, growth factors, thyroid, and sex hormones. Estrogens are considered as the “key regulator” of bone metabolism in women [69], positively affecting the formation and proliferation of bone-forming osteoblasts and simultaneously inhibiting apoptosis of bone-resorbing osteoclasts, although the influence of PG should not be completely overlooked. Indeed, a recent study [70] indicated that E2 exerts an immediate positive effect on the production of osteoprotegerin, a bone formation marker, while PG seems to have a delayed positive effect.

- NMC women

Bone mineral accrual in adolescence and young adulthood is determined by MC, with optimal estrogenic impregnation essential to provide the high peak bone mass that can lower fracture risk later in life [71–75]. Bone formation assessed by osteocalcin and bone resorption assessed by type I carboxyterminal telopeptide (ICTP) did not change significantly across MC in NMC female rowers [57]. With regard to training, a systematic review on the influence of sports practice on BMD and bone geometry in healthy children and adolescents [76] highlighted that female gymnastic, soccer, tennis, and capoeira practitioners have better values than control subjects and comparisons of female soccer players and swimmers showed that sports requiring impact and body overloading promoted BMD content [76,77]. In addition, women injure the knee anterior cruciate ligament (ACL) four to six times more often than men, which has prompted the suggestion that fluctuations in women’s endocrine environment might be a factor [78]. The presence of sex hormones or relaxing receptors in ACL might explain their effect on this structure, but other extrinsic or intrinsic factors may contribute to this process [79,80]. Recent reviews [81,82] seem to show a decreased risk of ACL injury during L vs. F and PeO, with increased ACL laxity in PeO at high E2 levels vs. other MC phases. However, no association was found between increased risks of ACL tears and increased laxity [82]. Moreover, other authors have reported no significantly different ACL laxity in high-level female athletes in F, PeO, and L, at rest or during exercise [83,84].

- AM women

Menstrual dysfunction in female athletes and delayed onset of menarche in adolescent girls have been associated with lower BMD [85,86], which can, however, be modulated by physical training. Indeed, heavy weight-bearing training in sports is associated with higher bone mass in the athletes compared to controls with the same age and menstrual status and could moderate the decrease in bone mass in AM athletes [87], although residual deficits seem to persist without catch-up raising concerns for suboptimal peak bone mass acquisition [88]. Moreover, the favorable action of training appears attenuated in sports practices that exert lower strain [89]. Last, the data are sparse, but menstrual dysfunction may increase the risk of ACL injury [78].

- COC women

The effects of COCs vary more widely, and factors such as concentration in estrogens and/or progestins, age of the studied population, age of initiation of COC use, and physical aptitude may explain the differences between studies [89,90]. A meta-analysis [91] of studies on non-athletic women over 30 years old using a range of COCs reported either positive or no effect on women's bone health, with most studies reporting no change in spine, hip, or total body BMD between COC users with various doses and progestins and non-users [92,93]. However, other authors [94,95] have noted that young females who initiate COC use early after menarche may experience skeletal detriments. Last, Martin et al. [70] observed no significant difference in the bone formation marker level between COC phases, whereas the resorption marker level was significantly lower in the last vs. the early phase of COC consumption. In female athletes, Jürimäe et al. [57] reported decreases in both osteocalcin and ICTP in COC vs. NMC. Most of the other studies have been conducted in oligo-/AM athletes, and the data indicated either a slight gain in BMD, essentially in the lumbar spine after six months of COC use [96], or tendencies without real gain [97]. Recently, the impact of the route of estrogen administration on bone turnover markers in oligoamenorrhic athletes and its mediators [98] was demonstrated, and Ackerman et al. [99] reported lumbar spine and femoral neck BMD improvement with transdermal estradiol plus cyclic oral progesterone but not with COC administration in oligo-/AM athletes. In parallel, different studies have suggested a potential 20% reduction in risk of ACL rupture under COCs [81,100,101]. It was hypothesized that the relative progestative dominance in COCs mitigates the estrogen effect [81]. However, all the authors noted small sample sizes, the heterogeneity of the subjects, and methodological concerns as study limitations [102]. Last, Nose-Ogura et al. [103] showed that COCs decreased serum relaxin-2 levels in athletes with high relaxin-2 concentrations during L. This may be of interest as recent investigations have demonstrated that these athletes have a high risk of ACL injuries, but the mechanism remains to be explained.

3.2. CNS and Neuromuscular Responses (Part 1): Decision Making

A substantial body of literature in neuroscience shows that sex steroid hormones influence cognitive processes [104–106]. The clearest evidence of the direct neurological effects of E2 and PG was the discovery of their receptors in multiple brain sites. Both E2 (ER α and ER β) and PG receptors (PR-A and PR-B) have been found in brain areas associated with reproduction, but also in brain areas involved in cognitive functions and emotional processing, such as the hypothalamus, amygdala, hippocampus, and prefrontal cortex [107–110]. E2 and PG also act as modulators for other neurotransmitter systems, including the cholinergic, serotonergic, GABAergic, dopaminergic, and glutamatergic pathways, all of which play roles in executive function, learning, memory, or reward processing [111–113].

3.2.1. Cognitive Function

- NMC women

A decades-old theory postulates that men perform better in visuospatial skills while women outperform in verbal skills [114]. This theory was applied to MC with the as-

assumption that these “sexually dimorphic” cognitive abilities/skills would differ across MC [115]. It was therefore expected that women would perform better on visuospatial tasks during phases with low E2 and PG levels and that, in contrast, performance on verbal tasks would be improved during LaF and MiL; in view of recent critical reviews, evidence is nevertheless insufficient to support the sexually dimorphic hypothesis [116–120]. Indeed, regarding visuospatial ability, only a few studies on mental rotation, the most commonly used test [120], have supported the hypothesis of superior performance in EaF [121–123], whereas the others showed no significant findings [124–126]. Moreover, on the other visuospatial abilities (including spatial perception, spatial navigation, and spatial math tasks), only some reported improved performance in F vs. L [122,127]. Other studies established no MC influence on visuospatial memory or ability or reported findings conflicting with the hypothesis [125,128–130]. The two main cognitive domains identified as favoring women [131] are verbal fluency and verbal memory [120], but other verbal skills such as semantic retrieval, implicit verbal memory, and verbal working memory have also been studied. Although some studies showed improved verbal task performances in LaF or MiL [123,128,132], most found no effect of the MC phase on verbal skills or reported findings conflicting with the sexually dimorphic hypothesis [122,124,125,133–136]. MC studies have also examined executive functioning tasks that require diverse higher-order abilities such as judgment, planning, and control of other domains. Again, the studies were inconclusive. Indeed, one study on flexible thinking and problem-solving showed better performance in EaL [136], whereas another study observed no MC effect [130]. Results on inhibition and selective attention performance varied, being either impaired or improved in LaF and improved or unimproved with high E2 levels, depending on the task [133,137,138]. Two studies on spatial memory suggested that high E2 levels were related to improved performance [139,140].

- COC women

A recent systematic review showed that the impact of COCs on cognitive abilities remains controversial [141]. Indeed, the studies investigating associations between COC use and visuospatial abilities have shown mixed results, with most reporting no significant difference between COC users and NMC women [124,125,142,143]. However, other studies, using a variety of tasks and a broad range of COC formulations, have shown improved visuospatial ability [144–146], whereas others have shown impairment [124,147]. Wharton et al. [148] analyzed the cognitive impact of COC subtypes and found no overall difference in visuospatial ability between COC users and non-users. However, they showed that the new-generation pills with anti-androgenic progestins impaired visuospatial ability, whereas androgenic progestin COCs improved it compared to NMC women [149] and suggested that the opposing effects of anti- and pro-androgenic progestins may potentially mask each other when COC subtypes are examined collectively, which may explain the inconsistencies in the literature. Data on the impact of COC on verbal memory are also discrepant, with either no change [143,148,150] or improvement [125,141,142] both in comparison to NMC women and across the COC cycle. When improvement occurs, this is likely attributable to the effect of ethinylestradiol [104,123]. Studies have also investigated the COC effects on other verbal skills, with inconsistent findings. Only one study found that COC use decreases verbal fluency [124], with this negative impact more pronounced in androgenic COC formulations, whereas other studies showed no significant effects of COC use [125,143,144]. Most studies on executive function, attention, and working memory have found no significant effect of COC use [125,143,151], but some have reported improvements in attention, concentration, and working memory [142,152,153]. As with most research in this area, there has been no sub-analysis with respect to the impact of the progestin.

3.2.2. Emotions and Social Interactions

Few studies have explored the impact of hormonal status on emotions and social interactions in elite athletes, but a number of studies have done so with a larger young, healthy female population.

- NMC women

Whereas PeO with its high E2 level is generally associated with a positive mood and high levels of well-being and self-esteem [154], pre-menstruation and menstruation are often associated with a negative mood, with direct links to low E2 and PG. During F, women have a low level of negative affect, which increases during L and reaches a paroxysm at the time of pre-menstruation. With regard to social relations, Derntl et al. [155] put forward the idea that women discriminate emotions more easily in F than in L, suggesting that the levels of empathy and social sensitivity differ with the phase of MC. Reynolds et al. [156] showed that women with higher average PG levels reported higher anxiety levels than women with lower PG, coupled with a greater increase in anxiety across MC, providing support for a link between PG levels and subjective anxiety. Numerous studies have reported that from 30% to 95% of women experience undesirable premenstrual mood changes during LaL, characterized by symptoms such as tension, irritability, restlessness, anxiety, and depression, with a positive correlation between pain and states of anxiety and depression [157–159]. Menstruation is relatively often accompanied by dysmenorrhea in healthy young women, which may have emotional consequences, including sleep disturbance, daytime fatigue, and drowsiness [160–164]. Subjective sleep quality appears to be lowest around menses, especially in women suffering from PMS [165–167], but the clinical significance was found to be no longer statistically significant when potentially confounding variables such as perceived stress, and social support were included [168,169]. In addition, MC had an impact on psychosocial measures in all women, with and without PMS, in F and L, but PMS was associated with more reports of daily stress and social conflict. These negative emotional effects have been shown to decrease quality of life, impacting personal and professional relationships, as well as school or work performance and absenteeism [170–175].

- COC women

Recent articles [176–178] have reviewed the current knowledge on how COCs affect mood. COCs seem to reduce the variations across MC, whether or not the premenstrual mood is specifically improved [176,177,179,180]. Ekenros et al. [179] reported that the onset of COC use significantly decreased PMS but did not affect mood symptoms, whereas Robakis et al. [177] showed that some women experienced the beneficial effects of COCs specifically on premenstrual mood symptoms. A recent review [178] reported that COC use in most women shows no effect or a beneficial effect on mood, with the fewest mood effects obtained with the less androgenic progestins and continuous or non-oral COCs. The links between mood and changes in androgens in women starting on COCs were also studied [180,181], with no relationship found, even though some women may be more sensitive to changes in TES than others. Last, women taking hormonal contraceptives had less slow-wave sleep than NMC women, with the longest mean nightly sleep time occurring with progestin-only oral contraception but with only minor consequences for the quality of sleep [182,183].

3.3. CNS and Neuromuscular Responses (Part 2): Motor Achievement

The discovery of the impact of E2 and PG at every level of the CNS [184,185] down to the muscle itself [186] prompted researchers to investigate the potential effects of sex hormone variations on balance and motor control in women. Although the importance of estrogen action is unclear, postural control [187,188] and motor control [189,190] have been found to vary across the MC phases (Table 1).

3.3.1. Postural Control

- NMC women

Many studies have shown variations in postural instability over the MC, but the results have been discrepant based on task difficulty mainly [16,187,188,191–199]. Overall, the researchers assumed that, as the main structures contributing to balance are influenced

by hormonal fluctuations, differences in balance would be seen over MC unless adaptive mechanisms take place [200]. Two hypotheses have emerged based on when postural instability occurs in the course of MC. Researchers reporting less stability during PeO have argued that E2 triggers ligament laxity and weakens muscle strength [201–203] as it has an inhibitory effect on collagen synthesis [204,205]. Conversely, researchers who found more instability around menses have argued that hormonal changes taking place at the beginning and end of MC might affect many aspects of postural stability simultaneously rather than just one source of postural information, such as the vestibular system [187].

- COC women

Only a few studies have looked at COC women, showing stabilization of posture or a better balance for COC users [194,206,207]. The consistent lower limb dynamics of COC users might demand less reliance on the neuromuscular control apparatus to acutely alter feed-forward strategies during dynamic tasks. This may explain the lower rate of lower limb musculoskeletal injuries in this population compared to non-COC users [208], with a protective effect on knee injuries [206].

Table 1. Detailed results about motor achievement.

Variables	NMC Women	COC Women
Postural control	<p>No consensus</p> <ul style="list-style-type: none"> • No change [16,197,198] • More instability in EaF [187,193,194] or reverse [188,191,192,195,196,199], with instability found if task is sufficiently difficult (either the task or a change in sensori-input) 	<p>Too few studies</p> <ul style="list-style-type: none"> • Stabilized posture or better balance [194,206,207] vs. non-COC users
	<p>No consensus</p> <ul style="list-style-type: none"> • No change at all [19,209,210] or change in few tasks only [211,212] or in all tasks [213–216] • No impact of training with mixed results in athletes [18,19,212] 	<p>Too few studies</p> <ul style="list-style-type: none"> • No change across COC cycle and vs. non-COC users [217,218]
Strength and resistance training	<p>No consensus</p> <ul style="list-style-type: none"> • No change [30,219] • ↘ isometric endurance in F [220] or ↗ force in F and PeO [221,222] • ↗ limb proprioception in PeO and L [223] <p>Consensus?</p> <ul style="list-style-type: none"> • ↗ muscle strength in F with resistance training [186,224–226] 	<p>No consensus</p> <ul style="list-style-type: none"> • ↘ hand grip muscular endurance [227,228] with inhibiting effect on myofibrillar protein synthesis [229] • No difference in maximal force-generating capacity, jumping or hopping [18,19,31,230] • No endurance or strength changes with training [224,231,232]

Legend: ↗: increase; ↘: decrease.

3.3.2. Motor Control

- NMC women

Authors have found similarly mixed results, independently of the tested task or athlete level [18,19,209–216]. No variation in jumping or sprinting abilities across MC was

reported [18,19], but in tennis, it should be noted that, although the speed of the serve did not vary, its accuracy decreased in PeO [212]. Many parts of the body implicated in motor control are known to be impacted by sex hormone variations, but whether the sum of those mechanisms is detrimental to the production of motor tasks remains unknown. In addition to the CNS changes described earlier, other factors might play a role in motor control regulation over the MC. Bayer et al. [211] suggested that functional cerebral asymmetries, probably due to hormonal modulations in interhemispheric interaction, could affect fine motor coordination across MC, with fluctuations in hand asymmetry. Ikarashi et al. [215] showed a failure of excitability of the primary motor cortex during L vs. PeO, resulting in weaker motor learning and motor performance. In terms of neuromuscular control, some researchers found various changes over MC, similar to findings in muscle co-activation patterns [192,233], whereas others reported no modification [209].

- COC women

The few studies on motor control have mainly found no variation in performance across the cycle in women taking COCs, but they also found no difference for non-COC users [217,218], making it difficult to conclude about a possible smoothing effect of COCs on motor abilities over MC based on the current literature.

3.3.3. Strength and Resistance Training

- NMC women

MC effects on strength remain contradictory [30,219–223].

However, it seems that sex hormones can influence resistance training responses [186,224–226,234]. The gain in muscle strength might be due to a better process of satellite-cell incorporation-induced muscle hypertrophy, but further research is warranted, given the methodological issues and the lack of consensus, particularly on the potential alteration in skeletal muscle protein metabolism across MC [234].

- COC women

Older research found that COC use altered muscular strength [227,228] and an inhibiting effect on protein synthesis [229]. More recent papers, however, showed no difference in maximal force-generating capacity, jumping, or hopping with COC use [18,19,31,230] and did not suggest that COC use affects strength or endurance in response to strength-only or combined strength/endurance training [224,231,232]. However, further research is necessary to determine whether COC androgenicity plays a significant role in strength development [224].

3.4. Cardiovascular, Respiratory, Gastrointestinal, and Urinary Function

3.4.1. Cardiovascular Response

Some studies have examined the impact of female hormonal status on cardiac function and hemodynamics (HR, stroke volume, cardiac output, diastolic and systolic blood pressure) and autonomic control (heart rate variability: HRV, baroreflex sensitivity) (Table 2).

- NMC women

Studies have generally shown that resting cardiac function or hemodynamics does not depend on MC [235–237], but opposite results have been reported [168,238,239]. Lack of change in cardiovascular baroreflex sensitivity across MC was found by most [240–242] but not all [243] authors. In parallel, most but not all [244] studies have shown variations in HRV across MC, with an increase in the low-frequency peak (LF) in L, inducing a higher LF/HF ratio, coupled or not to a change in the QT interval or parasympathetic tone [245–252]. The alteration in the balance of E2 and PG may be responsible for the increased sympathetic activity in L, which appears, however, partly dependent on major lifestyle factors [253,254]. Last, circulating levels of cardiac natriuretic hormones did not show any significant change across MC in healthy women [255]. During exercise, most studies reported no change in stroke volume or cardiac output [237,256,257] in well-trained NMC athletes across MC, regardless of the environment, with two discrepant studies [258,259].

- AM women

No change was observed in the single study investigating the effect of menstrual disturbance on cardiovagal baroreflex sensitivity, vagal tone, and cardiovascular responses to orthostatic stress in young AM vs. NMC women in EaF [260], and the authors concluded that AM women do not display signs of impaired autonomic function or orthostatic responses.

- COC women

Early studies have shown higher systolic blood pressure and/or HR with COC use [235,261–264], but more recent studies did not report any change in either cardiac function or hemodynamics [236,262,265]. Most of the studies nevertheless did not note a difference in either HRV or baroreflex sensitivity after several months of COC use [236,262,266], with only one study showing impairment in autonomic control [267]. Last, the data suggest that progestin-only contraceptives do not modulate the autonomic balance [268]. Few studies have been conducted during exercise, and the data are discrepant, with either a greater increase in blood volume, stroke volume, and cardiac output during exercise with COCs [269] or no COC effects on HR [258] and cardiac vagal withdrawal at the onset of dynamic exercise [257].

3.4.2. Respiratory Response

We first summarize here the current knowledge on the impact of hormonal status on respiratory parameters in healthy women in normal and hypoxic conditions. In addition, as most endurance athletes develop exercise-induced bronchoconstriction (EIB), often referred to as athletes' asthma, we also report the data on the link between hormonal status and respiratory disorders, even though a recent systematic review suggested no link between sex and EIB [270].

E2 alone is not considered to have significant effects on the respiratory system [271,272]. In contrast, PG has been suggested to stimulate hyperventilation at rest and during exercise and to enhance respiratory drive at rest in women during L by acting centrally on hypothalamic sites [273–275] and through peripheral chemosensitivity [274]. Some studies have thus observed an increase in ventilation (VE) response at rest and during exercise in MiL in NMC non-athletes [276–280], although others have not [67,281–283]. No changes in lactate or ventilatory thresholds were reported [279]. Consistent with the increased VE, decreases in PaCO₂ and PETCO₂ and increases in carbon dioxide ventilatory equivalent (VE/VCO₂) were observed during incremental exercise tests in NMC non-athletes in MiL [272], with PaCO₂ negatively correlated with E2 and PG [278]. Dombovy et al. [284] reported no change in exercise VE in MiL but observed a significant decrease in VCO₂ and thus an increase in VE/CO₂. The change in VE is not expected to limit VO₂max, and most works have shown no change in VO₂max across MC at sea level or at 3600 m for high-altitude native women [219,285]. Nevertheless, an increase in the oxygen ventilatory equivalent (VE/VO₂) ratio during submaximal exercise is sometimes observed in L [279].

- NMC women

In trained NMC females, an increase in tidal volume during L vs. EaF and MiF was reported [278], whereas no change in VE during maximal or submaximal exercise [257,258,276] or in VO₂max was generally found across MC [258]. It has not been excluded, however, that VO₂ depends on E2 concentrations or the E2/PG ratio, as Barba-Moreno et al. [258] recently showed higher VO₂ in MiF than EaF during submaximal exercise in trained NMC females. A higher ventilatory drive in L than F has been found in most studies, as in non-athletes, but to a lesser extent, and without a significant performance impairment, likely due to the great variability in performance responses among female athletes [258,277,279]. Endurance athletes are known to have lower hypoxic and hypercapnic voluntary drive [286,287] and, not always coupled with the VE data, an increase in hypoxic and/or hypercapnic chemosensitivity has generally been observed at rest during MiL [277,284,288,289]. This contributes to reduced exercise tolerance, possibly through an increase in dyspnea perception [286–290]. However, other studies have found no difference in the ventilatory response to hypoxia at

rest [281,283,291] or during exercise [284], probably due to the huge inter-variation in PG concentrations. Richalet et al. [292] recently observed that the increase in hypoxic ventilatory response during exercise was accompanied by higher exercise SaO₂ during EaL and MiL and concluded that MC has an impact on the ventilatory response during exercise in hypoxia and, consequently, on tolerance to high altitude. This should be taken into consideration for women exercising in altitude. Last, few studies have investigated the potential MC impact on the susceptibility to upper respiratory tract infections (URTI) in NMC athletes, which remains under debate [293–295] despite the observation of the effect of an increase in estrogens on nasal mucosal immunity and nasal congestion in non-athletes [296].

Table 2. Detailed results about cardiovascular responses.

Variables	NMC Women	AM Women	COC Women
Cardiac function and hemodynamics	<p>Rest: No consensus</p> <ul style="list-style-type: none"> No change in function and hemodynamics in healthy [235,236] or athletes [237] in temperate/dry/humid hot environments ↗ HR at PeO [238] ↗ systolic and diastolic blood pressure in LaL vs. EaF [239] ↘ HR and diastolic pressure in PMS women [168] <p>Exercise: No consensus</p> <ul style="list-style-type: none"> No change in cardiac function [237,256,257] ↗ HR in L vs. MiF [258] ↗ post-exercise cardiovagal reactivation in EaF with aerobic training [259] 	<p>Too few studies</p> <ul style="list-style-type: none"> No change [260] 	<p>Rest: No consensus</p> <ul style="list-style-type: none"> ↗ HR and/or systolic blood pressure [235,261] without change in cardiac output or total peripheral resistance [262–264] No change [236,262,265] <p>Exercise: Too few studies</p> <ul style="list-style-type: none"> ↗ blood volume, stroke volume, and cardiac output [269] No change in HR [258]
	Autonomic control	<p>Consensus</p> <ul style="list-style-type: none"> ↗ LF and LF/HF ratio (HRV) in L in most studies [245–252], no change in [244] No change in baroreflex sensitivity in most studies [240–242], ↗ in PeO [243] 	<p>Too few studies</p> <ul style="list-style-type: none"> No change [260]

Legend: ↗: increase; ↘: decrease.

Asthma and menstruation are closely linked, with menstrual symptoms correlated with the level of asthma control and its intensity in young women and irregular MC more frequently observed in asthmatics [297]. In NMC athletes, respiratory symptoms due to EIB or asthma, known as premenstrual asthma (PMA), worsen during L [298,299], increasing bronchodilator use during MiL vs. MiF. There was a negative correlation between the percent change in pre- to post-exercise FEV₁ and PG but not E2 concentration. In line with these results, Oguzulgen et al. [298] found a significant increase in exhaled NO levels, induced sputum eosinophil counts, and daytime symptom scores, indicating a parallel worsening of airway inflammation during L, but Kirsch et al. [300] showed that E2 activates endothelial NO synthase in human airway epithelial cells via the epithelial estrogen receptor. On the other hand, many authors found that self-reported PMA in non-athlete women was associated with a decrease in peak expiratory flow during LaL,

but they found no difference in forced vital capacity, FEV₁ or PC₂₀, with or without the increased use of inhaled β_2 -agonists [301–304].

- AM women

Ventilatory drive and exercise ventilation seem to remain stable in AM athletes [277] and are comparable to the F and L values observed in NMC athletes [256]. Shimizu et al. [295] observed more frequent URTI in AM compared to NMC distance runners and suggested that the low estrogen levels in AM might be related to higher susceptibility to infection in these athletes through a decrease in salivary IgA, which protects against the entry of pathogens into the body.

- COC women

In some but not all studies [67], monophasic COC use was found to increase VE, VE/VO₂, and breathing frequency in endurance athletes [37,258] during the hormonal vs. the early and late withdrawal phase, but this was not accompanied by a decrease in performance. In addition, Richalet et al. [292] showed that COCs had no effect on ventilatory responses to altitude hypoxia, whereas Regensteiner et al. [272] showed an increase in the hypoxic ventilatory response during mild exercise in L vs. F when progestin was used in normoxia. COC use may contribute to an aggravation of asthma by stimulating estrogen receptors in the bronchial epithelium [300,304]. Studies of the pro-inflammatory effects of COCs have indeed shown a strong increase in the plasma levels of C-reactive protein (CRP) and fibrinogen, but not interleukin-6 (IL-6) [305].

3.4.3. Gastrointestinal and Urinary Function

Competitive sports activities are a clear risk factor for both gastrointestinal and urinary disorders in female athletes.

- Gastrointestinal function

Regular moderate physical activity is thought to protect against intestinal inflammatory diseases [306]. However, gastrointestinal symptoms (GIs) in the upper or lower gastrointestinal tract are common and a limiting factor for elite athletes, particularly during prolonged strenuous exercise, which can induce intestinal injury, increase permeability and endotoxemia, and impair gastric emptying, slowing small intestinal transit and causing malabsorption [307,308]. From 30% to 50% of athletes report GIs during training [309], with a prevalence reaching 70% in endurance disciplines [55,310,311]. Celiac disease and irritable bowel syndrome appear more prevalent among female than male athletes [312], with an additional influence of MC on GIs. GIs worsen in most healthy young women either during LaL or EaF [313–315], with higher reports of stomach pain at menses than at other MC phases, especially in dysmenorrheic women [314]. During L, women excrete hard stools and have delayed transit, while at the time of menses, stools are looser and more frequent. Studies [314,316] also reported changes in bowel habits in healthy women taking COCs, with more GIs on the first days of menstrual bleeding. However, MC does not appear to alter rectal motility or sensitivity [317,318]. In parallel, intense physical activity induces changes in gut microbiota composition [319,320], which is known to play an important role in athletes' health, well-being, and sports performance. A possible direct influence of sex hormones on the brain-gut-microbiota axis has been suggested, in view of the effects of PG on gut motility during pregnancy, resulting in constipation, increased reflux, and biliary dysfunction [313].

- Urinary function

Recent reviews [321–325] have highlighted that female athletes show a three-fold higher risk of developing urinary incontinence (UI) than male athletes or female non-athletes. The UI is mainly explained by the imbalance of forces between the abdomen and pelvis [324], with increased intra-abdominal pressure generated during high-impact exercise, which overloads the pelvic organs and creates a pelvic floor dysfunction in high-performance athletes [321,324]. The risk of UI appears dependent on the amount of training

and the type of sport, with a prevalence varying from 10% in low-impact to 80% in high-impact sports [323,325–329]. UI may influence sports performance [328] either directly during competition or indirectly by interfering with everyday life or training [323,328]. No studies have investigated the impact of MC or contraceptive use on UI, as it is assumed to be the result of a mechanical effect, but a recent study [329] reported that UI was significantly associated with low energy availability across all sports categories.

In addition, proteinuria and hematuria are common in elite athletes, believed to be benign and transient [330]. The prevalence of proteinuria during exercise (17%) is strictly related to the exercise intensity rather than the duration, whereas hematuria (30%) is influenced by both [330,331]. Most often, they are of renal origin, probably due to a temporary hemodynamic impairment, partially of glomerular but principally of tubular function [332]. Factors contributing to exercise proteinuria and hematuria may include vascular changes, hypoxia, lactate accumulation, oxidant stress, foot-strike, bladder trauma, and hormonal changes [333]. No effect of sex or hormonal status appears to occur [330].

3.5. Endocrine Response, Metabolism and Immunity

As mentioned in Section 2.1., very few studies directly exploring the impact of hormonal status on performance and metabolism have been conducted on elite athletes. To identify the potential mechanisms, we here present the research on endocrine response, metabolism, and immunity, although without performance being directly explored. Female athletes with hyperandrogenism linked to either polycystic ovary syndrome or differences/disorders of sex development are not included.

3.5.1. Anabolic Hormones

- NMC women (Table 3)

There is no consensus on whether MC phases influence TES concentrations, either at rest or during exercise [186,334–338]. Regardless of the MC phase, it is important to note that basal TES values were higher in elite female athletes than non-elites, with a more marked exercise response, which could indicate greater capacities for higher work rates and recovery [339,340]. Regarding GH, there is a wide consensus that basal and/or exercise GH response is higher at PeO vs. the other MC phases [38,341–344], associated with higher E2 levels that facilitate the central drive of pulsatile GH secretion. The data appear less clear for IGF-1 [342–345]. Gleeson et al. [344] hypothesized that the effect on IGF-1 levels was more subtle, with only a modestly elevated baseline IGF-1 from PeO onward despite a two-fold increase in GH secretion due to a reduction in GH sensitivity.

- AM women (Table 3)

The 24-h hormone profiles in AM vs. NMC athletes are characterized by decreased LH pulsatility, with lower TES and higher SHBG concentrations [346]. Most studies have reported increases baseline levels with distorted patterns of GH pulses [36,347,348]. However, studies have reported a similar GH secretion pattern in oligomenorrheic and NMC women exposed to a psychological stressor [349], and no major differences in GH or IGF-1 responses during exercise bouts could be detected in AM compared to NMC endurance athletes recruited from national teams and competitive clubs [65].

- COC women (Table 3)

There is a clear consensus that baseline blood and saliva TES concentrations decrease with COC use [12,335,350–352], possibly due to an increase in SHBG concentration, although the extent of the reduction was variable across women [181]. However, Edwards et al. [353] found the same TES increase over the course of the competition, whereas Crewther et al. [351] reported reduced TES responses to training and competition with COCs. From an anabolic viewpoint, this decrease in TES may be compensated by the increase in GH. Indeed, most studies have shown higher GH both at rest and during exercise in temperate or hot environments with COCs [38,348,354], probably because of elevated levels of total estrogens, while there are too few works to conclude on IGF-1 [36,348].

Table 3. Detailed results about anabolic hormone responses.

	NMC Women	AM Women	COC Women
TES	<p>Rest: No consensus</p> <ul style="list-style-type: none"> No change [334–336] or ↗ in PeO [339] <p>Exercise: No consensus</p> <ul style="list-style-type: none"> ↗ or not in F during exercise [186,337] or ↗ in MiL [338] 	<p>Too few studies</p> <ul style="list-style-type: none"> ↘ [346] 	<p>Rest: Consensus</p> <ul style="list-style-type: none"> ↘ (30–50%) vs. non-users [12,335,350–352] <p>Exercise: No consensus</p> <ul style="list-style-type: none"> No change [353] ↘ responses to training and competition [351]
GH	<p>Consensus</p> <ul style="list-style-type: none"> ↗ in PeO [38,341–344] 	<p>No consensus</p> <ul style="list-style-type: none"> ↗ with distorted pattern of pulses [36,347,348] No change vs. NMC to exercise or psychological stressor [349] 	<p>Consensus</p> <ul style="list-style-type: none"> ↗ at rest and during exercise in temperate or hot environment [38,348,354]
IGF-1	<p>No consensus</p> <ul style="list-style-type: none"> No change [342,345] ↗ in PeO parallel to GH [343,344] 	<p>Too few studies</p> <ul style="list-style-type: none"> No change vs. NMC in exercise levels of endurance athletes [65] 	<p>Too few studies</p> <ul style="list-style-type: none"> No change vs. NMC [36,348]

Legend: ↗: increase; ↘: decrease.

3.5.2. Other Hormones

- NMC women

Cortisol levels at rest and during exercise appear to be independent of the MC phase, with the same increment in response to prolonged submaximal exercise [335,355–358] as adrenocorticotrophic hormone (ACTH) [355]. However, cortisol responses to awakening remain discrepant, with either no change across MC [359,360] or a blunted response in LaL and EaF [361,362]. The relationship between changes in E2 and PG and thyrotropin (TSH), T3, and PRL concentrations with or without stimulation has been investigated, with little or no effect observed [363,364]. Submaximal exercise elicits increases in plasma arginine, vasopressin, and renin independent of MC [355,365], but aldosterone appears significantly elevated during MiL [365]. MC does not affect beta-endorphin, insulin, C-peptide, amylin, glucagon, leptin, or adiponectin, with the same responses to prolonged exercise during EaF and MiL [58,358,366].

- AM women

Most [347,348,357,367–370] but not all studies [65,371,372] have shown higher basal cortisol levels in AM vs. NMC athletes, with inverse associations between cortisol and LH [370]. This mild hypercortisolism could be due to extrapituitary modulators of adrenal responsiveness to ACTH [373] and interpreted as a redistribution of adrenal steroid metabolism in favor of glucocorticoid production to ensure adequate blood glucose levels in a condition of energy deficiency [368]. Cortisol responses to exercise, however, appeared blunted in most studies [372,373], possibly due to a normal limitation of adrenal secretory capacity [373]. In contrast, some studies observed either a larger cortisol increment in AM athletes in response to exercise [357] or the same response as in NMC athletes [65,374], despite a smaller cumulative ACTH response in the CRF test, which was interpreted as functional changes due to intensive training [374]. Several authors have reported decreased total T3 in AM athletes, coupled with lower energy intake and availability [31–33],

increased insulin sensitivity and decreased insulin levels [372,373,375], providing a mechanism through which adipose tissue detects energy deficiency and, in turn, downregulates leptin gene expression and secretion, with parallel hypoleptinemia [375]. There is, however, no consensus for PRL. Indeed, normal basal and stimulated PRL levels were found in women runners with menstrual dysfunction [376]. In contrast, Rickenlund et al. [36] reported that the 24-h hormone profiles in AM athletes were characterized by a decreased peak amplitude of PRL, and in some studies, but not all [65], the failure of PRL to increase in response to exercise has been highlighted [369,372], possibly due to the lack of E2 [372]. Hothari et al. [374] but not Meyer et al. [377] reported higher basal beta-endorphin in AM subjects, whereas the response to exercise was similar in AM and NMC athletes [366,377,378], suggesting that the MC alterations in AM athletes are probably not due to an increase in opioid tone. Last, resting levels of aldosterone seemed to be higher [365], and a reduced adrenergic response to intense exercise was shown in AM athletes [371] that might decrease performance by reducing the sympathetic drive essential for the cardiovascular and metabolic adjustments needed.

- COC women

COC use has been associated with increased resting blood, saliva cortisol, or urinary cortisol [350,356,379], with similar change [350] or a blunted response [351,354,356] to exercise, with or without a training effect. However, other studies observed no change in cortisol levels in moderately trained subjects or elite female athletes [335,380,381], either at rest or after exercise, indicating a similar immune-endocrine function in both temperate and hot environments [381]. Weeke et al. [364] reported an increase in TSH with COC vs. NMC, with similar fasting plasma glucose, C-peptide, insulin, and adiponectin levels [58,382]. Yet, Rickenlund et al. [348] reported that COC treatment was able to correct the lower levels of insulin in endurance athletes with menstrual disturbance, suggesting that COCs improve metabolic balance in AM athletes.

3.5.3. Metabolism and Immunity

- NMC women

The literature suggests that E2 may alter carbohydrate (CHO), fat and protein metabolism antagonistically to PG, which often appears to promote proteolysis and lipolysis. In parallel, both E2 and PG were reported to suppress gluconeogenic output during exercise [383]. Some studies have thus reported greater lipid oxidation in L, with higher glucose rates of appearance and disappearance during exercise in F than in L [384,385]. These effects were found to be blunted or completely annulated by CHO supplementation, however, during prolonged exercise [384,386]. Other works have shown that maximal peripheral lipolysis during exercise was not significantly affected across MC, either at rest or during moderate exercise [387], with no change in substrate oxidation in NMC females in EaF, MiF, and MiL [388,389]. Both worse [390] and better [391] running economies in L vs. F have been reported. In the same way, data on blood markers of muscle damage and inflammation [creatinine kinase (CK), myoglobin, lactate dehydrogenase, IL-6, tumor necrosis factor alpha (TNF α), and CRP] are discrepant in well-trained women, with [350] or without [392,393] an impact of MC phase, with higher concentrations of pro-inflammatory interleukins in PMS vs. non-PMS women [45]. Only few studies investigated the variations in immunity in trained NMC female runners without respiratory disorders and reported no significant change across MC [293,394].

- AM women

No differences in ratings of perceived exertion or plasma lactate were found between AM and NMC runners following maximal and submaximal exercise tests [256], whereas blood glucose was either decreased [28] or not [371] in AM vs. NMC athletes. Data on inflammatory markers and endothelial function (TNF α , IL-6, CRP, CK, soluble vascular adhesion molecule-1, cholesterol, triglycerides, glutathione peroxidase, and reductase) are

discrepant with no change [379], or altered [395,396] or improved [397] values in AM vs. NMC subjects. Last, lower saliva IgA levels were observed in AM vs. NMC athletes [295].

- COC women

Some authors have explored performance and metabolic responses to COCs in parallel, with mixed results [31,33,35,37,38]. Studies not exploring physical performance have also reported divergent results with COCs, with either no decreases in overall CHO and lipid oxidation rates [398] or an increase in fat oxidation during prolonged exercise with a concomitant rise in lipolytic hormones [354,389,399,400], suggesting a preference for lipid metabolism by skeletal muscle in COC vs. NMC women, although this disappeared during heavy exercise. Moreover, it seems that the fed or fasting conditions for exercise performance have a greater impact on substrate oxidation than COCs [400]. In some studies, COC use was reported to increase total and LDL cholesterol [30,36,67,379], with elevated chronic low-grade inflammation and oxidative stress that could be detrimental to physical activity and elevate cardiovascular risk [401], such as basal CRP [379,380] alone [380] or combined with TNF α [379]. During exercise, an increase in CK [402,403] and a decrease in IL-6 with COCs vs. F was reported in moderate-level athletes [350], although this was blunted in elite female athletes [380]. No other cytokine change was found in either temperate or hot conditions [381], but COC users vs. non-users were reported to have an impaired sweating onset threshold and thermosensitivity [404].

3.6. Anti-Doping: Athlete Biological Passport (ABP)

The World Anti-Doping Agency (WADA) officially implemented the ABP in 2009 to monitor variations in defined biomarkers over time [405]. The ABP has three modules: hematological, steroidal, and endocrinological. The hematological module was the first to be introduced, with the aim of detecting any form of blood doping. The steroidal module was launched in 2014 with the aim of detecting doping with anabolic agents. The third endocrinological module to detect doping with growth factors has not yet been implemented. The objective of the passport is to provide a profile of the individual athlete's variables as a guide for detecting doping practices. Its strength is the personalized threshold values calculated for each athlete on the basis of population data and the previous results obtained for this athlete, which allows for precise monitoring of markers. All the results from anti-doping tests are recorded, and the passports are generated on the dedicated ADAMS (Anti-Doping Administrative & Management System) platform. The construction of these modules was based on the study of multiparametric markers obtained in great part from the data from large population studies [406,407].

3.6.1. ABP: Steroidal Module

- NMC women

Since the urine concentrations of steroidal hormones such as testosterone (T), epitestosterone (E), androsterone (A), etiocholanolone (Etio), 5 α -androstane-3 α ,17 β -diol (5 α Adiol) and 5 β -androstane-3 α ,17 β -diol (5 β Adiol) are recorded for the establishment of the ABP, understanding the natural hormonal fluctuations in female athletes is of the utmost importance especially given the physiological phenomena that can affect these biomarkers. Indeed, Kuuraane et al. [408] pointed out that sex has an effect, with lower concentrations of these biomarkers in females compared to males. Mareck-Engelke et al. [409,410] performed the first studies in female subjects and established that one of the most sensitive markers, the T/E ratio, was significantly dependent on MC. This observation was more recently confirmed by other authors [411,412], who studied urinary steroid profiles throughout the MC in healthy female volunteers and concluded that E was one of the biomarkers that fluctuated the most. In addition, Schulze et al. [412] established that T and its metabolites exhibited higher concentrations in PeO, with similar variations over two consecutive MCs, but inter-individual variations remained very high. Recently, Mullen et al. [413] demonstrated that the variability of the ABP biomarkers in Swedish and Norwegian athletes was

higher in females compared to males. Last, Knutsson et al. [414] observed lower levels of E in PeO and higher levels of 5 α Adiol in L in women with moderate to high self-reported levels of recreational physical activity.

- COC women

Studies have been performed with COC and emergency (i.e., progestin-only, levonorgestrel) contraceptives in healthy women [415] or elite athletes [416]. One of the main results was that E concentrations were significantly lower in COC users vs. non-users, whereas T showed no difference, leading to a higher T/E ratio. No impact was observed on the A/Etio ratio or the 5 α Adiol/5 β Adiol ratio. With emergency contraceptives tested in few subjects, significantly lower concentrations were observed for E, A, Etio, and 5 β Adiol, although none of the ratios monitored in the ABP changed significantly.

- Women with other drug administration

The intake of some drugs can impact the steroid profile, the most studied substance in this field being anabolic androgenic steroids (AAS). Buisson et al. [417] investigated the effect of oral intake of 100 mg DHEA per day over 4 weeks for 11 female subjects training regularly. The ADAMS platform indicated that 10 of the 11 passports were clearly suspicious, with most of the ratios exceeding the individual threshold. Knutsson et al. [414] studied in 24 women the impact of 10 weeks of treatment with 10 mg testosterone cream and reported atypical results, mainly for the T/E ratio in 6 subjects, with only 2 subjects having an atypical 5 α Adiol/E ratio [418,419]. Sometimes, athletes can only be tested once, and in such cases, the interpretation of a stand-alone data item can be complicated, especially for female athletes. For example, in women self-reporting the use of enanthate testosterone gel [420] or in testosterone doping cases [421], the urine steroid profile could not be considered suspicious in view of the single test results, but the serum samples lead to higher suspicious TES concentrations. In addition, a few works have been performed on other prohibited substances [422], such as nonsteroidal aromatase inhibitors (letrozole, aminoglutethimide, and anastrozole), showing an increased concentration of all steroid profile parameters for at least one month, but not enough to indicate doping.

3.6.2. ABP: Hematological Module

For the purpose of detecting any form of blood doping, 12 blood parameters are recorded on the ADAMS platform for each doping test performed on athletes: hematocrit, hemoglobin (HBG), immature reticulocyte fraction, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular volume, platelets, red blood cell count, red cell distribution width, reticulocyte count, reticulocytes percentage (RET%), and white blood cells (TD2019BAR). HBG and RET% remain the main biomarkers monitored longitudinally, as well as two scores: the OFF-hr Score (OFFS) and the Abnormal Blood Profile Score (ABPS) calculated automatically for each test result [423,424].

- NMC women

Only one study examined the impact of MC in healthy women [425]. Lower RET% in F vs. PeO and L was found, with no difference in HBG, hematocrit, and red blood cell count. The authors concluded that most of the module parameters were stable throughout MC, but they emphasized the importance of information on iron supplementation when evaluating hematological passports. It should be noted, however, that no study to date has been conducted on female athletes and that none has investigated the impact of AM or COC use.

- Women with other drug administration

One study [426] investigated the impact of MC on the GH biomarkers after administration of growth hormone-releasing hormone (GHRH) in young, healthy NMC women vs. men. Whereas IGF-1 provided the most promising results to detect GHRH administration in male subjects, monitoring the women's GH biomarkers longitudinally appeared more

challenging because of the much greater intra-individual variation probably linked to the hormonal status.

4. Practical Considerations and Perspectives

4.1. Summary of Current Knowledge and Limitations

4.1.1. Impact of Hormonal Status on Physical and Cognitive Performance

Most of the studies on elite female athletes have shown no significant change in physical performance across MC, although it should be noted that no study tested prolonged endurance exercise. Most of them reported a better mood with high E2 levels, with a correlation between PG levels and subjective anxiety and a huge negative effect in LaL and EaF in women suffering from PMS. However, there is no consensus, as a wide range of inter-individual responses was noted, and most works failed to directly investigate in parallel the impact of the MC phase on performance and psychological mood states. There is no study on the MC impact on postural and motor control in elite athletes. Regarding AM athletes, it is not possible to conclude on the potential direct short- and medium-term effects of the lack of E2 and PG, and altered endurance or resistance, mood, coordination, and memory performance may occur. The results on COC use have not been conclusive, whatever the type of exercise, as various central or peripheral changes have not been confirmed or correlated with performances over time. Similarly, no conclusions can be drawn on the emotion-related positive or negative effects of COC. It should be noted that only the effects of COCs have been studied, most often in monophasic administration, yet increasingly more athletes are using bi- or triphasic COCs or progestin-only contraceptives.

4.1.2. Impact of Hormonal Status on Health Risks

LaL and EaF, when E2 and PG concentrations are at their lowest, may be deleterious to some of the mental and/or physical health parameters, whereas high PG levels might limit the risk of ACL injuries. Yet caution is required until all these findings are specifically validated in the elite athlete population. Both food intake and fat mass are known to be greatly decreased in many AM athletes, often with parallel lower fat-free mass. In NMC and COC athletes, data are much more inconclusive, and the mechanisms remain unelucidated. The very low E2 levels in AM athletes predispose them to a greater risk to bone health, which nevertheless appears blunted by high-strain physical training. The early initiation of COC use may alter bone health, but most studies indicate a possible beneficial effect of hormonal contraception in AM athletes, although this depends on the administration route. In addition, COC use seems to reduce the risk of ACL injury because of the progestative component, although no clear conclusions can be drawn at this time. The limited studies on the impact of hormonal status on visuospatial abilities, verbal skills, executive functions, and postural and motor control have been inconclusive for sedentary or recreationally trained women. The data to date, however, do not rule out or contradict the possibility that E2 and PG influence cognitive and motor function in elite athletes, who are confronted with much more difficult and highly specific tasks. Part of cardiovascular function is unquestionably modulated by hormonal status. Indeed, although baroreflex sensitivity does not change with hormonal status in NMC, AM, or COC women, resting HVR appears modified during L with an increased sympathetic tone, probably resulting from an altered balance between E2 and PG. There are, however, contradictory data with COCs and too few studies during exercise. No change in VO_2 max across MC was noted in young, healthy women without respiratory disorders, and the higher ventilatory drive observed in L in untrained subjects is blunted with training. There is consensus regarding the negative repercussions of L and COC use on asthma in sedentary and recreational women, with the involvement of PG and, to a lesser extent, E2, but studies are still needed in elite female athletes, as the effects of AM on EIB and URTI remain unknown. Although female athletes often experience alterations in urinary function, this is unrelated to hormonal status, in contrast to gastrointestinal function, which is significantly impacted in LaL and EaF. Regarding the endocrine and metabolic impact of MC, it clearly

does not influence basal cortisol levels, whereas GH levels are increased via E2 at ovulation. There is no consensus for the other hormones because of either the contradictory results or the insufficient number of studies. Similarly, and contrary to an ingrained belief, there is no consensus on significant metabolic changes between F and L and with COC intake, with only small differences, if any, in a fasting state, which seems to be offset by food intake. In AM athletes with energy deficiency, there is a drop in basal T3, insulin, leptin, and IgA but with metabolism more adapted to the lack of sex hormones than actually altered. TES levels are significantly lowered with COCs, with most studies showing an increase in GH concentrations, probably thanks to their estrogen component. CRP and CK levels appear to be increased under COC use, but mechanisms remain to be determined, and there are too many discrepancies for the other hormonal or metabolic markers to conclude. Last, the impact of hormonal status on the steroidal module of the ABP is significant for the T/E ratio, with only one study on the hematological module. Given the possible confounding factors, new investigations in elite athletes are essential to confirm and interpret the ABP data, which was mainly obtained in healthy sedentary women.

4.1.3. Limitations

As we have seen, a consensus has been difficult to reach on most of the results, regardless of the parameters, and it is therefore difficult/impossible to draw strong conclusions. We identified the major methodological shortcomings that might influence the strength of the deductions and limit the current knowledge.

First, it must be highlighted that: (i) many studies were performed with extremely small sample sizes, significantly limiting their power, especially given the very wide inter-individual variations in E2 and PG concentrations; (ii) reproducibility between cycles was rarely studied; (iii) many studies followed cross-sectional designs with sometimes no or an inadequate control group, which can strongly bias the results because variability in hormone levels and physical or cognitive capacity cannot be accounted for.

Second, comparisons were often made: (i) without checking the exact time in the phase for the E2 and PG measurements, despite the great variability of MC duration, particularly with a shortened luteal phase; (ii) without sufficient precision, often with only one data point in F and one in L; (iii) without taking into account whether or not a participant suffered from PMS; (iv) using mean values, which mask individual effects regarding who is more impacted and therefore more at risk; (v) without controlling for the great diversity of estrogen/progestin doses and the progestative molecules of the different COCs, all of which are parameters that can interfere with the results; and (vi) without taking into account progestin-only use, either oral or IUD.

Third, (i) composite scores for cognitive tasks may have prevented the detection of specific effects on cognitive processes; and (ii) tasks that were too easy for healthy young women, who generally have high cognitive capacity, may have resulted in a ceiling effect.

Fourth, the very limited number of studies on the influence of hormonal status on the performance and health of the very specific population of elite athletes is surprising.

4.2. New Approach to Ensure Optimal Performance and Health

In the future, studies should include large panels of elite female athletes and ensure objective and precise measurements of the different moments of the follicular and luteal phases (EaF, MiF, LaF, PeO, EaL, MiL, LaL), taking into account the extended or shortened durations of these phases. Other factors that should be included are the presence or not of PMS and the doses and molecules of hormonal contraception, if any.

We here present lines of research that we think should be priorities and that would benefit from a multidisciplinary approach that takes into account the athlete's environment. Indeed, it is obvious that the impact of hormonal status on the female athlete's life can only be understood and taken into account when it is considered within the context of a specific sports discipline, with simultaneous analyses of the cognitive, emotional, and physical markers, using multidisciplinary methods that break down the barriers between

field and laboratory studies. This research will permit the development of an innovative and personalized approach not only to ensure the optimal performance of elite female athletes on D-Day but also to maintain their good health during and after their careers. It therefore appears crucial to set up a longitudinal battery of complementary physical, psychological and sensorimotor tests, along with questionnaires, to determine as accurately as possible the physical and mental state corresponding to each hormonal status in order to optimize the performances and health of elite female athletes, whether or not they suffer from PMS or airway disorders. In addition, specific elicitation interviews might be proposed to address emotional variations, whether connoted positively or negatively by the athlete herself [427], in order to provide insight into the articulations/transitions between emotions and actions [428]. This situated activity-based approach used not only in simulated but also in real-life sports situations [429–431] analyzes the meanings of situations from the athlete's point of view from a narrative of experience in its actual dynamics and complexity. By examining decision-making and technical or operational choices, it would therefore be possible to determine the effective strategies that elite athletes use. The effect of hormonal status has never been explored, but it seems likely that it modulates benchmarks used in action. This could result in inappropriate technical decisions during the execution of an action, thus decreasing the performance of elite female athletes at certain hormonal phases. Other factors in the environment of elite female athletes have also been neglected and yet are crucial. Indeed, responses to the training load may depend on the MC phase. To optimize the training load for maximal performance, i.e., limiting the risk of overreaching/overtraining or injuries, the first step is to accurately quantify the load. Particular attention should be paid to the environments that are increasingly popular with athletes of both genders, such as training at altitude and hypoxia. Competitions, especially when held in extreme conditions, as in ultra-endurance running [432] and cold-water swimming [433], may potentiate hormonal status repercussions in the female athlete through the additional psychological/physiological stress. Exposure to pollution such as particulate matter 10 μm (PM10), nitrogen dioxide (NO₂), fluorinated organic compounds, and pesticides has also recently been suggested to perturb women's follicular phase duration, cycle regularity, and fertility [434–436]. As endurance athletes are increasingly exposed to these pollutants through inhalation during training or routes such as clothing and food/drink packaging, it is essential to take them into account in future studies on MC disruption and hormonal variations in female athletes over the course of their sports careers. Similarly, although numerous studies have focused on the insufficient energy intake of AM athletes, curiously few have focused on the food intake of female athletes who are not considered as energy deficient. However, nutritional intake is certainly essential and directly linked to the metabolism of these athletes during the cycle or with COC use. It therefore may be necessary to strictly monitor both food intake and metabolism in NMC and COC athletes, without overlooking the microbiota, which probably has a non-negligible impact on mental and physical health, performance and the ABP. Moreover, the evolution of EIB and the prevalence of the use of beta-agonists and glucocorticoids based on the hormonal status of elite female athletes should be investigated, as they may affect their physical and psychological performances and health in the short, medium or long term and may also be confounding factors on their ABP.

5. Conclusions

As pointed out in this review, the current knowledge on elite female athletes remains sparse and discrepant. A longitudinal multidisciplinary approach may be the best research choice to obtain early, sensitive, and specific tools that are able to determine whether the phase of the cycle, the absence of the cycle, or the use of various contraceptives has an impact on the physical and cognitive performances of elite female athletes. Monitoring would also determine whether these elite athletes have distinct hormone-dependent profiles and would help define new psycho-physiological performance and health markers that take into account the athlete's environment: training load and competition stress,

psychological and emotional state, food intake, and respiratory tract disorders with the use of therapeutic substances.

Author Contributions: All authors contributed to the scientific research presented. C.C., C.T., S.S.-L., A.V. and C.L.-S. contributed to the psychological and cognitive aspects presented. V.B., C.J., N.V.-R., N.R. and K.C. contributed to the physiological and clinical aspects presented. C.B. contributed to the Athlete Biological Passport presentation. C.C. was in charge of the graphical abstract, and K.C. was in charge of the supervision of the article. All authors collaborated and formed a consensus on the resulting conclusions and recommendations. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: The authors would like to thank the other members of the *FEMMES (FEMale MEdals in Sport)* team as well as Cathy Carmen, Nathalie Crépin, Magnus Ericsson, and Sandra Ferary for their expert assistance.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

5 α Adiol	urinary 5 α -androstane-3 α :17 β -diol
5 β Adiol	urinary 5 β -androstane-3 α ,17 β -diol
A	urinary androsterone
ABP	athlete biological passport
ABPS	abnormal blood profil score
ACL	anterior cruciate ligament
ACTH	adrenocorticotrophic hormone
AM	amenorrhea
BMD	bone mineral density
CCK	cholecystokinin
CHO	carbohydrate
CK	creatine kinase
CNS	central nervous system
COC	combined oral contraceptive
CRF	cortisol-releasing factor
CRP	C-reactive protein
DHEA	dehydroepiandrosterone
DXA	dual-energy absorptiometry
E	urinary epitestosterone
E2	estradiol
EaF	early follicular phase
EaL	early luteal phase
Etio	urinary etiocholanolone
F	follicular phase
FAT	female athlete triad
FEV ₁	forced expiratory volume in one second
FSH	follicle-stimulating hormone
GI	gastrointestinal symptom
GLP-1	glucagon-like-peptide-1
GH	growth hormone
GHRH	growth hormone-releasing hormone
GnRH	gonadotrophin-releasing hormone
HBG	hemoglobin
HF	high-frequency peak (HRV)
HR	heart rate
HRV	heart rate variability
ICTP	type 1 carboxyterminal telopeptide

IgA	immunoglobulin A
IGF-1	insulin-like growth factor
IGFBP-1	insulin-like growth factor-binding protein-1
IGFBP-3	insulin-like growth factor-binding protein-3
IL-6	interleukin-6
IOC	International Olympic Committee
IUD	intrauterine device
L	luteal phase
LaF	late follicular phase
LaL	late luteal phase
LF	low-frequency peak (HRV)
LH	luteinizing hormone
MC	menstrual cycle
MiF	mid-follicular phase
MiL	mid-luteal phase
NMC	normal menstrual cycle
NO	nitric oxide
OFFS	OFF-hr Score
PaCO ₂	arterial partial pressure of carbon dioxide
PC ₂₀	provocative concentration of methacholine that results in a 20% drop in FEV1
PeO	peri-ovulatory time
PETCO ₂	end-tidal carbon dioxide
PG	progesterone
PMA	premenstrual asthma
PMS	premenstrual syndrome
POMS	profile of mood state
PRL	prolactin
RED-S	relative energy deficiency in sport
RET%	reticulocytes percentage
SaO ₂	blood oxygen saturation
SHBG	sex hormone-binding globulin
T3	tri-iodothyronine
T	urinary testosterone
T/E	urinary testosterone/epitestosterone ratio
TES	blood testosterone
TNF α	tumor necrosis factor alpha
TSH	thyrotropin
UI	urinary incontinence
URTI	upper respiratory tract infection
VE	ventilation
VE/VCO ₂	carbon dioxide ventilatory equivalent
VE/VO ₂	oxygen ventilatory equivalent
VO ₂	oxygen consumption
VO ₂ max	maximal oxygen consumption

References

1. Hargreaves, J. *Sporting Females: Critical Issues in the History and Sociology of Women's Sport*. Available online: <https://www.routledge.com/Sporting-Females-Critical-Issues-in-the-History-and-Sociology-of-Womens/Hargreaves/p/book/9780415070287> (accessed on 26 April 2021).
2. Sims, S.T.; Heather, A.K. Myths and Methodologies: Reducing Scientific Design Ambiguity in Studies Comparing Sexes and/or Menstrual Cycle Phases. *Exp. Physiol.* **2018**, *103*, 1309–1317. [[CrossRef](#)]
3. Johnson, J.L.; Greaves, L.; Repta, R. Better Science with Sex and Gender: Facilitating the Use of a Sex and Gender-Based Analysis in Health Research. *Int. J. Equity Health* **2009**, *8*, 14. [[CrossRef](#)]
4. De Souza, M.J. Menstrual Disturbances in Athletes: A Focus on Luteal Phase Defects. *Med. Sci. Sports Exerc.* **2003**, *35*, 1553–1563. [[CrossRef](#)] [[PubMed](#)]
5. DiMarco, C.S. Speroff L, Glass RH, Kase NG, Editors. *Clinical Gynecologic Endocrinology and Infertility*. 6th Ed. Baltimore: Lippincott, Williams & Wilkins, 1999:1–1200. *Fertil. Steril.* **2000**, *74*, 425–426. [[CrossRef](#)]

6. Nattiv, A.; Agostini, R.; Drinkwater, B.; Yeager, K.K. The Female Athlete Triad. The Inter-Relatedness of Disordered Eating, Amenorrhea, and Osteoporosis. *Clin. Sports Med.* **1994**, *13*, 405–418. [[CrossRef](#)]
7. Oxfeldt, M.; Dalgaard, L.B.; Jørgensen, A.A.; Hansen, M. Hormonal Contraceptive Use, Menstrual Dysfunctions, and Self-Reported Side Effects in Elite Athletes in Denmark. *Int. J. Sports Physiol. Perform.* **2020**, *15*, 1377–1384. [[CrossRef](#)] [[PubMed](#)]
8. Torstveit, M.K.; Sundgot-Borgen, J. The Female Athlete Triad: Are Elite Athletes at Increased Risk? *Med. Sci. Sports Exerc.* **2005**, *37*, 184–193. [[CrossRef](#)] [[PubMed](#)]
9. Cheng, J.; Santiago, K.A.; Abutalib, Z.; Temme, K.E.; Hulme, A.; Goolsby, M.A.; Esopenko, C.L.; Casey, E.K. Menstrual Irregularity, Hormonal Contraceptive Use, and Bone Stress Injuries in Collegiate Female Athletes in the United States. *PM & R* **2020**. [[CrossRef](#)]
10. Larsen, B.; Morris, K.; Quinn, K.; Osborne, M.; Minahan, C. Practice Does Not Make Perfect: A Brief View of Athletes' Knowledge on the Menstrual Cycle and Oral Contraceptives. *J. Sci. Med. Sport* **2020**, *23*, 690–694. [[CrossRef](#)]
11. Martin, D.; Sale, C.; Cooper, S.B.; Elliott-Sale, K.J. Period Prevalence and Perceived Side Effects of Hormonal Contraceptive Use and the Menstrual Cycle in Elite Athletes. *Int. J. Sports Physiol. Perform.* **2018**, *13*, 926–932. [[CrossRef](#)]
12. Zimmerman, Y.; Eijkemans, M.J.C.; Coelingh Bennink, H.J.T.; Blankenstein, M.A.; Fauser, B.C.J.M. The Effect of Combined Oral Contraception on Testosterone Levels in Healthy Women: A Systematic Review and Meta-Analysis. *Hum. Reprod. Update* **2014**, *20*, 76–105. [[CrossRef](#)]
13. Schaumberg, M.A.; Emmerton, L.M.; Jenkins, D.G.; Burton, N.W.; Janse de Jonge, X.A.K.; Skinner, T.L. Use of Oral Contraceptives to Manipulate Menstruation in Young, Physically Active Women. *Int. J. Sports Physiol. Perform.* **2018**, *13*, 82–87. [[CrossRef](#)] [[PubMed](#)]
14. McNulty, K.L.; Elliott-Sale, K.J.; Dolan, E.; Swinton, P.A.; Ansdell, P.; Goodall, S.; Thomas, K.; Hicks, K.M. The Effects of Menstrual Cycle Phase on Exercise Performance in Eumenorrheic Women: A Systematic Review and Meta-Analysis. *Sports Med.* **2020**, *50*, 1813–1827. [[CrossRef](#)] [[PubMed](#)]
15. Elliott-Sale, K.J.; McNulty, K.L.; Ansdell, P.; Goodall, S.; Hicks, K.M.; Thomas, K.; Swinton, P.A.; Dolan, E. The Effects of Oral Contraceptives on Exercise Performance in Women: A Systematic Review and Meta-Analysis. *Sports Med.* **2020**, *50*, 1785–1812. [[CrossRef](#)] [[PubMed](#)]
16. Hertel, J.; Williams, N.I.; Olmsted-Kramer, L.C.; Leidy, H.J.; Putukian, M. Neuromuscular Performance and Knee Laxity Do Not Change across the Menstrual Cycle in Female Athletes. *Knee Surg. Sports Traumatol. Arthr.* **2006**, *14*, 817–822. [[CrossRef](#)]
17. Tsampoukos, A.; Peckham, E.A.; James, R.; Nevill, M.E. Effect of Menstrual Cycle Phase on Sprinting Performance. *Eur. J. Appl. Physiol.* **2010**, *109*, 659–667. [[CrossRef](#)]
18. Julian, R.; Hecksteden, A.; Fullagar, H.H.K.; Meyer, T. The Effects of Menstrual Cycle Phase on Physical Performance in Female Soccer Players. *PLoS ONE* **2017**, *12*, e0173951. [[CrossRef](#)] [[PubMed](#)]
19. Tounsi, M.; Jaafar, H.; Aloui, A.; Souissi, N. Soccer-Related Performance in Eumenorrheic Tunisian High-Level Soccer Players: Effects of Menstrual Cycle Phase and Moment of Day. *J. Sports Med. Phys. Fit.* **2018**, *58*, 497–502. [[CrossRef](#)]
20. Köse, B. Analysis of the Effect of Menstrual Cycle Phases on Aerobic-Anaerobic Capacity and Muscle Strength. *J. Educ. Train. Stud.* **2018**, *6*, 23. [[CrossRef](#)]
21. Romero-Moraleda, B.; Coso, J.D.; Gutiérrez-Hellín, J.; Ruiz-Moreno, C.; Grgic, J.; Lara, B. The Influence of the Menstrual Cycle on Muscle Strength and Power Performance. *J. Hum. Kinet.* **2019**, *68*, 123–133. [[CrossRef](#)]
22. Štefanovský, M.; Péterová, A.; Vanderka, M.; Lengvarský, L. Influence of Selected Phases of the Menstrual Cycle on Performance in Special Judo Fitness Test and Wingate Test. *Acta Gymnica* **2016**, *46*, 136–142. [[CrossRef](#)]
23. Gordon, D.; Hughes, F.; Young, K.; Scruton, A.; Keiller, D.; Caddy, O.; Baker, J.; Barnes, R. The Effects of Menstrual Cycle Phase on the Development of Peak Torque under Isokinetic Conditions. *Isokinet. Exerc. Sci.* **2013**, *21*. [[CrossRef](#)]
24. Burrows, M.; Bird, S. Velocity at VO₂ Max and Peak Treadmill Velocity Are Not Influenced within or across the Phases of the Menstrual Cycle. *Eur. J. Appl. Physiol.* **2005**, *93*, 575–580. [[CrossRef](#)]
25. Vaiksaar, S.; Jürimäe, J.; Mäestu, J.; Purge, P.; Kalytka, S.; Shakhlina, L.; Jürimäe, T. No Effect of Menstrual Cycle Phase and Oral Contraceptive Use on Endurance Performance in Rowers. *J. Strength Cond. Res.* **2011**, *25*, 1571–1578. [[CrossRef](#)] [[PubMed](#)]
26. Kishali, N.F.; Imamoglu, O.; Katkat, D.; Atan, T.; Akyol, P. Effects of Menstrual Cycle on Sports Performance. *Int. J. Neurosci.* **2006**, *116*, 1549–1563. [[CrossRef](#)] [[PubMed](#)]
27. Vanheest, J.L.; Rodgers, C.D.; Mahoney, C.E.; De Souza, M.J. Ovarian Suppression Impairs Sport Performance in Junior Elite Female Swimmers. *Med. Sci. Sports Exerc.* **2014**, *46*, 156–166. [[CrossRef](#)]
28. Tornberg, Å.B.; Melin, A.; Koivula, F.M.; Johansson, A.; Skouby, S.; Faber, J.; Sjödin, A. Reduced Neuromuscular Performance in Amenorrheic Elite Endurance Athletes. *Med. Sci. Sports Exerc.* **2017**, *49*, 2478–2485. [[CrossRef](#)] [[PubMed](#)]
29. Ackerman, K.E.; Holtzman, B.; Cooper, K.M.; Flynn, E.F.; Bruinvels, G.; Tenforde, A.S.; Popp, K.L.; Simpkin, A.J.; Parziale, A.L. Low Energy Availability Surrogates Correlate with Health and Performance Consequences of Relative Energy Deficiency in Sport. *Br. J. Sports Med.* **2019**, *53*, 628–633. [[CrossRef](#)]
30. Peters, C.; Burrows, M. Androgenicity of the Progestin in Oral Contraceptives Does Not Affect Maximal Leg Strength. *Contraception* **2006**, *74*, 487–491. [[CrossRef](#)]
31. Lebrun, C.M.; Petit, M.A.; McKenzie, D.C.; Taunton, J.E.; Prior, J.C. Decreased Maximal Aerobic Capacity with Use of a Triphasic Oral Contraceptive in Highly Active Women: A Randomised Controlled Trial. *Br. J. Sports Med.* **2003**, *37*, 315–320. [[CrossRef](#)]
32. Rechichi, C.; Dawson, B. Effect of Oral Contraceptive Cycle Phase on Performance in Team Sport Players. *J. Sci. Med. Sport* **2009**, *12*, 190–195. [[CrossRef](#)]

33. Rechichi, C.; Dawson, B. Oral Contraceptive Cycle Phase Does Not Affect 200-m Swim Time Trial Performance. *J. Strength Cond. Res.* **2012**, *26*, 961–967. [[CrossRef](#)]
34. Redman, L.M.; Weatherby, R.P. Measuring Performance during the Menstrual Cycle: A Model Using Oral Contraceptives. *Med. Sci. Sports Exerc.* **2004**, *36*, 130–136. [[CrossRef](#)]
35. Reilly, T.; Whitley, H. Effects of Menstrual Cycle Phase and Oral Contraceptive Use on Endurance Exercise. *J. Sports Sci.* **1994**, *2*, 150.
36. Rickenlund, A.; Carlström, K.; Ekblom, B.; Brismar, T.B.; Von Schoultz, B.; Hirschberg, A.L. Effects of Oral Contraceptives on Body Composition and Physical Performance in Female Athletes. *J. Clin. Endocrinol. Metab.* **2004**, *89*, 4364–4370. [[CrossRef](#)]
37. Rechichi, C.; Dawson, B.; Goodman, C. Oral Contraceptive Phase Has No Effect on Endurance Test. *Int. J. Sports Med.* **2008**, *29*, 277–281. [[CrossRef](#)]
38. Sunderland, C.; Nevill, M. Effect of the Menstrual Cycle on Performance of Intermittent, High-Intensity Shuttle Running in a Hot Environment. *Eur. J. Appl. Physiol.* **2003**, *88*, 345–352. [[CrossRef](#)]
39. Cockerill, I.M.; Nevill, A.M.; Byrne, N.C. Mood, Mileage and the Menstrual Cycle. *Br. J. Sports Med.* **1992**, *26*, 145–150. [[CrossRef](#)]
40. Brown, N.; Knight, C.J.; Forrest Née Whyte, L.J. Elite Female Athletes' Experiences and Perceptions of the Menstrual Cycle on Training and Sport Performance. *Scand. J. Med. Sci. Sports* **2021**, *31*, 52–69. [[CrossRef](#)]
41. Bruinvels, G.; Burden, R.; Brown, N.; Richards, T.; Pedlar, C. The Prevalence and Impact of Heavy Menstrual Bleeding (Menorrhagia) in Elite and Non-Elite Athletes. *PLoS ONE* **2016**, *11*, e0149881. [[CrossRef](#)]
42. Bruinvels, G.; Goldsmith, E.; Blagrove, R.; Simpkin, A.; Lewis, N.; Morton, K.; Suppiah, A.; Rogers, J.P.; Ackerman, K.E.; Newell, J.; et al. Prevalence and Frequency of Menstrual Cycle Symptoms Are Associated with Availability to Train and Compete: A Study of 6812 Exercising Women Recruited Using the Strava Exercise App. *Br. J. Sports Med.* **2021**, *55*, 438–443. [[CrossRef](#)] [[PubMed](#)]
43. Solli, G.S.; Sandbakk, S.B.; Noordhof, D.A.; Ihalainen, J.K.; Sandbakk, Ø. Changes in Self-Reported Physical Fitness, Performance, and Side Effects Across the Phases of the Menstrual Cycle Among Competitive Endurance Athletes. *Int. J. Sports Physiol. Perform.* **2020**, *15*, 1324–1333. [[CrossRef](#)] [[PubMed](#)]
44. Foster, R.; Vaisberg, M.; de Araújo, M.P.; Martins, M.A.; Capel, T.; Bachi, A.L.L.; de Bella, Z.I.K.J.-D. Relationship between Anxiety and Interleukin 10 in Female Soccer Players with and Without Premenstrual Syndrome (PMS). *Rev. Bras. Ginecol. Obs.* **2017**, *39*, 602–607. [[CrossRef](#)] [[PubMed](#)]
45. Foster, R.; Vaisberg, M.; Bachi, A.L.L.; de Dos Santos, J.M.B.; de Paula Vieira, R.; Luna-Junior, L.A.; Araújo, M.P.; Parmigiano, T.R.; Borges, F.; Di-Bella, Z.I.K.J. Premenstrual Syndrome, Inflammatory Status, and Mood States in Soccer Players. *Neuroimmunomodulation* **2019**, *26*, 1–6. [[CrossRef](#)]
46. Findlay, R.J.; Macrae, E.H.R.; Whyte, I.Y.; Easton, C.; Forrest Née Whyte, L.J. How the Menstrual Cycle and Menstruation Affect Sporting Performance: Experiences and Perceptions of Elite Female Rugby Players. *Br. J. Sports Med.* **2020**, *54*, 1108–1113. [[CrossRef](#)]
47. Baskaran, C.; Plessow, F.; Ackerman, K.E.; Singhal, V.; Eddy, K.T.; Misra, M. A Cross-Sectional Analysis of Verbal Memory and Executive Control across Athletes with Varying Menstrual Status and Non-Athletes. *Psychiatry Res.* **2017**, *258*, 605–606. [[CrossRef](#)]
48. Baskaran, C.; Cunningham, B.; Plessow, F.; Singhal, V.; Woolley, R.; Ackerman, K.E.; Slattery, M.; Lee, H.; Lawson, E.A.; Eddy, K.; et al. Estrogen Replacement Improves Verbal Memory and Executive Control in Oligomenorrheic/Amenorrheic Athletes in a Randomized Controlled Trial. *J. Clin. Psychiatry* **2017**, *78*, e490–e497. [[CrossRef](#)]
49. Brennan, I.M.; Feltrin, K.L.; Nair, N.S.; Hausken, T.; Little, T.J.; Gentilcore, D.; Wishart, J.M.; Jones, K.L.; Horowitz, M.; Feinle-Bisset, C. Effects of the Phases of the Menstrual Cycle on Gastric Emptying, Glycemia, Plasma GLP-1 and Insulin, and Energy Intake in Healthy Lean Women. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2009**, *297*, G602–G610. [[CrossRef](#)]
50. Hormes, J.M.; Timko, C.A. All Cravings Are Not Created Equal. Correlates of Menstrual versus Non-Cyclic Chocolate Craving. *Appetite* **2011**, *57*, 1–5. [[CrossRef](#)]
51. Bryant, M.; Truesdale, K.P.; Dye, L. Modest Changes in Dietary Intake across the Menstrual Cycle: Implications for Food Intake Research. *Br. J. Nutr.* **2006**, *96*, 888–894. [[CrossRef](#)]
52. McNeil, J.; Doucet, É. Possible Factors for Altered Energy Balance across the Menstrual Cycle: A Closer Look at the Severity of PMS, Reward Driven Behaviors and Leptin Variations. *Eur. J. Obs. Gynecol. Reprod. Biol.* **2012**, *163*, 5–10. [[CrossRef](#)] [[PubMed](#)]
53. Kammoun, I.; Ben Saâda, W.; Sifaou, A.; Haouat, E.; Kandara, H.; Ben Salem, L.; Ben Slama, C. Change in Women's Eating Habits during the Menstrual Cycle. *Ann. Endocrinol.* **2017**, *78*, 33–37. [[CrossRef](#)] [[PubMed](#)]
54. Tucci, S.A.; Murphy, L.E.; Boyland, E.J.; Halford, J.C. Influence of premenstrual syndrome and oral contraceptive effects on food choice during the follicular and luteal phase of the menstrual cycle. *Endocrinol. Nutr.* **2009**, *56*, 170–175. [[CrossRef](#)]
55. Rossi, K.A. Nutritional Aspects of the Female Athlete. *Clin. Sports Med.* **2017**, *36*, 627–653. [[CrossRef](#)] [[PubMed](#)]
56. Thein-Nissenbaum, J.M.; Rauh, M.J.; Carr, K.E.; Loud, K.J.; McGuine, T.A. Associations between Disordered Eating, Menstrual Dysfunction, and Musculoskeletal Injury among High School Athletes. *J. Orthop. Sports Phys.* **2011**, *41*, 60–69. [[CrossRef](#)]
57. Jürimäe, J.; Vaiksaar, S.; Mäestu, J.; Purge, P.; Jürimäe, T. Adiponectin and Bone Metabolism Markers in Female Rowers: Eumenorrheic and Oral Contraceptive Users. *J. Endocrinol. Investig.* **2011**, *34*, 835–839. [[CrossRef](#)]
58. Rael, B.; Romero-Parra, N.; Alfaro-Magallanes, V.M.; Barba-Moreno, L.; Cupeiro, R.; Janse de Jonge, X.; Peinado, A.B.; IronFEMME Study Group. Body Composition Over the Menstrual and Oral Contraceptive Cycle in Trained Females. *Int. J. Sports Physiol. Perform.* **2020**, 375–381. [[CrossRef](#)]
59. Stachon, A.J. Menstrual Changes in Body Composition of Female Athletes. *Coll. Antropol.* **2016**, *40*, 111–122.

60. Mountjoy, M.; Sundgot-Borgen, J.; Burke, L.; Carter, S.; Constantini, N.; Lebrun, C.; Meyer, N.; Sherman, R.; Steffen, K.; Budgett, R.; et al. The IOC Consensus Statement: Beyond the Female Athlete Triad—Relative Energy Deficiency in Sport (RED-S). *Br. J. Sports Med.* **2014**, *48*, 491–497. [[CrossRef](#)]
61. Ackerman, K.E.; Slusarz, K.; Guereca, G.; Pierce, L.; Slattery, M.; Mendes, N.; Herzog, D.B.; Misra, M. Higher Ghrelin and Lower Leptin Secretion Are Associated with Lower LH Secretion in Young Amenorrheic Athletes Compared with Eumenorrheic Athletes and Controls. *Am. J. Physiol. Endocrinol. Metab.* **2012**, *302*, E800–E806. [[CrossRef](#)]
62. Carlberg, K.A.; Buckman, M.T.; Peake, G.T.; Riedesel, M.L. Body Composition of Oligo/Amenorrheic Athletes. *Med. Sci. Sports Exerc.* **1983**, *15*, 215–217. [[CrossRef](#)]
63. Loucks, A.B.; Horvath, S.M. Athletic Amenorrhea: A Review. *Med. Sci. Sports Exerc.* **1985**, *17*, 56–72. [[CrossRef](#)] [[PubMed](#)]
64. Singhal, V.; de Lourdes Eguiguren, M.; Eisenbach, L.; Clarke, H.; Slattery, M.; Eddy, K.; Ackerman, K.E.; Misra, M. Body Composition, Hemodynamic, and Biochemical Parameters of Young Female Normal-Weight Oligo-Amenorrheic and Eumenorrheic Athletes and Nonathletes. *Ann. Nutr. Metab.* **2014**, *65*, 264–271. [[CrossRef](#)] [[PubMed](#)]
65. Melin, A.K.; Ritz, C.; Faber, J.; Skouby, S.; Pingel, J.; Sundgot-Borgen, J.; Sjödin, A.; Tornberg, Å.B. Impact of Menstrual Function on Hormonal Response to Repeated Bouts of Intense Exercise. *Front. Physiol.* **2019**, *10*, 942. [[CrossRef](#)] [[PubMed](#)]
66. Friedrich, M.; Junak, M. Assessment of Dietary Choices of Young Women in the Contexts of Hormonal Contraceptives. *Rocz. Panstw. Zakl. Hig.* **2017**, *68*, 69–76.
67. Nakamura, M.; Nose-Ogura, S. Effect of Administration of Monophasic Oral Contraceptive on the Body Composition and Aerobic and Anaerobic Capacities of Female Athletes. *J. Obs. Gynaecol. Res.* **2021**, *47*, 792–799. [[CrossRef](#)]
68. Casazza, G.A.; Suh, S.-H.; Miller, B.F.; Navazio, F.M.; Brooks, G.A. Effects of Oral Contraceptives on Peak Exercise Capacity. *J. Appl. Physiol.* **2002**, *93*, 1698–1702. [[CrossRef](#)]
69. Khosla, S.; Monroe, D.G. Regulation of Bone Metabolism by Sex Steroids. *Cold Spring Harb. Perspect. Med.* **2018**, *8*. [[CrossRef](#)]
70. Martin, D.; Cooper, S.B.; Tang, J.C.Y.; Fraser, W.D.; Sale, C.; Elliott-Sale, K.J. Bone Metabolic Marker Concentrations across the Menstrual Cycle and Phases of Combined Oral Contraceptive Use. *Bone* **2021**, *145*, 115864. [[CrossRef](#)]
71. Monson, J.P.; Drake, W.M.; Carroll, P.V.; Weaver, J.U.; Rodriguez-Arnao, J.; Savage, M.O. Influence of Growth Hormone on Accretion of Bone Mass. *Horm. Res.* **2002**, *58* (Suppl. 1), 52–56. [[CrossRef](#)]
72. De Souza, M.J.; Williams, N.I. Beyond Hypoestrogenism in Amenorrheic Athletes: Energy Deficiency as a Contributing Factor for Bone Loss. *Curr. Sports Med. Rep.* **2005**, *4*, 38–44. [[CrossRef](#)] [[PubMed](#)]
73. Papageorgiou, M.; Dolan, E.; Elliott-Sale, K.J.; Sale, C. Reduced Energy Availability: Implications for Bone Health in Physically Active Populations. *Eur. J. Nutr.* **2018**, *57*, 847–859. [[CrossRef](#)] [[PubMed](#)]
74. Iida, T.; Chikamura, C.; Ishikawa, H.; Aoi, S.; Ikeda, H.; Harada, T.; Katada, K.; Ishizaki, F.; Yatsuya, H.; Ono, Y. Factors Predicting Bone Mineral Density (BMD) Changes in Young Women over a One-Year Study: Changes in Body Weight and Bone Metabolic Markers during the Menstrual Cycle and Their Effects on BMD. *Acta Med. Okayama* **2012**, *66*, 9.
75. Mozzanega, B.; Gizzo, S.; Bernardi, D.; Salmasso, L.; Patrelli, T.S.; Mioni, R.; Finos, L.; Nardelli, G.B. Cyclic Variations of Bone Resorption Mediators and Markers in the Different Phases of the Menstrual Cycle. *J. Bone Min. Metab.* **2013**, *31*, 461–467. [[CrossRef](#)]
76. Krahenbühl, T.; de Guimarães, R.F.; de Barros Filho, A.A.; Gonçalves, E.M. Bone geometry and physical activity in children and adolescents: Systematic review. *Rev. Paul. Pediatr.* **2018**, *36*, 230–237. [[CrossRef](#)] [[PubMed](#)]
77. Lanhers, C.; Courteix, D.; Valente-Dos-Santos, J.; Ferry, B.; Gracia-Marco, L.; Pereira, B.; Borda, I.M.; Lespessailles, E.; Duclos, M. Gonadal Hormones May Predict Structural Bone Fragility in Elite Female Soccer Player. *J. Sports Sci.* **2020**, *38*, 827–837. [[CrossRef](#)]
78. Hewett, T.E.; Zazulak, B.T.; Myer, G.D. Effects of the Menstrual Cycle on Anterior Cruciate Ligament Injury Risk: A Systematic Review. *Am. J. Sports Med.* **2007**, *35*, 659–668. [[CrossRef](#)]
79. Drago, J.L.; Castillo, T.N.; Korotkova, T.A.; Kennedy, A.C.; Kim, H.J.; Stewart, D.R. Trends in Serum Relaxin Concentration among Elite Collegiate Female Athletes. *Int. J. Womens Health* **2011**, *3*, 19–24. [[CrossRef](#)]
80. Khowailed, I.A.; Petrofsky, J.; Lohman, E.; Daher, N.; Mohamed, O. 17 β -Estradiol Induced Effects on Anterior Cruciate Ligament Laxness and Neuromuscular Activation Patterns in Female Runners. *J. Womens Health* **2015**, *24*, 670–680. [[CrossRef](#)]
81. Herzberg, S.D.; Motu'apuaka, M.L.; Lambert, W.; Fu, R.; Brady, J.; Guise, J.-M. The Effect of Menstrual Cycle and Contraceptives on ACL Injuries and Laxity: A Systematic Review and Meta-Analysis. *Orthop. J. Sports Med.* **2017**, *5*, 2325967117718781. [[CrossRef](#)] [[PubMed](#)]
82. Somerson, J.S.; Isby, I.J.; Hagen, M.S.; Kweon, C.Y.; Gee, A.O. The Menstrual Cycle May Affect Anterior Knee Laxity and the Rate of Anterior Cruciate Ligament Rupture: A Systematic Review and Meta-Analysis. *JBS Rev.* **2019**, *7*, e2. [[CrossRef](#)] [[PubMed](#)]
83. Belanger, M.J.; Moore, D.C.; Crisco, J.J.; Fadale, P.D.; Hulstyn, M.J.; Ehrlich, M.G. Knee Laxity Does Not Vary with the Menstrual Cycle, before or after Exercise. *Am. J. Sports Med.* **2004**, *32*, 1150–1157. [[CrossRef](#)] [[PubMed](#)]
84. Beynon, B.D.; Bernstein, I.M.; Belisle, A.; Brattbakk, B.; Devanny, P.; Risinger, R.; Durant, D. The Effect of Estradiol and Progesterone on Knee and Ankle Joint Laxity. *Am. J. Sports Med.* **2005**, *33*, 1298–1304. [[CrossRef](#)] [[PubMed](#)]
85. Brook, E.M.; Tenforde, A.S.; Broad, E.M.; Matzkin, E.G.; Yang, H.Y.; Collins, J.E.; Blauwet, C.A. Low Energy Availability, Menstrual Dysfunction, and Impaired Bone Health: A Survey of Elite Para Athletes. *Scand. J. Med. Sci. Sports* **2019**, *29*, 678–685. [[CrossRef](#)] [[PubMed](#)]
86. Thein-Nissenbaum, J.; Hammer, E. Treatment Strategies for the Female Athlete Triad in the Adolescent Athlete: Current Perspectives. *Open Access J. Sports Med.* **2017**, *8*, 85–95. [[CrossRef](#)] [[PubMed](#)]

87. Maimoun, L.; Coste, O.; Georgopoulos, N.A.; Roupas, N.D.; Mahadea, K.K.; Tsouka, A.; Mura, T.; Philibert, P.; Gaspari, L.; Mariano-Goulart, D.; et al. Despite a High Prevalence of Menstrual Disorders, Bone Health Is Improved at a Weight-Bearing Bone Site in World-Class Female Rhythmic Gymnasts. *J. Clin. Endocrinol. Metab.* **2013**, *98*, 4961–4969. [[CrossRef](#)]
88. Singhal, V.; Reyes, K.C.; Pfister, B.; Ackerman, K.; Slattery, M.; Cooper, K.; Toth, A.; Gupta, N.; Goldstein, M.; Eddy, K.; et al. Bone Accrual in Oligo-Amenorrhoeic Athletes, Eumenorrhoeic Athletes and Non-Athletes. *Bone* **2019**, *120*, 305–313. [[CrossRef](#)] [[PubMed](#)]
89. Christo, K.; Prabhakaran, R.; Lamparello, B.; Cord, J.; Miller, K.K.; Goldstein, M.A.; Gupta, N.; Herzog, D.B.; Klibanski, A.; Misra, M. Bone Metabolism in Adolescent Athletes with Amenorrhea, Athletes with Eumenorrhoea, and Control Subjects. *Pediatrics* **2008**, *121*, 1127–1136. [[CrossRef](#)]
90. Hadji, P.; Colli, E.; Regidor, P.-A. Bone Health in Estrogen-Free Contraception. *Osteoporos Int.* **2019**, *30*, 2391–2400. [[CrossRef](#)]
91. Kuohung, W.; Borgatta, L.; Stubblefield, P. Low-Dose Oral Contraceptives and Bone Mineral Density: An Evidence-Based Analysis. *Contraception* **2000**, *61*, 77–82. [[CrossRef](#)]
92. Lopez, L.M.; Grimes, D.A.; Schulz, K.F.; Curtis, K.M.; Chen, M. Steroidal Contraceptives: Effect on Bone Fractures in Women. *Cochrane Database Syst. Rev.* **2014**, CD006033. [[CrossRef](#)] [[PubMed](#)]
93. Reed, S.D.; Scholes, D.; LaCroix, A.Z.; Ichikawa, L.E.; Barlow, W.E.; Ott, S.M. Longitudinal Changes in Bone Density in Relation to Oral Contraceptive Use. *Contraception* **2003**, *68*, 177–182. [[CrossRef](#)]
94. Almstedt, H.C.; Cook, M.M.; Bramble, L.F.; Dabir, D.V.; LaBrie, J.W. Oral Contraceptive Use, Bone Mineral Density, and Bone Turnover Markers over 12 Months in College-Aged Females. *J. Bone Min. Metab.* **2020**, *38*, 544–554. [[CrossRef](#)]
95. Brajic, T.S.; Berger, C.; Schlammerl, K.; Macdonald, H.; Kalyan, S.; Hanley, D.A.; Adachi, J.D.; Kovacs, C.S.; Prior, J.C.; CaMos Research Group. Combined Hormonal Contraceptives Use and Bone Mineral Density Changes in Adolescent and Young Women in a Prospective Population-Based Canada-Wide Observational Study. *J. Musculoskelet. Neuronal. Interact.* **2018**, *18*, 227–236.
96. Cobb, K.L.; Bachrach, L.K.; Sowers, M.; Nieves, J.; Greendale, G.A.; Kent, K.K.; Brown, B.W.; Pettit, K.; Harper, D.M.; Kelsey, J.L. The Effect of Oral Contraceptives on Bone Mass and Stress Fractures in Female Runners. *Med. Sci. Sports Exerc.* **2007**, *39*, 1464–1473. [[CrossRef](#)] [[PubMed](#)]
97. Dadgostar, H.; Soleimany, G.; Movaseghi, S.; Dadgostar, E.; Lotfian, S. The Effect of Hormone Therapy on Bone Mineral Density and Cardiovascular Factors among Iranian Female Athletes with Amenorrhea/Oligomenorrhea: A Randomized Clinical Trial. *Med. J. Islam Repub. Iran.* **2018**, *32*, 27. [[CrossRef](#)]
98. Singhal, V.; Ackerman, K.E.; Bose, A.; Flores, L.P.T.; Lee, H.; Misra, M. Impact of Route of Estrogen Administration on Bone Turnover Markers in Oligoamenorrhoeic Athletes and Its Mediators. *J. Clin. Endocrinol. Metab.* **2019**, *104*, 1449–1458. [[CrossRef](#)]
99. Ackerman, K.E.; Singhal, V.; Baskaran, C.; Slattery, M.; Campoverde Reyes, K.J.; Toth, A.; Eddy, K.T.; Bouxsein, M.L.; Lee, H.; Klibanski, A.; et al. Oestrogen Replacement Improves Bone Mineral Density in Oligo-Amenorrhoeic Athletes: A Randomised Clinical Trial. *Br. J. Sports Med.* **2019**, *53*, 229–236. [[CrossRef](#)]
100. Hicks-Little, C.A.; Thatcher, J.R.; Hauth, J.M.; Goldfuss, A.J.; Cordova, M.L. Menstrual Cycle Stage and Oral Contraceptive Effects on Anterior Tibial Displacement in Collegiate Female Athletes. *J. Sports Med. Phys. Fit.* **2007**, *47*, 255–260.
101. Konopka, J.A.; Hsue, L.; Chang, W.; Thio, T.; Dragoo, J.L. The Effect of Oral Contraceptive Hormones on Anterior Cruciate Ligament Strength. *Am. J. Sports Med.* **2020**, *48*, 85–92. [[CrossRef](#)]
102. Samuelson, K.; Balk, E.M.; Severson, E.L.; Fleming, B.C. Limited Evidence Suggests a Protective Association Between Oral Contraceptive Pill Use and Anterior Cruciate Ligament Injuries in Females: A Systematic Review. *Sports Health* **2017**, *9*, 498–510. [[CrossRef](#)]
103. Nose-Ogura, S.; Yoshino, O.; Yamada-Nomoto, K.; Nakamura, M.; Harada, M.; Dohi, M.; Okuwaki, T.; Osuga, Y.; Kawahara, T.; Saito, S. Oral Contraceptive Therapy Reduces Serum Relaxin-2 in Elite Female Athletes. *J. Obs. Gynaecol. Res.* **2017**, *43*, 530–535. [[CrossRef](#)]
104. Sherwin, B.B. Estrogen and Cognitive Functioning in Women. *Endocr. Rev.* **2003**, *24*, 133–151. [[CrossRef](#)]
105. Singh, M.; Su, C. Progesterone and Neuroprotection. *Horm. Behav.* **2013**, *63*, 284–290. [[CrossRef](#)]
106. Hampson, E. Regulation of Cognitive Function by Androgens and Estrogens. *Curr. Opin. Behav. Sci.* **2018**, *23*, 49–57. [[CrossRef](#)]
107. Brinton, R.D.; Thompson, R.F.; Foy, M.R.; Baudry, M.; Wang, J.; Finch, C.E.; Morgan, T.E.; Pike, C.J.; Mack, W.J.; Stanczyk, F.Z.; et al. Progesterone Receptors: Form and Function in Brain. *Front. Neuroendocr.* **2008**, *29*, 313–339. [[CrossRef](#)] [[PubMed](#)]
108. Hara, Y.; Waters, E.M.; McEwen, B.S.; Morrison, J.H. Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. *Physiol. Rev.* **2015**, *95*, 785–807. [[CrossRef](#)] [[PubMed](#)]
109. Rubin, R.D.; Watson, P.D.; Duff, M.C.; Cohen, N.J. The Role of the Hippocampus in Flexible Cognition and Social Behavior. *Front. Hum. Neurosci.* **2014**, *8*, 742. [[CrossRef](#)] [[PubMed](#)]
110. Toffoletto, S.; Lanzenberger, R.; Gingnell, M.; Sundström-Poromaa, I.; Comasco, E. Emotional and Cognitive Functional Imaging of Estrogen and Progesterone Effects in the Female Human Brain: A Systematic Review. *Psychoneuroendocrinology* **2014**, *50*, 28–52. [[CrossRef](#)]
111. Barth, C.; Villringer, A.; Sacher, J. Sex Hormones Affect Neurotransmitters and Shape the Adult Female Brain during Hormonal Transition Periods. *Front. Neurosci.* **2015**, *9*, 37. [[CrossRef](#)]
112. Comasco, E.; Frokjaer, V.G.; Sundström-Poromaa, I. Functional and Molecular Neuroimaging of Menopause and Hormone Replacement Therapy. *Front. Neurosci.* **2014**, *8*, 388. [[CrossRef](#)] [[PubMed](#)]

113. Sotomayor-Zárate, R.; Cruz, G.; Renard, G.; Espinosa, P.; Ramirez, V. Sex Hormones and Brain Dopamine Functions. *Cent. Nerv. Syst. Agents Med. Chem.* **2014**, *14*. [[CrossRef](#)]
114. Maccoby, E.; Jacklin, C. Sex Differences in Intellectual Functioning. In *Proceedings of the Invitational Conference on Testing Problems*; American Psychological Association (APA): New York, NY, USA, 1972; pp. 37–55.
115. Kimura, D. Sex and Cognition | The MIT Press. Available online: <https://mitpress.mit.edu/books/sex-and-cognition> (accessed on 26 April 2021).
116. Sundström Poromaa, I.; Gingnell, M. Menstrual Cycle Influence on Cognitive Function and Emotion Processing—from a Reproductive Perspective. *Front. Neurosci.* **2014**, *8*, 380. [[CrossRef](#)] [[PubMed](#)]
117. Sundström-Poromaa, I. The Menstrual Cycle Influences Emotion but Has Limited Effect on Cognitive Function. *Vitam Horm* **2018**, *107*, 349–376. [[CrossRef](#)] [[PubMed](#)]
118. Beltz, A.M.; Moser, J.S. Ovarian Hormones: A Long Overlooked but Critical Contributor to Cognitive Brain Structures and Function. *Ann. N. Y. Acad. Sci.* **2020**, *1464*, 156–180. [[CrossRef](#)]
119. Le, J.; Thomas, N.; Gurvich, C. Cognition, The Menstrual Cycle, and Premenstrual Disorders: A Review. *Brain Sci.* **2020**, *10*, 198. [[CrossRef](#)]
120. Andreano, J.M.; Cahill, L. Sex Influences on the Neurobiology of Learning and Memory. *Learn. Mem.* **2009**, *16*, 248–266. [[CrossRef](#)]
121. Courvoisier, D.S.; Renaud, O.; Geiser, C.; Paschke, K.; Gaudy, K.; Jordan, K. Sex Hormones and Mental Rotation: An Intensive Longitudinal Investigation. *Horm. Behav.* **2013**, *63*, 345–351. [[CrossRef](#)]
122. Hampson, E.; Levy-Cooperman, N.; Korman, J.M. Estradiol and Mental Rotation: Relation to Dimensionality, Difficulty, or Angular Disparity? *Horm. Behav.* **2014**, *65*, 238–248. [[CrossRef](#)]
123. Maki, P.M.; Rich, J.B.; Shayna Rosenbaum, R. Implicit Memory Varies across the Menstrual Cycle: Estrogen Effects in Young Women. *Neuropsychologia* **2002**, *40*, 518–529. [[CrossRef](#)]
124. Griksiene, R.; Ruksenas, O. Effects of Hormonal Contraceptives on Mental Rotation and Verbal Fluency. *Psychoneuroendocrinology* **2011**, *36*, 1239–1248. [[CrossRef](#)] [[PubMed](#)]
125. Mordecai, K.L.; Rubin, L.H.; Maki, P.M. Effects of Menstrual Cycle Phase and Oral Contraceptive Use on Verbal Memory. *Horm. Behav.* **2008**, *54*, 286–293. [[CrossRef](#)]
126. Zhu, X.; Kelly, T.H.; Curry, T.E.; Lal, C.; Joseph, J.E. Altered Functional Brain Asymmetry for Mental Rotation: Effect of Estradiol Changes across the Menstrual Cycle. *Neuroreport* **2015**, *26*, 814–819. [[CrossRef](#)] [[PubMed](#)]
127. Pletzer, B.; Kronbichler, M.; Ladurner, G.; Nuerk, H.-C.; Kerschbaum, H. Menstrual Cycle Variations in the BOLD-Response to a Number Bisection Task: Implications for Research on Sex Differences. *Brain Res.* **2011**, *1420*, 37–47. [[CrossRef](#)] [[PubMed](#)]
128. Hussain, D.; Hanafi, S.; Konishi, K.; Brake, W.G.; Bohbot, V.D. Modulation of Spatial and Response Strategies by Phase of the Menstrual Cycle in Women Tested in a Virtual Navigation Task. *Psychoneuroendocrinology* **2016**, *70*, 108–117. [[CrossRef](#)]
129. Scheuringer, A.; Pletzer, B. Sex Differences and Menstrual Cycle Dependent Changes in Cognitive Strategies during Spatial Navigation and Verbal Fluency. *Front. Psychol.* **2017**, *8*, 381. [[CrossRef](#)]
130. Solís-Ortiz, S.; Corsi-Cabrera, M. Sustained Attention Is Favored by Progesterone during Early Luteal Phase and Visuo-Spatial Memory by Estrogens during Ovulatory Phase in Young Women. *Psychoneuroendocrinology* **2008**, *33*, 989–998. [[CrossRef](#)]
131. Gulinello, M.; Gong, Q.H.; Smith, S.S. Progesterone Withdrawal Increases the Alpha4 Subunit of the GABA(A) Receptor in Male Rats in Association with Anxiety and Altered Pharmacology—A Comparison with Female Rats. *Neuropharmacology* **2002**, *43*, 701–714. [[CrossRef](#)]
132. Rosenberg, L.; Park, S. Verbal and Spatial Functions across the Menstrual Cycle in Healthy Young Women. *Psychoneuroendocrinology* **2002**, *27*, 835–841. [[CrossRef](#)]
133. Hatta, T.; Nagaya, K. Menstrual Cycle Phase Effects on Memory and Stroop Task Performance. *Arch. Sex. Behav.* **2009**, *38*, 821–827. [[CrossRef](#)]
134. Jacobs, E.; D’Esposito, M. Estrogen Shapes Dopamine-Dependent Cognitive Processes: Implications for Women’s Health. *J. Neurosci.* **2011**, *31*, 5286–5293. [[CrossRef](#)]
135. Rumberg, B.; Baars, A.; Fiebach, J.; Ladd, M.E.; Forsting, M.; Senf, W.; Gizewski, E.R. Cycle and Gender-Specific Cerebral Activation during a Verb Generation Task Using fMRI: Comparison of Women in Different Cycle Phases, under Oral Contraception, and Men. *Neurosci. Res.* **2010**, *66*, 366–371. [[CrossRef](#)]
136. Solís-Ortiz, S.; Guevara, M.A.; Corsi-Cabrera, M. Performance in a Test Demanding Prefrontal Functions Is Favored by Early Luteal Phase Progesterone: An Electroencephalographic Study. *Psychoneuroendocrinology* **2004**, *29*, 1047–1057. [[CrossRef](#)] [[PubMed](#)]
137. Colzato, L.S.; Pratt, J.; Hommel, B. Estrogen Modulates Inhibition of Return in Healthy Human Females. *Neuropsychologia* **2012**, *50*, 98–103. [[CrossRef](#)] [[PubMed](#)]
138. Thimm, M.; Weis, S.; Hausmann, M.; Sturm, W. Menstrual Cycle Effects on Selective Attention and Its Underlying Cortical Networks. *Neuroscience* **2014**, *258*, 307–317. [[CrossRef](#)] [[PubMed](#)]
139. Engler-Chiurazzi, E.B.; Singh, M.; Simpkins, J.W. Reprint of: From the 90’s to Now: A Brief Historical Perspective on More than Two Decades of Estrogen Neuroprotection. *Brain Res.* **2016**, *1645*, 79–82. [[CrossRef](#)]
140. Hampson, E.; Morley, E.E. Estradiol Concentrations and Working Memory Performance in Women of Reproductive Age. *Psychoneuroendocrinology* **2013**, *38*, 2897–2904. [[CrossRef](#)]
141. Warren, A.M.; Gurvich, C.; Worsley, R.; Kulkarni, J. A Systematic Review of the Impact of Oral Contraceptives on Cognition. *Contraception* **2014**, *90*, 111–116. [[CrossRef](#)] [[PubMed](#)]

142. Gogos, A. Natural and Synthetic Sex Hormones: Effects on Higher-Order Cognitive Function and Prepulse Inhibition. *Biol. Psychol.* **2013**, *93*, 17–23. [[CrossRef](#)]
143. Islam, F.; Sparkes, C.; Roodenrys, S.; Astheimer, L. Short-Term Changes in Endogenous Estrogen Levels and Consumption of Soy Isoflavones Affect Working and Verbal Memory in Young Adult Females. *Nutr. Neurosci.* **2008**, *11*, 251–262. [[CrossRef](#)] [[PubMed](#)]
144. Beltz, A.M.; Hampson, E.; Berenbaum, S.A. Oral Contraceptives and Cognition: A Role for Ethinyl Estradiol. *Horm. Behav.* **2015**, *74*, 209–217. [[CrossRef](#)] [[PubMed](#)]
145. Cicinelli, E.; De Tommaso, M.; Cianci, A.; Colacurci, N.; Rella, L.; Loiudice, L.; Cicinelli, M.V.; Livrea, P. Oral Contraceptive Therapy Modulates Hemispheric Asymmetry in Spatial Attention. *Contraception* **2011**, *84*, 634–636. [[CrossRef](#)] [[PubMed](#)]
146. McFadden, D. Masculinizing Effects on Otoacoustic Emissions and Auditory Evoked Potentials in Women Using Oral Contraceptives. *Hear. Res.* **2000**, *142*, 23–33. [[CrossRef](#)]
147. Griksiene, R.; Monciunskaitė, R.; Arnatkeviciute, A.; Ruksenas, O. Does the Use of Hormonal Contraceptives Affect the Mental Rotation Performance? *Horm. Behav.* **2018**, *100*, 29–38. [[CrossRef](#)] [[PubMed](#)]
148. Wharton, W.; Hirshman, E.; Merritt, P.; Doyle, L.; Paris, S.; Gleason, C. Oral Contraceptives and Androgenicity: Influences on Visuospatial Task Performance in Younger Individuals. *Exp. Clin. Psychopharmacol.* **2008**, *16*, 156–164. [[CrossRef](#)]
149. Gurchich, C.; Warren, A.M.; Worsley, R.; Hudaib, A.-R.; Thomas, N.; Kulkarni, J. Effects of Oral Contraceptive Androgenicity on Visuospatial and Social-Emotional Cognition: A Prospective Observational Trial. *Brain Sci.* **2020**, *10*, 194. [[CrossRef](#)] [[PubMed](#)]
150. Mihalik, J.P.; Ondrak, K.S.; Guskiewicz, K.M.; McMurray, R.G. The Effects of Menstrual Cycle Phase on Clinical Measures of Concussion in Healthy College-Aged Females. *J. Sci. Med. Sport* **2009**, *12*, 383–387. [[CrossRef](#)]
151. Nielsen, S.E.; Ertman, N.; Lakhani, Y.S.; Cahill, L. Hormonal Contraception Usage Is Associated with Altered Memory for an Emotional Story. *Neurobiol. Learn. Mem.* **2011**, *96*, 378–384. [[CrossRef](#)]
152. Holloway, J.L.; Beck, K.D.; Servatius, R.J. Facilitated Acquisition of the Classically Conditioned Eyeblink Response in Females Is Augmented in Those Taking Oral Contraceptives. *Behav. Brain Res.* **2011**, *216*, 301–307. [[CrossRef](#)]
153. Rosen, M.L.; López, H.H. Menstrual Cycle Shifts in Attentional Bias for Courtship Language. *Evol. Hum. Behav.* **2009**, *30*, 131–140. [[CrossRef](#)]
154. Farage, M.A.; Osborn, T.W.; MacLean, A.B. Cognitive, Sensory, and Emotional Changes Associated with the Menstrual Cycle: A Review. *Arch. Gynecol. Obs.* **2008**, *278*, 299–307. [[CrossRef](#)] [[PubMed](#)]
155. Derntl, B.; Windischberger, C.; Robinson, S.; Lamplmayr, E.; Kryspin-Exner, I.; Gur, R.C.; Moser, E.; Habel, U. Facial Emotion Recognition and Amygdala Activation Are Associated with Menstrual Cycle Phase. *Psychoneuroendocrinology* **2008**, *33*, 1031–1040. [[CrossRef](#)] [[PubMed](#)]
156. Reynolds, T.A.; Makhanova, A.; Marcinkowska, U.M.; Jasienska, G.; McNulty, J.K.; Eckel, L.A.; Nikonova, L.; Maner, J.K. Progesterone and Women’s Anxiety across the Menstrual Cycle. *Horm. Behav.* **2018**, *102*, 34–40. [[CrossRef](#)]
157. Baker, F.C.; Driver, H.S. Circadian Rhythms, Sleep, and the Menstrual Cycle. *Sleep. Med.* **2007**, *8*, 613–622. [[CrossRef](#)] [[PubMed](#)]
158. Golub, S. *Lifting the Curse of Menstruation: A Feminist Appraisal of the Influence of Menstruation on Women’s Lives*; Routledge: New York, NY, USA, 2017; ISBN 978-1-317-95973-1.
159. Woods, N.F.; Most, A.; Dery, G.K. Prevalence of Perimenstrual Symptoms. *Am. J. Public Health* **1982**, *72*, 1257–1264. [[CrossRef](#)]
160. Alonso, C.; Coe, C. Disruptions of Social Relationships Accentuate the Association between Emotional Distress and Menstrual Pain in Young Women. *Health Psychol.* **2001**, *20*, 411–416. [[CrossRef](#)]
161. Chen, H.-M.; Chen, C.-H. Related Factors and Consequences of Menstrual Distress in Adolescent Girls with Dysmenorrhea. *Kaohsiung J. Med. Sci.* **2005**, *21*, 121–127. [[CrossRef](#)]
162. Dorn, L.D.; Negriff, S.; Huang, B.; Pabst, S.; Hillman, J.; Braverman, P.; Susman, E.J. Menstrual Symptoms in Adolescent Girls: Association with Smoking, Depressive Symptoms, and Anxiety. *J. Adolesc. Health* **2009**, *44*, 237–243. [[CrossRef](#)]
163. Iacovides, S.; Avidon, I.; Baker, F.C. What We Know about Primary Dysmenorrhea Today: A Critical Review. *Hum. Reprod. Update* **2015**, *21*, 762–778. [[CrossRef](#)]
164. Matteson, K.A.; Zaluski, K.M. Menstrual Health as a Part of Preventive Health Care. *Obs. Gynecol. Clin. N. Am.* **2019**, *46*, 441–453. [[CrossRef](#)]
165. Koikawa, N.; Takami, Y.; Kawasaki, Y.; Kawana, F.; Shiroshita, N.; Ogasawara, E.; Kasai, T. Changes in the Objective Measures of Sleep between the Initial Nights of Menses and the Nights during the Midfollicular Phase of the Menstrual Cycle in Collegiate Female Athletes. *J. Clin. Sleep Med.* **2020**, *16*, 1745–1751. [[CrossRef](#)]
166. Shechter, A.; Boivin, D.B. Sleep, Hormones, and Circadian Rhythms throughout the Menstrual Cycle in Healthy Women and Women with Premenstrual Dysphoric Disorder. *Int. J. Endocrinol.* **2010**, *2010*, e259345. [[CrossRef](#)] [[PubMed](#)]
167. Woosley, J.A.; Lichstein, K.L. Dysmenorrhea, the Menstrual Cycle, and Sleep. *Behav. Med.* **2014**, *40*, 14–21. [[CrossRef](#)] [[PubMed](#)]
168. Girdler, S.S.; Pedersen, C.A.; Stern, R.A.; Light, K.C. Menstrual Cycle and Premenstrual Syndrome: Modifiers of Cardiovascular Reactivity in Women. *Health Psychol.* **1993**, *12*, 180–192. [[CrossRef](#)]
169. Romans, S.E.; Kreindler, D.; Einstein, G.; Laredo, S.; Petrovic, M.J.; Stanley, J. Sleep Quality and the Menstrual Cycle. *Sleep. Med.* **2015**, *16*, 489–495. [[CrossRef](#)]
170. Andersch, B.; Milsom, I. An Epidemiologic Study of Young Women with Dysmenorrhea. *Am. J. Obs. Gynecol.* **1982**, *144*, 655–660. [[CrossRef](#)]
171. Chantler, I.; Mitchell, D.; Fuller, A. Actigraphy Quantifies Reduced Voluntary Physical Activity in Women with Primary Dysmenorrhea. *J. Pain* **2009**, *10*, 38–46. [[CrossRef](#)]

172. Eryilmaz, G.; Ozdemir, F.; Pasinlioglu, T. Dysmenorrhea Prevalence among Adolescents in Eastern Turkey: Its Effects on School Performance and Relationships with Family and Friends. *J. Pediatr. Adolesc. Gynecol.* **2010**, *23*, 267–272. [[CrossRef](#)]
173. Ortiz, M.I.; Rangel-Flores, E.; Carrillo-Alarcón, L.C.; Veras-Godoy, H.A. Prevalence and Impact of Primary Dysmenorrhea among Mexican High School Students. *Int. J. Gynecol. Obstet.* **2009**, *107*, 240–243. [[CrossRef](#)]
174. Patel, V.; Tanksale, V.; Sahasrabhojane, M.; Gupte, S.; Nevrekar, P. The Burden and Determinants of Dysmenorrhoea: A Population-Based Survey of 2262 Women in Goa, India. *BJOG* **2006**, *113*, 453–463. [[CrossRef](#)]
175. Pitangui, A.C.R.; de Gomes, M.R.A.; Lima, A.S.; Schwingel, P.A.; dosAlbuquerque, A.P.S.; de Araújo, R.C. Menstruation Disturbances: Prevalence, Characteristics, and Effects on the Activities of Daily Living among Adolescent Girls from Brazil. *J. Pediatric. Adolesc. Gynecol.* **2013**, *26*, 148–152. [[CrossRef](#)]
176. Lewis, C.A. Effects of Hormonal Contraceptives on Mood: A Focus on Emotion Recognition and Reactivity, Reward Processing, and Stress Response. *Curr. Psychiatry Rep.* **2019**, *15*, 115. [[CrossRef](#)]
177. Robakis, T.; Williams, K.E.; Nutkiewicz, L.; Rasgon, N.L. Hormonal Contraceptives and Mood: Review of the Literature and Implications for Future Research. *Curr. Psychiatry Rep.* **2019**, *21*, 57. [[CrossRef](#)]
178. Schaffir, J.; Worly, B.L.; Gur, T.L. Combined Hormonal Contraception and Its Effects on Mood: A Critical Review. *Eur. J. Contracept. Reprod. Health Care* **2016**, *21*, 347–355. [[CrossRef](#)]
179. Ekenros, L.; Bäckström, T.; Hirschberg, A.L.; Fridén, C. Changes in Premenstrual Symptoms in Women Starting or Discontinuing Use of Oral Contraceptives. *Gynecol. Endocrinol.* **2019**, *35*, 422–426. [[CrossRef](#)] [[PubMed](#)]
180. Greco, T.; Graham, C.A.; Bancroft, J.; Tanner, A.; Doll, H.A. The Effects of Oral Contraceptives on Androgen Levels and Their Relevance to Premenstrual Mood and Sexual Interest: A Comparison of Two Triphasic Formulations Containing Norgestimate and Either 35 or 25 Microg of Ethinyl Estradiol. *Contraception* **2007**, *76*, 8–17. [[CrossRef](#)] [[PubMed](#)]
181. Graham, C.A.; Bancroft, J.; Doll, H.A.; Greco, T.; Tanner, A. Does Oral Contraceptive-Induced Reduction in Free Testosterone Adversely Affect the Sexuality or Mood of Women? *Psychoneuroendocrinology* **2007**, *32*, 246–255. [[CrossRef](#)]
182. Baker, F.; Waner, J.; Vieira, E.; Taylor, S.; Driver, H.; Mitchell, D. Sleep and 24 Hour Body Temperatures: A Comparison in Young Men, Naturally Cycling Women and Women Taking Hormonal Contraceptives. *J. Physiol.* **2004**, *530*, 565–574. [[CrossRef](#)]
183. Guida, M.; Rega, A.; Vivone, I.; Saccone, G.; Sarno, L.; Di Carlo, C.; Aquino, C.I.; Troisi, J. Variations in Sleep Associated with Different Types of Hormonal Contraceptives. *Gynecol. Endocrinol.* **2020**, *36*, 166–170. [[CrossRef](#)]
184. Smith, S.S. Progesterone Enhances Inhibitory Responses of Cerebellar Purkinje Cells Mediated by the GABAA Receptor Subtype. *Brain Res. Bull.* **1989**, *23*, 317–322. [[CrossRef](#)]
185. Woolley, C.S. Effects of Estrogen in the CNS. *Curr. Opin. Neurobiol.* **1999**, *9*, 349–354. [[CrossRef](#)]
186. Sung, E.; Han, A.; Hinrichs, T.; Vorgerd, M.; Machado, C.; Platen, P. Effects of Follicular versus Luteal Phase-Based Strength Training in Young Women. *Springerplus* **2014**, *3*, 668. [[CrossRef](#)] [[PubMed](#)]
187. Darlington, C.L.; Ross, A.; King, J.; Smith, P.F. Menstrual Cycle Effects on Postural Stability but Not Optokinetic Function. *Neurosci. Lett.* **2001**, *307*, 147–150. [[CrossRef](#)]
188. Iman Akef, K.; Haneul, L. Neuromuscular Control of Ankle-Stabilizing Muscles-Specific Effects of Sex and Menstrual Cycle. *Int. J. Sports Med.* **2020**, *42*, 270–276. [[CrossRef](#)]
189. Posthuma, B.W.; Bass, M.J.; Bull, S.B.; Nisker, J.A. Detecting Changes in Functional Ability in Women with Premenstrual Syndrome. *Am. J. Obs. Gynecol.* **1987**, *156*, 275–278. [[CrossRef](#)]
190. Clark, R.A.; Bartold, S.; Bryant, A.L. Tibial Acceleration Variability during Consecutive Gait Cycles Is Influenced by the Menstrual Cycle. *Clin. Biomech.* **2010**, *25*, 557–562. [[CrossRef](#)] [[PubMed](#)]
191. Sung, E.-S.; Kim, J.-H. The Influence of Ovulation on Postural Stability (Biodex Balance System) in Young Female. *J. Exerc. Rehabil.* **2018**, *14*, 638–642. [[CrossRef](#)]
192. Petrofsky, J.; Lee, H. Greater Reduction of Balance as a Result of Increased Plantar Fascia Elasticity at Ovulation during the Menstrual Cycle. *Tohoku J. Exp. Med.* **2015**, *237*, 219–226. [[CrossRef](#)]
193. Fridén, C.; Ramsey, D.K.; Backstrom, T.; Benoit, D.L.; Saartok, T.; Lindén Hirschberg, A. Altered Postural Control during the Luteal Phase in Women with Premenstrual Symptoms. *Neuroendocrinology* **2005**, *81*, 150–157. [[CrossRef](#)]
194. Mokošáková, M.; Senko, T.; Okuliarová, M.; Kršková, L.; Hlavačka, F.; Zeman, M. Effect of Oral Contraceptives Intake on Postural Stability in Young Healthy Women throughout the Menstrual Cycle. *Gen. Physiol. Biophys.* **2018**, *37*, 581–588. [[CrossRef](#)] [[PubMed](#)]
195. Lee, H.; Petrofsky, J. Differences Between Men and Women in Balance and Tremor in Relation to Plantar Fascia Laxity During the Menstrual Cycle. *J. Athl. Train.* **2018**, *53*, 255–261. [[CrossRef](#)]
196. Özer Kaya, D.; Toprak Çelenay, Ş. Fluctuations of State Anxiety, Spinal Structure, and Postural Stability across the Menstrual Cycle in Active Women. *Turk. J. Med. Sci.* **2016**, *46*, 977–984. [[CrossRef](#)] [[PubMed](#)]
197. Ericksen, H.; Gribble, P.A. Sex Differences, Hormone Fluctuations, Ankle Stability, and Dynamic Postural Control. *J. Athl. Train.* **2012**, *47*, 143–148. [[CrossRef](#)] [[PubMed](#)]
198. Fridén, C.; Hirschberg, A.L.; Saartok, T.; Bäckström, T.; Leanderson, J.; Renström, P. The Influence of Premenstrual Symptoms on Postural Balance and Kinesthesia during the Menstrual Cycle. *Gynecol. Endocrinol.* **2003**, *17*, 433–439. [[CrossRef](#)]
199. Lee, H.; Yim, J. Increased Postural Sway and Changes in the Neuromuscular Activities of the Ankle Stabilizing Muscles at Ovulation in Healthy Young Women. *Tohoku J. Exp. Med.* **2016**, *240*, 287–294. [[CrossRef](#)] [[PubMed](#)]
200. Tse, Y.Y.F.; Petrofsky, J.S.; Berk, L.; Daher, N.; Lohman, E.; Laymon, M.S.; Cavalcanti, P. Postural Sway and Rhythmic Electroencephalography Analysis of Cortical Activation during Eight Balance Training Tasks. *Med. Sci. Monit.* **2013**, *19*, 175–186. [[CrossRef](#)]

201. Lee, H.; Petrofsky, J.S.; Daher, N.; Berk, L.; Laymon, M.; Khowailed, I.A. Anterior Cruciate Ligament Elasticity and Force for Flexion during the Menstrual Cycle. *Med. Sci. Monit.* **2013**, *19*, 1080–1088. [[CrossRef](#)]
202. Lee, H.; Petrofsky, J.; Daher, N.; Berk, L.; Laymon, M. Differences in Anterior Cruciate Ligament Elasticity and Force for Knee Flexion in Women: Oral Contraceptive Users versus Non-Oral Contraceptive Users. *Eur. J. Appl. Physiol.* **2013**, *114*. [[CrossRef](#)]
203. Park, S.-K.; Stefanyshyn, D.J.; Ramage, B.; Hart, D.A.; Ronsky, J.L. Alterations in Knee Joint Laxity during the Menstrual Cycle in Healthy Women Leads to Increases in Joint Loads during Selected Athletic Movements. *Am. J. Sports Med.* **2009**, *37*, 1169–1177. [[CrossRef](#)]
204. Miller, B.F.; Hansen, M.; Olesen, J.L.; Schwarz, P.; Babraj, J.A.; Smith, K.; Rennie, M.J.; Kjaer, M. Tendon Collagen Synthesis at Rest and after Exercise in Women. *J. Appl. Physiol.* **2007**, *102*, 541–546. [[CrossRef](#)]
205. Silbernagel, K.G.; Brorsson, A.; Olsson, N.; Eriksson, B.I.; Karlsson, J.; Nilsson-Helander, K. Sex Differences in Outcome After an Acute Achilles Tendon Rupture. *Orthop. J. Sports Med.* **2015**, *3*, 2325967115586768. [[CrossRef](#)] [[PubMed](#)]
206. Möller Nielsen, J.; Hammar, M. Sports Injuries and Oral Contraceptive Use. Is There a Relationship? *Sports Med.* **1991**, *12*, 152–160. [[CrossRef](#)]
207. Bryant, A.L.; Crossley, K.M.; Bartold, S.; Hohmann, E.; Clark, R.A. Estrogen-Induced Effects on the Neuro-Mechanics of Hopping in Humans. *Eur. J. Appl. Physiol.* **2011**, *111*, 245–252. [[CrossRef](#)]
208. Möller-Nielsen, J.; Hammar, M. Women's Soccer Injuries in Relation to the Menstrual Cycle and Oral Contraceptive Use. *Med. Sci. Sports Exerc.* **1989**, *21*, 126–129.
209. Abt, J.P.; Sell, T.C.; Laudner, K.G.; McCrory, J.L.; Loucks, T.L.; Berga, S.L.; Lephart, S.M. Neuromuscular and Biomechanical Characteristics Do Not Vary across the Menstrual Cycle. *Knee Surg. Sports Traumatol. Arthrosc.* **2007**, *15*, 901–907. [[CrossRef](#)]
210. Lebrun, C.M.; McKenzie, D.C.; Prior, J.C.; Taunton, J.E. Effects of Menstrual Cycle Phase on Athletic Performance. *Med. Sci. Sports Exerc.* **1995**, *27*, 437–444. [[CrossRef](#)] [[PubMed](#)]
211. Bayer, U.; Hausmann, M. Menstrual Cycle-Related Changes of Functional Cerebral Asymmetries in Fine Motor Coordination. *Brain Cogn.* **2012**, *79*, 34–38. [[CrossRef](#)] [[PubMed](#)]
212. Otaka, M.; Chen, S.-M.; Zhu, Y.; Tsai, Y.-S.; Tseng, C.-Y.; Fogt, D.L.; Lim, B.-H.; Huang, C.-Y.; Kuo, C.-H. Does Ovulation Affect Performance in Tennis Players? *BMJ Open Sport Exerc. Med.* **2018**, *4*, e000305. [[CrossRef](#)]
213. Davies, B.N.; Elfrod, J.C.; Jamieson, K.F. Variations in Performance in Simple Muscle Tests at Different Phases of the Menstrual Cycle. *J. Sports Med. Phys. Fit.* **1991**, *31*, 532–537.
214. Fridén, C.; Hirschberg, A.L.; Saartok, T.; Renström, P. Knee Joint Kinaesthesia and Neuromuscular Coordination during Three Phases of the Menstrual Cycle in Moderately Active Women. *Knee Surg. Sports Traumatol. Arthrosc.* **2006**, *14*, 383–389. [[CrossRef](#)]
215. Ikarashi, K.; Sato, D.; Iguchi, K.; Baba, Y.; Yamashiro, K. Menstrual Cycle Modulates Motor Learning and Memory Consolidation in Humans. *Brain Sci.* **2020**, *10*, 696. [[CrossRef](#)] [[PubMed](#)]
216. Zhu, X.; Niu, Y.; Li, W.; Zhang, Z.; Liu, P.; Chen, X.; Liu, H. Menstrual Cycle Phase Modulates Auditory-Motor Integration for Vocal Pitch Regulation. *Front. Neurosci.* **2016**, *10*, 600. [[CrossRef](#)] [[PubMed](#)]
217. Chaudhari, A.M.W.; Lindenfeld, T.N.; Andriacchi, T.P.; Hewett, T.E.; Riccobene, J.; Myer, G.D.; Noyes, F.R. Knee and Hip Loading Patterns at Different Phases in the Menstrual Cycle: Implications for the Gender Difference in Anterior Cruciate Ligament Injury Rates. *Am. J. Sports Med.* **2007**, *35*, 793–800. [[CrossRef](#)]
218. Ekenros, L.; Hirschberg, A.L.; Heijne, A.; Fridén, C. Oral Contraceptives Do Not Affect Muscle Strength and Hop Performance in Active Women. *Clin. J. Sport Med.* **2013**, *23*, 202–207. [[CrossRef](#)]
219. Janse de Jonge, X.A.K. Effects of the Menstrual Cycle on Exercise Performance. *Sports Med.* **2003**, *33*, 833–851. [[CrossRef](#)]
220. Petrofsky, J.; Al Malty, A.; Suh, H.J. Isometric Endurance, Body and Skin Temperature and Limb and Skin Blood Flow during the Menstrual Cycle. *Med. Sci. Monit.* **2007**, *13*, CR111–CR117.
221. Pallavi, L.C.; D Souza, U.J.; Shivaprakash, G. Assessment of Musculoskeletal Strength and Levels of Fatigue during Different Phases of Menstrual Cycle in Young Adults. *J. Clin. Diagn Res.* **2017**, *11*, CC11–CC13. [[CrossRef](#)] [[PubMed](#)]
222. Tenan, M.S.; Hackney, A.C.; Griffin, L. Maximal Force and Tremor Changes across the Menstrual Cycle. *Eur. J. Appl. Physiol.* **2016**, *116*, 153–160. [[CrossRef](#)]
223. Hu, X.; Li, J.; Wang, L. Sex Differences in Lower Limb Proprioception and Mechanical Function Among Healthy Adults. *Mot. Control.* **2020**, 571–587. [[CrossRef](#)]
224. Thompson, B.; Almarjawi, A.; Sculley, D.; Janse de Jonge, X. The Effect of the Menstrual Cycle and Oral Contraceptives on Acute Responses and Chronic Adaptations to Resistance Training: A Systematic Review of the Literature. *Sports Med.* **2020**, *50*, 171–185. [[CrossRef](#)]
225. Wikström-Frisén, L.; Boraxbekk, C.J.; Henriksson-Larsén, K. Effects on Power, Strength and Lean Body Mass of Menstrual/Oral Contraceptive Cycle Based Resistance Training. *J. Sports Med. Phys. Fit.* **2017**, *57*, 43–52. [[CrossRef](#)]
226. Graja, A.; Kacem, M.; Hammouda, O.; Borji, R.; Bouzid, M.A.; Souissi, N.; Rebai, H. Physical, Biochemical, and Neuromuscular Responses to Repeated Sprint Exercise in Eumenorrhic Female Handball Players: Effect of Menstrual Cycle Phases. *J. Strength Cond. Res.* **2020**, *18*. [[CrossRef](#)]
227. Petrofsky, J.S.; LeDonne, D.M.; Rinehart, J.S.; Lind, A.R. Isometric Strength and Endurance during the Menstrual Cycle. *Eur. J. Appl. Physiol. Occup. Physiol.* **1976**, *35*, 1–10. [[CrossRef](#)]
228. Wirth, J.C.; Lohman, T.G. The Relationship of Static Muscle Function to Use of Oral Contraceptives. *Med. Sci. Sports Exerc.* **1982**, *14*, 16–20. [[CrossRef](#)]

229. Hansen, M.; Langberg, H.; Holm, L.; Miller, B.F.; Petersen, S.G.; Doessing, S.; Skovgaard, D.; Trappe, T.; Kjaer, M. Effect of Administration of Oral Contraceptives on the Synthesis and Breakdown of Myofibrillar Proteins in Young Women. *Scand. J. Med. Sci. Sports* **2011**, *21*, 62–72. [[CrossRef](#)] [[PubMed](#)]
230. Elliott, K.J.; Cable, N.T.; Reilly, T. Does Oral Contraceptive Use Affect Maximum Force Production in Women? *Br. J. Sports Med.* **2005**, *39*, 15–19. [[CrossRef](#)]
231. Romance, R.; Vargas, S.; Espinar, S.; Petro, J.L.; Bonilla, D.A.; Schöenfeld, B.J.; Kreider, R.B.; Benítez-Porres, J. Oral Contraceptive Use Does Not Negatively Affect Body Composition and Strength Adaptations in Trained Women. *Int. J. Sports Med.* **2019**, *40*, 842–849. [[CrossRef](#)]
232. Myllyaho, M.M.; Ihalainen, J.K.; Hackney, A.C.; Valtonen, M.; Nummela, A.; Vaara, E.; Häkkinen, K.; Kyröläinen, H.; Taipale, R.S. Hormonal Contraceptive Use Does Not Affect Strength, Endurance, or Body Composition Adaptations to Combined Strength and Endurance Training in Women. *J. Strength Cond. Res.* **2021**, *35*, 449–457. [[CrossRef](#)] [[PubMed](#)]
233. Dedrick, G.S.; Sizer, P.S.; Merkle, J.N.; Hounshell, T.R.; Robert-McComb, J.J.; Sawyer, S.F.; Brismée, J.-M.; Roger James, C. Effect of Sex Hormones on Neuromuscular Control Patterns during Landing. *J. Electromyogr. Kinesiol.* **2008**, *18*, 68–78. [[CrossRef](#)]
234. Knowles, O.E.; Aisbett, B.; Main, L.C.; Drinkwater, E.J.; Orellana, L.; Lamon, S. Resistance Training and Skeletal Muscle Protein Metabolism in Eumenorrheic Females: Implications for Researchers and Practitioners. *Sports Med.* **2019**, *49*, 1637–1650. [[CrossRef](#)] [[PubMed](#)]
235. Heintz, B.; Schmauder, C.; Witte, K.; Breuer, I.; Baltzer, K.; Sieberth, H.G.; Lemmer, B. Blood Pressure Rhythm and Endocrine Functions in Normotensive Women on Oral Contraceptives. *J. Hypertens.* **1996**, *14*, 333–339. [[CrossRef](#)] [[PubMed](#)]
236. George, K.P.; Birch, K.M.; Jones, B.; Lea, R. Estrogen Variation and Resting Left Ventricular Structure and Function in Young Healthy Females. *Med. Sci. Sports Exerc.* **2000**, *32*, 297–303. [[CrossRef](#)]
237. Lei, T.-H.; Stannard, S.R.; Perry, B.G.; Schlader, Z.J.; Cotter, J.D.; Mündel, T. Influence of Menstrual Phase and Arid vs. Humid Heat Stress on Autonomic and Behavioural Thermoregulation during Exercise in Trained but Unacclimated Women. *J. Physiol.* **2017**, *595*, 2823–2837. [[CrossRef](#)] [[PubMed](#)]
238. Leicht, A.S.; Hirling, D.A.; Allen, G.D. Heart Rate Variability and Endogenous Sex Hormones during the Menstrual Cycle in Young Women. *Exp. Physiol.* **2003**, *88*, 441–446. [[CrossRef](#)]
239. Kanojia, S.; Sharma, V.K.; Gandhi, A.; Kapoor, R.; Kukreja, A.; Subramanian, S.K. Effect of Yoga on Autonomic Functions and Psychological Status during Both Phases of Menstrual Cycle in Young Healthy Females. *J. Clin. Diagn. Res.* **2013**, *7*, 2133–2139. [[CrossRef](#)]
240. Claydon, V.E.; Younis, N.R.; Hainsworth, R. Phase of the Menstrual Cycle Does Not Affect Orthostatic Tolerance in Healthy Women. *Clin. Auton. Res.* **2006**, *16*, 98–104. [[CrossRef](#)] [[PubMed](#)]
241. Cooke, W.H.; Ludwig, D.A.; Hogg, P.S.; Eckberg, D.L.; Convertino, V.A. Does the Menstrual Cycle Influence the Sensitivity of Vagally Mediated Baroreflexes? *Clin. Sci.* **2002**, *102*, 639–644. [[CrossRef](#)]
242. Middlekauff, H.R.; Park, J.; Gornbein, J.A. Lack of Effect of Ovarian Cycle and Oral Contraceptives on Baroreceptor and Nonbaroreceptor Control of Sympathetic Nerve Activity in Healthy Women. *Am. J. Physiol. Heart Circ. Physiol.* **2012**, *302*, H2560–H2566. [[CrossRef](#)]
243. Tanaka, M.; Sato, M.; Umehara, S.; Nishikawa, T. Influence of Menstrual Cycle on Baroreflex Control of Heart Rate: Comparison with Male Volunteers. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2003**, *285*, R1091–R1097. [[CrossRef](#)]
244. Yildirim, A.; Kabakci, G.; Akgul, E.; Tokgozoglul, L.; Oto, A. Effects of Menstrual Cycle on Cardiac Autonomic Innervation as Assessed by Heart Rate Variability. *Ann. Noninvasive Electrocardiol.* **2002**, *7*, 60–63. [[CrossRef](#)] [[PubMed](#)]
245. Bai, X.; Li, J.; Zhou, L.; Li, X. Influence of the Menstrual Cycle on Nonlinear Properties of Heart Rate Variability in Young Women. *Am. J. Physiol. Heart Circ. Physiol.* **2009**, *297*, H765–H774. [[CrossRef](#)] [[PubMed](#)]
246. Carter, J.R.; Lawrence, J.E.; Klein, J.C. Menstrual Cycle Alters Sympathetic Neural Responses to Orthostatic Stress in Young, Eumenorrheic Women. *Am. J. Physiol. Endocrinol. Metab.* **2009**, *297*, E85–E91. [[CrossRef](#)] [[PubMed](#)]
247. Princi, T.; Parco, S.; Accardo, A.; Radillo, O.; De Seta, F.; Guaschino, S. Parametric Evaluation of Heart Rate Variability during the Menstrual Cycle in Young Women. *Biomed. Sci. Instrum.* **2005**, *41*, 340–345.
248. Sato, N.; Miyake, S.; Akatsu, J.; Kumashiro, M. Power Spectral Analysis of Heart Rate Variability in Healthy Young Women during the Normal Menstrual Cycle. *Psychosom. Med.* **1995**, *57*, 331–335. [[CrossRef](#)]
249. Sato, N.; Miyake, S. Cardiovascular Reactivity to Mental Stress: Relationship with Menstrual Cycle and Gender. *J. Physiol. Anthr. Appl. Hum. Sci.* **2004**, *23*, 215–223. [[CrossRef](#)] [[PubMed](#)]
250. Tenan, M.S.; Brothers, R.M.; Tweedell, A.J.; Hackney, A.C.; Griffin, L. Changes in Resting Heart Rate Variability across the Menstrual Cycle. *Psychophysiology* **2014**, *51*, 996–1004. [[CrossRef](#)]
251. Yazar, Ş.; Yazıcı, M. Impact of Menstrual Cycle on Cardiac Autonomic Function Assessed by Heart Rate Variability and Heart Rate Recovery. *Med. Princ Pract.* **2016**, *25*, 374–377. [[CrossRef](#)] [[PubMed](#)]
252. Nakagawa, M.; Ooie, T.; Takahashi, N.; Taniguchi, Y.; Anan, F.; Yonemochi, H.; Saikawa, T. Influence of Menstrual Cycle on QT Interval Dynamics. *Pacing Clin. Electrophysiol.* **2006**, *29*, 607–613. [[CrossRef](#)]
253. Tada, Y.; Yoshizaki, T.; Tomata, Y.; Yokoyama, Y.; Sunami, A.; Hida, A.; Kawano, Y. The Impact of Menstrual Cycle Phases on Cardiac Autonomic Nervous System Activity: An Observational Study Considering Lifestyle (Diet, Physical Activity, and Sleep) among Female College Students. *J. Nutr. Sci. Vitam.* **2017**, *63*, 249–255. [[CrossRef](#)]

254. Choudhary, A.K.; Alam, T.; Jiwane, R.; Kishanrao, S.S. A Comparative Analysis of Dietary Habits on Sensory Motor Association and Heart Rate Variability during Menstrual Cycle. *J. Clin. Diagn Res.* **2016**, *10*, CC04–CC08. [\[CrossRef\]](#)
255. Maffei, S.; Clerico, A.; Iervasi, G.; Nannipieri, M.; Del Ry, S.; Giannessi, D.; Donato, L. Circulating Levels of Cardiac Natriuretic Hormones Measured in Women during Menstrual Cycle. *J. Endocrinol. Investig.* **1999**, *22*, 1–5. [\[CrossRef\]](#)
256. De Souza, M.J.; Maguire, M.S.; Rubin, K.R.; Maresh, C.M. Effects of Menstrual Phase and Amenorrhea on Exercise Performance in Runners. *Med. Sci. Sports Exerc.* **1990**, *22*, 575–580. [\[CrossRef\]](#)
257. Teixeira, A.L.; Ramos, P.S.; Vianna, L.C.; Ricardo, D.R. Effects of Ovarian Hormones and Oral Contraceptive Pills on Cardiac Vagal Withdrawal at the Onset of Dynamic Exercise. *PLoS ONE* **2015**, *10*, e0119626. [\[CrossRef\]](#) [\[PubMed\]](#)
258. Barba-Moreno, L.; Cupeiro, R.; Romero-Parra, N.; Janse de Jonge, X.A.K.; Peinado, A.B. Cardiorespiratory Responses to Endurance Exercise over the Menstrual Cycle and With Oral Contraceptive Use. *J. Strength Cond. Res.* **2019**. [\[CrossRef\]](#)
259. Nakamura, M.; Hayashi, K.; Aizawa, K.; Mesaki, N.; Kono, I. Effects of Regular Aerobic Exercise on Post-Exercise Vagal Reactivation in Young Female. *Eur. J. Sport Sci.* **2013**, *13*, 674–680. [\[CrossRef\]](#) [\[PubMed\]](#)
260. Wenner, M.M.; Prettyman, A.V.; Maser, R.E.; Farquhar, W.B. Preserved Autonomic Function in Amenorrheic Athletes. *J. Appl. Physiol.* **2006**, *101*, 590–597. [\[CrossRef\]](#) [\[PubMed\]](#)
261. Reinberg, A.E.; Touitou, Y.; Soudant, E.; Bernard, D.; Bazin, R.; Mechkouri, M. Oral Contraceptives Alter Circadian Rhythm Parameters of Cortisol, Melatonin, Blood Pressure, Heart Rate, Skin Blood Flow, Transepidermal Water Loss, and Skin Amino Acids of Healthy Young Women. *Chronobiol. Int.* **1996**, *13*, 199–211. [\[CrossRef\]](#) [\[PubMed\]](#)
262. Teixeira, A.L.; Ramos, P.S.; Vianna, L.C.; Ricardo, D.R. Heart Rate Variability across the Menstrual Cycle in Young Women Taking Oral Contraceptives. *Psychophysiology* **2015**, *52*, 1451–1455. [\[CrossRef\]](#)
263. Cagnacci, A.; Zanin, R.; Napolitano, A.; Arangino, S.; Volpe, A. Modification of 24-h Ambulatory Blood Pressure and Heart Rate during Contraception with the Vaginal Ring: A Prospective Study. *Contraception* **2013**, *88*, 539–543. [\[CrossRef\]](#) [\[PubMed\]](#)
264. Harvey, R.E.; Hart, E.C.; Charkoudian, N.; Curry, T.B.; Carter, J.R.; Fu, Q.; Minson, C.T.; Joyner, M.J.; Barnes, J.N. Oral Contraceptive Use, Muscle Sympathetic Nerve Activity, and Systemic Hemodynamics in Young Women. *Hypertension* **2015**, *66*, 590–597. [\[CrossRef\]](#) [\[PubMed\]](#)
265. Giribela, C.R.G.; Melo, N.R.; Silva, R.C.G.; Hong, V.M.; Guerra, G.M.; Baracat, E.C.; Consolim-Colombo, F.M. A Combined Oral Contraceptive Containing Drospirenone Changes Neither Endothelial Function nor Hemodynamic Parameters in Healthy Young Women: A Prospective Clinical Trial. *Contraception* **2012**, *86*, 35–41. [\[CrossRef\]](#) [\[PubMed\]](#)
266. Nisenbaum, M.G.; de Melo, N.R.; Giribela, C.R.G.; de Moraes, T.L.; Guerra, G.M.; de Angelis, K.; Mostarda, C.; Baracat, E.C.; Consolim-Colombo, F.M. Effects of a Contraceptive Containing Drospirenone and Ethinyl Estradiol on Blood Pressure and Autonomic Tone: A Prospective Controlled Clinical Trial. *Eur. J. Obs. Gynecol. Reprod. Biol.* **2014**, *175*, 62–66. [\[CrossRef\]](#) [\[PubMed\]](#)
267. Wilczak, A.; Marciniak, K.; Kłapciński, M.; Rydlewska, A.; Danel, D.; Jankowska, E.A. Relations between Combined Oral Contraceptive Therapy and Indices of Autonomic Balance (Baroreflex Sensitivity and Heart Rate Variability) in Young Healthy Women. *Ginekol. Pol.* **2013**, *84*, 915–921. [\[CrossRef\]](#)
268. Schueller, P.O.; Feuring, M.; Sharkova, Y.; Grimm, W.; Christ, M. Effects of Synthetic Progestagens on Autonomic Tone, Neurohormones and C-Reactive Protein Levels in Young Healthy Females in Reproductive Age. *Int. J. Cardiol.* **2006**, *111*, 42–48. [\[CrossRef\]](#)
269. Lehtovirta, P.; Kuikka, J.; Pyörälä, T. Hemodynamic Effects of Oral Contraceptives during Exercise. *Int. J. Gynaecol. Obs.* **1977**, *15*, 35–37. [\[CrossRef\]](#) [\[PubMed\]](#)
270. Rodriguez Bauza, D.E.; Silveyra, P. Sex Differences in Exercise-Induced Bronchoconstriction in Athletes: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* **2020**, *17*, 7270. [\[CrossRef\]](#)
271. Goodland, R.L.; Reynolds, J.G.; McCoord, A.B.; Pommerenke, W.T. Respiratory and Electrolyte Effects Induced by Estrogen and Progesterone. *Fertil. Steril.* **1953**, *4*, 300–317. [\[CrossRef\]](#)
272. Regensteiner, J.G.; McCullough, R.G.; McCullough, R.E.; Pickett, C.K.; Moore, L.G. Combined Effects of Female Hormones and Exercise on Hypoxic Ventilatory Response. *Respir Physiol.* **1990**, *82*, 107–114. [\[CrossRef\]](#)
273. Bayliss, D.A.; Millhorn, D.E. Central Neural Mechanisms of Progesterone Action: Application to the Respiratory System. *J. Appl. Physiol.* **1992**, *73*, 393–404. [\[CrossRef\]](#)
274. Behan, M.; Zabka, A.G.; Thomas, C.F.; Mitchell, G.S. Sex Steroid Hormones and the Neural Control of Breathing. *Respir Physiol. Neurobiol.* **2003**, *136*, 249–263. [\[CrossRef\]](#)
275. Skatrud, J.B.; Dempsey, J.A.; Kaiser, D.G. Ventilatory Response to Medroxyprogesterone Acetate in Normal Subjects: Time Course and Mechanism. *J. Appl. Physiol. Respir Environ. Exerc. Physiol.* **1978**, *44*, 939–944. [\[CrossRef\]](#) [\[PubMed\]](#)
276. Jurkowski, J.E.; Jones, N.L.; Toews, C.J.; Sutton, J.R. Effects of Menstrual Cycle on Blood Lactate, O₂ Delivery, and Performance during Exercise. *J. Appl. Physiol. Respir Environ. Exerc. Physiol.* **1981**, *51*, 1493–1499. [\[CrossRef\]](#) [\[PubMed\]](#)
277. Schoene, R.B.; Robertson, H.T.; Pierson, D.J.; Peterson, A.P. Respiratory Drives and Exercise in Menstrual Cycles of Athletic and Nonathletic Women. *J. Appl. Physiol. Respir Environ. Exerc. Physiol.* **1981**, *50*, 1300–1305. [\[CrossRef\]](#)
278. Slatkovska, L.; Jensen, D.; Davies, G.A.L.; Wolfe, L.A. Phasic Menstrual Cycle Effects on the Control of Breathing in Healthy Women. *Respir Physiol. Neurobiol.* **2006**, *154*, 379–388. [\[CrossRef\]](#)
279. Smekal, G.; von Duvillard, S.P.; Frigo, P.; Tegelhofer, T.; Pokan, R.; Hofmann, P.; Tschan, H.; Baron, R.; Wonisch, M.; Renededer, K.; et al. Menstrual Cycle: No Effect on Exercise Cardiorespiratory Variables or Blood Lactate Concentration. *Med. Sci. Sports Exerc.* **2007**, *39*, 1098–1106. [\[CrossRef\]](#) [\[PubMed\]](#)
280. Williams, T.J.; Krahenbuhl, G.S. Menstrual Cycle Phase and Running Economy. *Med. Sci. Sports Exerc.* **1997**, *29*, 1609–1618. [\[CrossRef\]](#)

281. Beidleman, B.A.; Rock, P.B.; Muza, S.R.; Fulco, C.S.; Forte, V.A.; Cymerman, A. Exercise VE and Physical Performance at Altitude Are Not Affected by Menstrual Cycle Phase. *J. Appl. Physiol.* **1999**, *86*, 1519–1526. [[CrossRef](#)]
282. Bemben, D.A.; Salm, P.C.; Salm, A.J. Ventilatory and Blood Lactate Responses to Maximal Treadmill Exercise during the Menstrual Cycle. *J. Sports Med. Phys. Fit.* **1995**, *35*, 257–262.
283. Macnutt, M.J.; De Souza, M.J.; Tomczak, S.E.; Homer, J.L.; Sheel, A.W. Resting and Exercise Ventilatory Chemosensitivity across the Menstrual Cycle. *J. Appl. Physiol.* **2012**, *112*, 737–747. [[CrossRef](#)]
284. Dombovy, M.L.; Bonekat, H.W.; Williams, T.J.; Staats, B.A. Exercise Performance and Ventilatory Response in the Menstrual Cycle. *Med. Sci. Sports Exerc.* **1987**, *19*, 111–117. [[CrossRef](#)]
285. Brutsaert, T.D.; Spielvogel, H.; Caceres, E.; Araoz, M.; Chatterton, R.T.; Vitzthum, V.J. Effect of Menstrual Cycle Phase on Exercise Performance of High-Altitude Native Women at 3600 m. *J. Exp. Biol.* **2002**, *205*, 233–239. [[CrossRef](#)] [[PubMed](#)]
286. Byrne-Quinn, E.; Weil, J.V.; Sodal, I.E.; Filley, G.F.; Grover, R.F. Ventilatory Control in the Athlete. *J. Appl. Physiol.* **1971**, *30*, 91–98. [[CrossRef](#)]
287. Saunders, N.A.; Leeder, S.R.; Rebuck, A.S. Ventilatory Response to Carbon Dioxide in Young Athletes: A Family Study. *Am. Rev. Respir. Dis.* **1976**, *113*, 497–502. [[CrossRef](#)]
288. Dutton, K.; Blanksby, B.A.; Morton, A.R. CO₂ Sensitivity Changes during the Menstrual Cycle. *J. Appl. Physiol.* **1989**, *67*, 517–522. [[CrossRef](#)]
289. Takase, K.; Nishiyasu, T.; Asano, K. Modulating Effects of the Menstrual Cycle on Cardiorespiratory Responses to Exercise under Acute Hypobaric Hypoxia. *Jpn. J. Physiol.* **2002**, *52*, 553–560. [[CrossRef](#)]
290. Martin, B.J.; Sparks, K.E.; Zwillich, C.W.; Weil, J.V. Low Exercise Ventilation in Endurance Athletes. *Med. Sci. Sports* **1979**, *11*, 181–185. [[PubMed](#)]
291. Muza, S.R.; Rock, P.B.; Fulco, C.S.; Zamudio, S.; Braun, B.; Cymerman, A.; Butterfield, G.E.; Moore, L.G. Women at Altitude: Ventilatory Acclimatization at 4300 m. *J. Appl. Physiol.* **2001**, *91*, 1791–1799. [[CrossRef](#)] [[PubMed](#)]
292. Richalet, J.-P.; Lhuissier, F.; Jean, D. Ventilatory Response to Hypoxia and Tolerance to High Altitude in Women: Influence of Menstrual Cycle, Oral Contraception, and Menopause. *High. Alt. Med. Biol.* **2020**, *21*, 12–19. [[CrossRef](#)]
293. Burrows, M.; Bird, S.R.; Bishop, N. The Menstrual Cycle and Its Effect on the Immune Status of Female Endurance Runners. *J. Sports Sci.* **2002**, *20*, 339–344. [[CrossRef](#)]
294. Nieman, D.C.; Nehlsen-Cannarella, S.L.; Fagoaga, O.R.; Henson, D.A.; Shannon, M.; Hjertman, J.M.; Schmitt, R.L.; Bolton, M.R.; Austin, M.D.; Schilling, B.K.; et al. Immune Function in Female Elite Rowers and Non-Athletes. *Br. J. Sports Med.* **2000**, *34*, 181–187. [[CrossRef](#)]
295. Shimizu, K.; Suzuki, N.; Nakamura, M.; Aizawa, K.; Imai, T.; Suzuki, S.; Eda, N.; Hanaoka, Y.; Nakao, K.; Suzuki, N.; et al. Mucosal Immune Function Comparison between Amenorrheic and Eumenorrheic Distance Runners. *J. Strength Cond. Res.* **2012**, *26*, 1402–1406. [[CrossRef](#)]
296. Philpott, C.M.; El-Alami, M.; Murty, G.E. The Effect of the Steroid Sex Hormones on the Nasal Airway during the Normal Menstrual Cycle. *Clin. Otolaryngol. Allied Sci.* **2004**, *29*, 138–142. [[CrossRef](#)] [[PubMed](#)]
297. Drosdzol, A.; Skrzypulec, V.; Wilk, K.; Rachel, M. The Influence of Bronchial Asthma on Menstrual Cycle. *J. Physiol. Pharm.* **2007**, *58* (Suppl. 5), 165–173.
298. Oguzulgen, I.K.; Turktas, H.; Erbas, D. Airway Inflammation in Premenstrual Asthma. *J. Asthma* **2002**, *39*, 517–522. [[CrossRef](#)]
299. Stanford, K.I.; Mickleborough, T.D.; Ray, S.; Lindley, M.R.; Koceja, D.M.; Stager, J.M. Influence of Menstrual Cycle Phase on Pulmonary Function in Asthmatic Athletes. *Eur. J. Appl. Physiol.* **2006**, *96*, 703–710. [[CrossRef](#)]
300. Kirsch, E.A.; Yuhanna, I.S.; Chen, Z.; German, Z.; Sherman, T.S.; Shaul, P.W. Estrogen Acutely Stimulates Endothelial Nitric Oxide Synthase in H441 Human Airway Epithelial Cells. *Am. J. Respir Cell Mol. Biol.* **1999**, *20*, 658–666. [[CrossRef](#)]
301. Juniper, E.F.; Kline, P.A.; Roberts, R.S.; Hargreave, F.E.; Daniel, E.E. Airway Responsiveness to Methacholine during the Natural Menstrual Cycle and the Effect of Oral Contraceptives. *Am. Rev. Respir. Dis.* **1987**, *135*, 1039–1042. [[CrossRef](#)]
302. Pauli, B.D.; Reid, R.L.; Munt, P.W.; Wigle, R.D.; Forkert, L. Influence of the Menstrual Cycle on Airway Function in Asthmatic and Normal Subjects. *Am. Rev. Respir. Dis.* **1989**, *140*, 358–362. [[CrossRef](#)]
303. Shames, R.S.; Heilbron, D.C.; Janson, S.L.; Kishiyama, J.L.; Au, D.S.; Adelman, D.C. Clinical Differences among Women with and without Self-Reported Perimenstrual Asthma. *Ann. Allergy Asthma Immunol.* **1998**, *81*, 65–72. [[CrossRef](#)]
304. Weinmann, G.G.; Zacur, H.; Fish, J.E. Absence of Changes in Airway Responsiveness during the Menstrual Cycle. *J. Allergy Clin. Immunol.* **1987**, *79*, 634–638. [[CrossRef](#)]
305. Kluff, C.; Leuven, J.A.G.; Helmerhorst, F.M.; Krans, H.M.J. Pro-Inflammatory Effects of Oestrogens during Use of Oral Contraceptives and Hormone Replacement Treatment. *Vasc. Pharm.* **2002**, *39*, 149–154. [[CrossRef](#)]
306. Packer, N.; Hoffman-Goetz, L.; Ward, G. Does Physical Activity Affect Quality of Life, Disease Symptoms and Immune Measures in Patients with Inflammatory Bowel Disease? A Systematic Review. *J. Sports Med. Phys. Fit.* **2010**, *50*, 1–18.
307. Costa, R.J.S.; Snipe, R.M.J.; Kitic, C.M.; Gibson, P.R. Systematic Review: Exercise-Induced Gastrointestinal Syndrome-Implications for Health and Intestinal Disease. *Aliment. Pharm.* **2017**, *46*, 246–265. [[CrossRef](#)]
308. Moses, F.M. Exercise-Associated Intestinal Ischemia. *Curr. Sports Med. Rep.* **2005**, *4*, 91–95. [[CrossRef](#)] [[PubMed](#)]
309. de Oliveira, E.P.; Burini, R.C.; Jeukendrup, A. Gastrointestinal Complaints during Exercise: Prevalence, Etiology, and Nutritional Recommendations. *Sports Med.* **2014**, *44* (Suppl. 1), S79–S85. [[CrossRef](#)]
310. Ho, G.W.K. Lower Gastrointestinal Distress in Endurance Athletes. *Curr. Sports Med. Rep.* **2009**, *8*, 85–91. [[CrossRef](#)] [[PubMed](#)]

311. Waterman, J.J.; Kapur, R. Upper Gastrointestinal Issues in Athletes. *Curr. Sports Med. Rep.* **2012**, *11*, 99–104. [[CrossRef](#)]
312. Diduch, B.K. Gastrointestinal Conditions in the Female Athlete. *Clin. Sports Med.* **2017**, *36*, 655–669. [[CrossRef](#)]
313. Bharadwaj, S.; Barber, M.D.; Graff, L.A.; Shen, B. Symptomatology of Irritable Bowel Syndrome and Inflammatory Bowel Disease during the Menstrual Cycle. *Gastroenterol. Rep.* **2015**, *3*, 185–193. [[CrossRef](#)]
314. Heitkemper, M.M.; Shaver, J.F.; Mitchell, E.S. Gastrointestinal Symptoms and Bowel Patterns across the Menstrual Cycle in Dysmenorrhea. *Nurs. Res.* **1988**, *37*, 108–113. [[CrossRef](#)]
315. Moore, J.; Barlow, D.; Jewell, D.; Kennedy, S. Do Gastrointestinal Symptoms Vary with the Menstrual Cycle? *Br. J. Obs. Gynaecol.* **1998**, *105*, 1322–1325. [[CrossRef](#)] [[PubMed](#)]
316. Judkins, T.C.; Dennis-Wall, J.C.; Sims, S.M.; Colee, J.; Langkamp-Henken, B. Stool Frequency and Form and Gastrointestinal Symptoms Differ by Day of the Menstrual Cycle in Healthy Adult Women Taking Oral Contraceptives: A Prospective Observational Study. *BMC Womens Health* **2020**, *20*, 136. [[CrossRef](#)] [[PubMed](#)]
317. Jackson, N.A.; Houghton, L.A.; Whorwell, P.J.; Curren, B. Does the Menstrual Cycle Affect Anorectal Physiology? *Dig. Dis. Sci.* **1994**, *39*, 2607–2611. [[CrossRef](#)] [[PubMed](#)]
318. Houghton, L.A.; Lea, R.; Jackson, N.; Whorwell, P.J. The Menstrual Cycle Affects Rectal Sensitivity in Patients with Irritable Bowel Syndrome but Not Healthy Volunteers. *Gut* **2002**, *50*, 471–474. [[CrossRef](#)]
319. Barton, W.; Penney, N.C.; Cronin, O.; Garcia-Perez, I.; Molloy, M.G.; Holmes, E.; Shanahan, F.; Cotter, P.D.; O'Sullivan, O. The Microbiome of Professional Athletes Differs from That of More Sedentary Subjects in Composition and Particularly at the Functional Metabolic Level. *Gut* **2018**, *67*, 625–633. [[CrossRef](#)] [[PubMed](#)]
320. Mohr, A.E.; Jäger, R.; Carpenter, K.C.; Kerksick, C.M.; Purpura, M.; Townsend, J.R.; West, N.P.; Black, K.; Gleeson, M.; Pyne, D.B.; et al. The Athletic Gut Microbiota. *J. Int. Soc. Sports Nutr.* **2020**, *17*, 24. [[CrossRef](#)]
321. Bo, K.; Fernandes, A.C.N.L.; Duarte, T.B.; Brito, L.G.O.; Ferreira, C.H.J. Is Pelvic Floor Muscle Training Effective for Symptoms of Overactive Bladder in Women? A Systematic Review. *Physiotherapy* **2020**, *106*, 65–76. [[CrossRef](#)]
322. Cerruto, M.A.; Balzarro, M.; Rubilotta, E.; Processali, T.; Latini, M.T.; Porcaro, A.B.; Scancarello, C.; Cantaluppi, S.; Di Dedda, M.C.; Antonelli, A.; et al. Lower Urinary Tract and Gastrointestinal Dysfunction in Sportswomen: A Systematic Review and Meta-Analysis of Observational Studies. *Minerva Urol. Nefrol.* **2020**, *72*, 698–711. [[CrossRef](#)]
323. De Mattos Lourenco, T.R.; Matsuoka, P.K.; Baracat, E.C.; Haddad, J.M. Urinary Incontinence in Female Athletes: A Systematic Review. *Int. Urogynecol. J.* **2018**, *29*, 1757–1763. [[CrossRef](#)]
324. Sorriquetá-Hernández, A.; Padilla-Fernandez, B.-Y.; Marquez-Sanchez, M.-T.; Flores-Fraile, M.-C.; Flores-Fraile, J.; Moreno-Pascual, C.; Lorenzo-Gomez, A.; Garcia-Cenador, M.-B.; Lorenzo-Gomez, M.-F. Benefits of Physiotherapy on Urinary Incontinence in High-Performance Female Athletes. Meta-Analysis. *J. Clin. Med.* **2020**, *9*, 3240. [[CrossRef](#)] [[PubMed](#)]
325. Teixeira, R.V.; Colla, C.; Sbruzzi, G.; Mallmann, A.; Paiva, L.L. Prevalence of Urinary Incontinence in Female Athletes: A Systematic Review with Meta-Analysis. *Int. Urogynecol. J.* **2018**, *29*, 1717–1725. [[CrossRef](#)]
326. Hagovska, M.; Švihra, J.; Buková, A.; Dračková, D.; Švihrová, V. Prevalence and Risk of Sport Types to Stress Urinary Incontinence in Sportswomen: A Cross-Sectional Study. *Neurourol. Urodyn.* **2018**, *37*, 1957–1964. [[CrossRef](#)] [[PubMed](#)]
327. Simeone, C.; Moroni, A.; Pettenò, A.; Antonelli, A.; Zani, D.; Orizio, C.; Cosciani Cunico, S. Occurrence Rates and Predictors of Lower Urinary Tract Symptoms and Incontinence in Female Athletes. *Urologia* **2010**, *77*, 139–146. [[CrossRef](#)]
328. Gram, M.C.D.; Bø, K. High Level Rhythmic Gymnasts and Urinary Incontinence: Prevalence, Risk Factors, and Influence on Performance. *Scand. J. Med. Sci. Sports* **2020**, *30*, 159–165. [[CrossRef](#)]
329. Whitney, K.E.; Holtzman, B.; Cook, D.; Bauer, S.; Maffazioli, G.D.N.; Parziale, A.L.; Ackerman, K.E. Low Energy Availability and Impact Sport Participation as Risk Factors for Urinary Incontinence in Female Athletes. *J. Pediatr. Urol.* **2021**. [[CrossRef](#)] [[PubMed](#)]
330. Boileau, M.; Fuchs, E.; Barry, J.M.; Hodges, C.V. Stress Hematuria: Athletic Pseudonephritis in Marathoners. *Urology* **1980**, *15*, 471–474. [[CrossRef](#)]
331. Bellinghieri, G.; Savica, V.; Santoro, D. Renal Alterations during Exercise. *J. Ren. Nutr.* **2008**, *18*, 158–164. [[CrossRef](#)]
332. Gilli, P.; De Paoli Vitali, E.; Tataranni, G.; Farinelli, A. Exercise-Induced Urinary Abnormalities in Long-Distance Runners. *Int. J. Sports Med.* **1984**, *5*, 237–240. [[CrossRef](#)] [[PubMed](#)]
333. Shephard, R.J. Exercise Proteinuria and Hematuria: Current Knowledge and Future Directions. *J. Sports Med. Phys. Fit.* **2016**, *56*, 1060–1076.
334. Enea, C.; Boisseau, N.; Ottavy, M.; Mulliez, J.; Millet, C.; Ingrand, I.; Diaz, V.; Dugué, B. Effects of Menstrual Cycle, Oral Contraception, and Training on Exercise-Induced Changes in Circulating DHEA-Sulphate and Testosterone in Young Women. *Eur. J. Appl. Physiol.* **2009**, *106*, 365–373. [[CrossRef](#)]
335. Vibarel-Rebot, N.; Rieth, N.; Lasne, F.; Jaffré, C.; Collomp, K. Oral Contraceptive Use and Saliva Diurnal Pattern of Metabolic Steroid Hormones in Young Healthy Women. *Contraception* **2015**, *91*, 245–247. [[CrossRef](#)] [[PubMed](#)]
336. O'Leary, C.B.; Lehman, C.; Koltun, K.; Smith-Ryan, A.; Hackney, A.C. Response of Testosterone to Prolonged Aerobic Exercise during Different Phases of the Menstrual Cycle. *Eur. J. Appl. Physiol.* **2013**, *113*, 2419–2424. [[CrossRef](#)]
337. Keizer, H.A.; Beckers, E.; de Haan, J.; Janssen, G.M.; Kuipers, H.; van Kranenburg, G.; Geurten, P. Exercise-Induced Changes in the Percentage of Free Testosterone and Estradiol in Trained and Untrained Women. *Int. J. Sports Med.* **1987**, *8* (Suppl. 3), 151–153. [[CrossRef](#)]
338. Lane, A.R.; O'Leary, C.B.; Hackney, A.C. Menstrual Cycle Phase Effects Free Testosterone Responses to Prolonged Aerobic Exercise. *Acta Physiol. Hung.* **2015**, *102*, 336–341. [[CrossRef](#)]

339. Crewther, B.T.; Cook, C.J. A Longitudinal Analysis of Salivary Testosterone Concentrations and Competitiveness in Elite and Non-Elite Women Athletes. *Physiol. Behav.* **2018**, *188*, 157–161. [[CrossRef](#)]
340. Cook, C.J.; Crewther, B.T.; Smith, A.A. Comparison of Baseline Free Testosterone and Cortisol Concentrations between Elite and Non-Elite Female Athletes. *Am. J. Hum. Biol.* **2012**, *24*, 856–858. [[CrossRef](#)] [[PubMed](#)]
341. Hansen, A.P.; Weeke, J. Fasting Serum Growth Hormone Levels and Growth Hormone Responses to Exercise during Normal Menstrual Cycles and Cycles of Oral Contraceptives. *Scand. J. Clin. Lab. Investig.* **1974**, *34*, 199–205. [[CrossRef](#)]
342. Hornum, M.; Cooper, D.M.; Brasel, J.A.; Bueno, A.; Sietsema, K.E. Exercise-Induced Changes in Circulating Growth Factors with Cyclic Variation in Plasma Estradiol in Women. *J. Appl. Physiol.* **1997**, *82*, 1946–1951. [[CrossRef](#)]
343. Ovesen, P.; Vahl, N.; Fisker, S.; Veldhuis, J.D.; Christiansen, J.S.; Jørgensen, J.O. Increased Pulsatile, but Not Basal, Growth Hormone Secretion Rates and Plasma Insulin-like Growth Factor I Levels during the Perioviulatory Interval in Normal Women. *J. Clin. Endocrinol. Metab.* **1998**, *83*, 1662–1667. [[CrossRef](#)] [[PubMed](#)]
344. Gleeson, H.K.; Shalet, S.M. GH Responsiveness Varies during the Menstrual Cycle. *Eur. J. Endocrinol.* **2005**, *153*, 775–779. [[CrossRef](#)]
345. Wang, H.S.; Lee, J.D.; Soong, Y.K. Serum Levels of Insulin-like Growth Factor I and Insulin-like Growth Factor-Binding Protein-1 and -3 in Women with Regular Menstrual Cycles. *Fertil. Steril.* **1995**, *63*, 1204–1209. [[CrossRef](#)]
346. Cano Sokoloff, N.; Misra, M.; Ackerman, K.E. Exercise, Training, and the Hypothalamic-Pituitary-Gonadal Axis in Men and Women. *Front. Horm. Res.* **2016**, *47*, 27–43. [[CrossRef](#)] [[PubMed](#)]
347. Laughlin, G.A.; Yen, S.S. Nutritional and Endocrine-Metabolic Aberrations in Amenorrheic Athletes. *J. Clin. Endocrinol. Metab.* **1996**, *81*, 4301–4309. [[CrossRef](#)] [[PubMed](#)]
348. Rickenlund, A.; Thorén, M.; Nybacka, A.; Frystyk, J.; Hirschberg, A.L. Effects of Oral Contraceptives on Diurnal Profiles of Insulin, Insulin-like Growth Factor Binding Protein-1, Growth Hormone and Cortisol in Endurance Athletes with Menstrual Disturbance. *Hum. Reprod.* **2010**, *25*, 85–93. [[CrossRef](#)] [[PubMed](#)]
349. McComb, J.J.R.; Qian, X.-P.; Veldhuis, J.D.; J. McGlone, J.; Norman, R.L. Neuroendocrine Responses to Psychological Stress in Eumenorrheic and Oligomenorrheic Women. *Stress* **2006**, *9*, 41–51. [[CrossRef](#)]
350. Timmons, B.W.; Hamadeh, M.J.; Devries, M.C.; Tarnopolsky, M.A. Influence of Gender, Menstrual Phase, and Oral Contraceptive Use on Immunological Changes in Response to Prolonged Cycling. *J. Appl. Physiol.* **2005**, *99*, 979–985. [[CrossRef](#)] [[PubMed](#)]
351. Crewther, B.T.; Hamilton, D.; Casto, K.; Kilduff, L.P.; Cook, C.J. Effects of Oral Contraceptive Use on the Salivary Testosterone and Cortisol Responses to Training Sessions and Competitions in Elite Women Athletes. *Physiol. Behav.* **2015**, *147*, 84–90. [[CrossRef](#)]
352. Mackay, K.; González, C.; Zbinden-Foncea, H.; Peñailillo, L. Effects of Oral Contraceptive Use on Female Sexual Salivary Hormones and Indirect Markers of Muscle Damage Following Eccentric Cycling in Women. *Eur. J. Appl. Physiol.* **2019**, *119*, 2733–2744. [[CrossRef](#)]
353. Edwards, D.A.; O'Neal, J.L. Oral Contraceptives Decrease Saliva Testosterone but Do Not Affect the Rise in Testosterone Associated with Athletic Competition. *Horm. Behav.* **2009**, *56*, 195–198. [[CrossRef](#)]
354. Bonen, A.; Haynes, F.W.; Graham, T.E. Substrate and Hormonal Responses to Exercise in Women Using Oral Contraceptives. *J. Appl. Physiol.* **1991**, *70*, 1917–1927. [[CrossRef](#)]
355. Altemus, M.; Roca, C.; Galliven, E.; Romanos, C.; Deuster, P. Increased Vasopressin and Adrenocorticotropin Responses to Stress in the Midluteal Phase of the Menstrual Cycle. *J. Clin. Endocrinol. Metab.* **2001**, *86*, 2525–2530. [[CrossRef](#)] [[PubMed](#)]
356. Boisseau, N.; Enea, C.; Diaz, V.; Dugué, B.; Corcuff, J.B.; Duclos, M. Oral Contraception but Not Menstrual Cycle Phase Is Associated with Increased Free Cortisol Levels and Low Hypothalamo-Pituitary-Adrenal Axis Reactivity. *J. Endocrinol. Investig.* **2013**, *36*, 955–964. [[CrossRef](#)]
357. Kanaley, J.A.; Boileau, R.A.; Bahr, J.M.; Misner, J.E.; Nelson, R.A. Cortisol Levels during Prolonged Exercise: The Influence of Menstrual Phase and Menstrual Status. *Int. J. Sports Med.* **1992**, *13*, 332–336. [[CrossRef](#)]
358. Kraemer, R.R.; Francois, M.; Webb, N.D.; Worley, J.R.; Rogers, S.N.; Norman, R.L.; Shah, U.; Castracane, V.D.; Daniel Castracane, V. No Effect of Menstrual Cycle Phase on Glucose and Glucoregulatory Endocrine Responses to Prolonged Exercise. *Eur. J. Appl. Physiol.* **2013**, *113*, 2401–2408. [[CrossRef](#)] [[PubMed](#)]
359. Bouma, E.M.C.; Riese, H.; Ormel, J.; Verhulst, F.C.; Oldehinkel, A.J. Adolescents' Cortisol Responses to Awakening and Social Stress; Effects of Gender, Menstrual Phase and Oral Contraceptives. The TRAILS Study. *Psychoneuroendocrinology* **2009**, *34*, 884–893. [[CrossRef](#)]
360. Kayacan, Y.; Makaracı, Y.; Ozgocer, T.; Ucar, C.; Yıldız, S. Cortisol Awakening Response and Heart Rate Variability in the Menstrual Cycle of Sportswomen. *Res. Q. Exerc. Sport* **2020**, 1–10. [[CrossRef](#)] [[PubMed](#)]
361. Hou, L.; Huang, Y.; Zhou, R. Premenstrual Syndrome Is Associated with Altered Cortisol Awakening Response. *Stress* **2019**, *22*, 640–646. [[CrossRef](#)] [[PubMed](#)]
362. Ozgocer, T.; Ucar, C.; Yıldız, S. Cortisol Awakening Response Is Blunted and Pain Perception Is Increased during Menses in Cyclic Women. *Psychoneuroendocrinology* **2017**, *77*, 158–164. [[CrossRef](#)]
363. Sawin, C.T.; Hershman, J.M.; Boyd, A.E.; Longcope, C.; Bacharach, P. The Relationship of Changes in Serum Estradiol and Progesterone during the Menstrual Cycle to the Thyrotropin and Prolactin Responses to Thyrotropin-Releasing Hormone. *J. Clin. Endocrinol. Metab.* **1978**, *47*, 1296–1302. [[CrossRef](#)]
364. Weeke, J.; Hansen, A.P. Serum Tsh and Serum T3 Levels during Normal Menstrual Cycles and during Cycles on Oral Contraceptives. *Acta Endocrinol.* **1975**, *79*, 431–438. [[CrossRef](#)]

365. De Souza, M.J.; Maresh, C.M.; Maguire, M.S.; Kraemer, W.J.; Flora-Ginter, G.; Goetz, K.L. Menstrual Status and Plasma Vasopressin, Renin Activity, and Aldosterone Exercise Responses. *J. Appl. Physiol.* **1989**, *67*, 736–743. [[CrossRef](#)] [[PubMed](#)]
366. Harber, V.J.; Sutton, J.R.; MacDougall, J.D.; Woolever, C.A.; Bhavnani, B.R. Plasma Concentrations of Beta-Endorphin in Trained Eumenorrheic and Amenorrheic Women. *Fertil. Steril.* **1997**, *67*, 648–653. [[CrossRef](#)]
367. Ding, J.H.; Sheckter, C.B.; Drinkwater, B.L.; Soules, M.R.; Bremner, W.J. High Serum Cortisol Levels in Exercise-Associated Amenorrhea. *Ann. Intern. Med.* **1988**, *108*, 530–534. [[CrossRef](#)] [[PubMed](#)]
368. Lindholm, C.; Hirschberg, A.L.; Carlström, K.; von Schoultz, B. Altered Adrenal Steroid Metabolism Underlying Hypercortisolism in Female Endurance Athletes. *Fertil. Steril.* **1995**, *63*, 1190–1194. [[CrossRef](#)]
369. De Souza, M.J.; Maguire, M.S.; Maresh, C.M.; Kraemer, W.J.; Rubin, K.R.; Loucks, A.B. Adrenal Activation and the Prolactin Response to Exercise in Eumenorrheic and Amenorrheic Runners. *J. Appl. Physiol.* **1991**, *70*, 2378–2387. [[CrossRef](#)] [[PubMed](#)]
370. Ackerman, K.E.; Patel, K.T.; Guereca, G.; Pierce, L.; Herzog, D.B.; Misra, M. Cortisol Secretory Parameters in Young Exercisers in Relation to LH Secretion and Bone Parameters. *Clin. Endocrinol.* **2013**, *78*, 114–119. [[CrossRef](#)]
371. Schaal, K.; Van Loan, M.D.; Casazza, G.A. Reduced Catecholamine Response to Exercise in Amenorrheic Athletes. *Med. Sci. Sports Exerc.* **2011**, *43*, 34–43. [[CrossRef](#)]
372. Loucks, A.B.; Horvath, S.M. Exercise-Induced Stress Responses of Amenorrheic and Eumenorrheic Runners. *J. Clin. Endocrinol. Metab.* **1984**, *59*, 1109–1120. [[CrossRef](#)]
373. De Souza, M.J.; Luciano, A.A.; Arce, J.C.; Demers, L.M.; Loucks, A.B. Clinical Tests Explain Blunted Cortisol Responsiveness but Not Mild Hypercortisolism in Amenorrheic Runners. *J. Appl. Physiol.* **1994**, *76*, 1302–1309. [[CrossRef](#)]
374. Hohtari, H.; Elovainio, R.; Salminen, K.; Laatikainen, T. Plasma Corticotropin-Releasing Hormone, Corticotropin, and Endorphins at Rest and during Exercise in Eumenorrheic and Amenorrheic Athletes. *Fertil. Steril.* **1988**, *50*, 233–238. [[CrossRef](#)]
375. Thong, F.S.; McLean, C.; Graham, T.E. Plasma Leptin in Female Athletes: Relationship with Body Fat, Reproductive, Nutritional, and Endocrine Factors. *J. Appl. Physiol.* **2000**, *88*, 2037–2044. [[CrossRef](#)] [[PubMed](#)]
376. Chang, F.E.; Richards, S.R.; Kim, M.H.; Malarkey, W.B. Twenty Four-Hour Prolactin Profiles and Prolactin Responses to Dopamine in Long Distance Running Women. *J. Clin. Endocrinol. Metab.* **1984**, *59*, 631–635. [[CrossRef](#)]
377. Meyer, W.R.; Muoio, D.; Hackney, T.C. Effect of Sex Steroids on Beta-Endorphin Levels at Rest and during Submaximal Treadmill Exercise in Anovulatory and Ovulatory Runners. *Fertil. Steril.* **1999**, *71*, 1085–1091. [[CrossRef](#)]
378. Hohtari, H.; Salminen-Lappalainen, K.; Laatikainen, T. Response of Plasma Endorphins, Corticotropin, Cortisol, and Luteinizing Hormone in the Corticotropin-Releasing Hormone Stimulation Test in Eumenorrheic and Amenorrheic Athletes. *Fertil. Steril.* **1991**, *55*, 276–280. [[CrossRef](#)]
379. Hinton, P.S.; Rector, R.S.; Peppers, J.E.; Imhoff, R.D.; Hillman, L.S. Serum Markers of Inflammation and Endothelial Function Are Elevated by Hormonal Contraceptive Use but Not by Exercise-Associated Menstrual Disorders in Physically Active Young Women. *J. Sports Sci. Med.* **2006**, *5*, 235–242. [[PubMed](#)]
380. Larsen, B.; Cox, A.; Colbey, C.; Drew, M.; McGuire, H.; Fazekas de St Groth, B.; Hughes, D.; Vlahovich, N.; Waddington, G.; Burke, L.; et al. Inflammation and Oral Contraceptive Use in Female Athletes Before the Rio Olympic Games. *Front. Physiol.* **2020**, *11*, 497. [[CrossRef](#)]
381. Larsen, B.; Cox, A.J.; Quinn, K.; Fisher, R.; Minahan, C. Immune Response in Women during Exercise in the Heat: A Spotlight on Oral Contraception. *J. Sports Sci. Med.* **2018**, *17*, 229–236.
382. Jankowski, C.M.; Ben-Ezra, V.; Gozansky, W.S.; Scheaffer, S.E. Effects of Oral Contraceptives on Glucoregulatory Responses to Exercise. *Metabolism* **2004**, *53*, 348–352. [[CrossRef](#)] [[PubMed](#)]
383. Oosthuysen, T.; Bosch, A.N. The Effect of the Menstrual Cycle on Exercise Metabolism: Implications for Exercise Performance in Eumenorrheic Women. *Sports Med.* **2010**, *40*, 207–227. [[CrossRef](#)]
384. Campbell, S.E.; Angus, D.J.; Febbraio, M.A. Glucose Kinetics and Exercise Performance during Phases of the Menstrual Cycle: Effect of Glucose Ingestion. *Am. J. Physiol. Endocrinol. Metab.* **2001**, *281*, E817–E825. [[CrossRef](#)]
385. Devries, M.C.; Hamadeh, M.J.; Phillips, S.M.; Tarnopolsky, M.A. Menstrual Cycle Phase and Sex Influence Muscle Glycogen Utilization and Glucose Turnover during Moderate-Intensity Endurance Exercise. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2006**, *291*, R1120–R1128. [[CrossRef](#)] [[PubMed](#)]
386. Bailey, S.P.; Zacher, C.M.; Mittleman, K.D. Effect of Menstrual Cycle Phase on Carbohydrate Supplementation during Prolonged Exercise to Fatigue. *J. Appl. Physiol.* **2000**, *88*, 690–697. [[CrossRef](#)] [[PubMed](#)]
387. Horton, T.J.; Miller, E.K.; Bourret, K. No Effect of Menstrual Cycle Phase on Glycerol or Palmitate Kinetics during 90 Min of Moderate Exercise. *J. Appl. Physiol.* **2006**, *100*, 917–925. [[CrossRef](#)] [[PubMed](#)]
388. Vaiksaar, S.; Jürimäe, J.; Mäestu, J.; Purge, P.; Kalytka, S.; Shakhlina, L.; Jürimäe, T. No Effect of Menstrual Cycle Phase on Fuel Oxidation during Exercise in Rowers. *Eur. J. Appl. Physiol.* **2011**, *111*, 1027–1034. [[CrossRef](#)]
389. Ortega-Santos, C.P.; Barba-Moreno, L.; Cupeiro, R.; Peinado, A.B. Substrate Oxidation in Female Adults during Endurance Exercise throughout Menstrual Cycle Phases: IronFEMME Pilot Study. *J. Hum. Sport Exerc.* **2018**, *13*. [[CrossRef](#)]
390. Goldsmith, E.; Glaister, M. The Effect of the Menstrual Cycle on Running Economy. *J. Sports Med. Phys. Fit.* **2020**, *60*, 610–617.
391. Dokumacı, B.; Hazır, T. Effects of the Menstrual Cycle on Running Economy: Oxygen Cost Versus Caloric Cost. *Res. Q. Exerc. Sport* **2019**, *90*, 318–326. [[CrossRef](#)]

392. Romero-Parra, N.; Barba-Moreno, L.; Rael, B.; Alfaro-Magallanes, V.M.; Cupeiro, R.; Díaz, Á.E.; Calderón, F.J.; Peinado, A.B. Influence of the Menstrual Cycle on Blood Markers of Muscle Damage and Inflammation Following Eccentric Exercise. *Int. J. Environ. Res. Public Health* **2020**, *17*, 1618. [CrossRef]
393. Sipavičienė, S.; Daniusevičiūtė, L.; Klizienė, I.; Kamandulis, S.; Skurvydas, A. Effects of Estrogen Fluctuation during the Menstrual Cycle on the Response to Stretch-Shortening Exercise in Females. *BioMed Res. Int.* **2013**, *2013*, 243572. [CrossRef] [PubMed]
394. Gillum, T.; Kuennen, M.; Miller, T.; Riley, L. The Effects of Exercise, Sex, and Menstrual Phase on Salivary Antimicrobial Proteins. *Exerc. Immunol. Rev.* **2014**, *20*, 23–38. [PubMed]
395. Rickenlund, A.; Eriksson, M.J.; Schenck-Gustafsson, K.; Hirschberg, A.L. Amenorrhea in Female Athletes Is Associated with Endothelial Dysfunction and Unfavorable Lipid Profile. *J. Clin. Endocrinol. Metab.* **2005**, *90*, 1354–1359. [CrossRef] [PubMed]
396. Ayres, S.; Baer, J.; Subbiah, M.T. Exercised-Induced Increase in Lipid Peroxidation Parameters in Amenorrheic Female Athletes. *Fertil. Steril.* **1998**, *69*, 73–77. [CrossRef]
397. Kanaley, J.A.; Ji, L.L. Antioxidant Enzyme Activity during Prolonged Exercise in Amenorrheic and Eumenorrheic Athletes. *Metabolism* **1991**, *40*, 88–92. [CrossRef]
398. Suh, S.-H.; Casazza, G.A.; Horning, M.A.; Miller, B.F.; Brooks, G.A. Effects of Oral Contraceptives on Glucose Flux and Substrate Oxidation Rates during Rest and Exercise. *J. Appl. Physiol.* **2003**, *94*, 285–294. [CrossRef] [PubMed]
399. Isacco, L.; Duché, P.; Boisseau, N. Influence of Hormonal Status on Substrate Utilization at Rest and during Exercise in the Female Population. *Sports Med.* **2012**, *42*, 327–342. [CrossRef] [PubMed]
400. Isacco, L.; Thivel, D.; Pelle, A.M.; Zouhal, H.; Duclos, M.; Duche, P.; Boisseau, N. Oral Contraception and Energy Intake in Women: Impact on Substrate Oxidation during Exercise. *Appl. Physiol. Nutr. Metab.* **2012**, *37*, 646–656. [CrossRef] [PubMed]
401. Cauci, S.; Buligan, C.; Marangone, M.; Francescato, M.P. Oxidative Stress in Female Athletes Using Combined Oral Contraceptives. *Sports Med. Open* **2016**, *2*, 40. [CrossRef]
402. Hicks, K.M.; Onambélé-Pearson, G.; Winwood, K.; Morse, C.I. Oral Contraceptive Pill Use and the Susceptibility to Markers of Exercise-Induced Muscle Damage. *Eur. J. Appl. Physiol.* **2017**, *117*, 1393–1402. [CrossRef]
403. Romero-Parra, N.; Rael, B.; Alfaro-Magallanes, V.M.; Janse de Jonge, X.; Cupeiro, R.; Peinado, A.B.; IronFEMME Study Group. The Effect of the Oral Contraceptive Cycle Phase on Exercise-Induced Muscle Damage after Eccentric Exercise in Resistance-Trained Women. *J. Strength Cond. Res.* **2021**, *35*, 353–359. [CrossRef]
404. Lei, T.-H.; Cotter, J.D.; Schlader, Z.J.; Stannard, S.R.; Perry, B.G.; Barnes, M.J.; Mündel, T. On Exercise Thermoregulation in Females: Interaction of Endogenous and Exogenous Ovarian Hormones. *J. Physiol.* **2019**, *597*, 71–88. [CrossRef]
405. Available online: <https://Wada-Ama.Org/En/Athlete-Biological-Passport> (accessed on 29 June 2021).
406. Sottas, P.-E.; Robinson, N.; Rabin, O.; Saugy, M. The Athlete Biological Passport. *Clin. Chem.* **2011**, *57*, 969–976. [CrossRef]
407. Sottas, P.-E.; Vernec, A. Current Implementation and Future of the Athlete Biological Passport. *Bioanalysis* **2012**, *4*, 1645–1652. [CrossRef] [PubMed]
408. Confounding Factors and Genetic Polymorphism in the Evaluation of Individual Steroid Profiling—PubMed. Available online: <https://pubmed.ncbi.nlm.nih.gov/24764553/> (accessed on 26 April 2021).
409. Mareck-Engelke, U.; Geyer, H.; Donike, M. Stability of steroid profiles (4): The circadian rhythm of urinary ratios and excretion rates of endogenous steroids in female and its menstrual dependency. In *Recent Advances in Doping Analysis*; Sport und Buch Strauss: Köln, Germany, 1995; pp. 135–155.
410. Mareck-Engelke, U.; Flenker, U.; Donike, M. Stability of steroid profiles (5): The annual rhythm of urinary ratios and excretion rates of endogenous steroids in female and its menstrual dependency. In *Recent Advances in Doping Analysis*; Sport und Buch Strauss: Köln, Germany, 1996; pp. 177–190.
411. Mullen, J.; Thoerngren, J.-O.; Schulze, J.; Ericsson, M.; Gårevik, N.; Lehtihet, M.; Ekström, L. Urinary Steroid Profile in Females—the Impact of Menstrual Cycle and Emergency Contraceptives. *Drug Test. Anal.* **2016**, *9*. [CrossRef] [PubMed]
412. Schulze, J.; Suominen, T.; Bergström, H.; Ericsson, M.; Bergman, L.B.; Ekström, L. Urinary Steroid Profile in Relation to the Menstrual Cycle. *Drug Test. Anal.* **2021**, *13*, 550–557. [CrossRef] [PubMed]
413. Mullen, J.; Bækken, L.V.; Törmäkangas, T.; Ekström, L.; Ericsson, M.; Hullstein, I.R.; Schulze, J.J. Inter-Individual Variation of the Urinary Steroid Profiles in Swedish and Norwegian Athletes. *Drug Test. Anal.* **2020**, *12*, 720–730. [CrossRef]
414. Elings Knutsson, J.; Andersson, A.; Bækken, L.V.; Pohanka, A.; Ekström, L.; Hirschberg, A.L. Disposition of Urinary and Serum Steroid Metabolites in Response to Testosterone Administration in Healthy Women. *J. Clin. Endocrinol. Metab.* **2021**, *106*, 697–707. [CrossRef]
415. Ekström, L.; Knutsson, J.E.; Mullen, J.; Ericsson, M.; Hirschberg, A.L. Impact of Hormonal Contraceptives on Urinary Steroid Profile in Relation to Serum Hormone Changes and CYP17A1 Polymorphism. *Drug Test. Anal.* **2019**, *11*, 1284–1289. [CrossRef]
416. Schulze, J.J.; Mullen, J.E.; Berglund Lindgren, E.; Ericsson, M.; Ekström, L.; Hirschberg, A.L. The Impact of Genetics and Hormonal Contraceptives on the Steroid Profile in Female Athletes. *Front. Endocrinol.* **2014**, *5*, 50. [CrossRef]
417. Buisson, C.; Frelat, C.; Privat, K.; Martinat, N.; Audran, M.; Collomp, K. Metabolic and Isotopic Signature of Short-Term DHEA Administration in Women: Comparison with Findings in Men. *Drug Test. Anal.* **2018**, *10*, 1744–1754. [CrossRef] [PubMed]
418. Geyer, H.; Flenker, U.; Mareck, U.; Platen, P.; Piper, T.; Schmechel, A. The detection of the misuse of testosterone gel. In *Recent Advances in Doping Analysis*; Sport und Buch Strauss: Köln, Germany, 2007; pp. 133–142.
419. Sensitivity of Doping Biomarkers after Administration of a Single Dose Testosterone Gel—Mullen—2018—Drug Testing and Analysis—Wiley Online Library. Available online: <https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.2341> (accessed on 26 April 2021).

420. Börjesson, A.; Lehtihet, M.; Andersson, A.; Dahl, M.-L.; Vicente, V.; Ericsson, M.; Ekström, L. Studies of Athlete Biological Passport Biomarkers and Clinical Parameters in Male and Female Users of Anabolic Androgenic Steroids and Other Doping Agents. *Drug Test. Anal.* **2020**, *12*, 514–523. [[CrossRef](#)] [[PubMed](#)]
421. Detection of Testosterone Doping in Female Athletes—PubMed. Available online: <https://pubmed.ncbi.nlm.nih.gov/31454165/> (accessed on 26 April 2021).
422. Xing, Y.; Liu, X.; Yan, M.; Chen, T.; Lu, F.; Xu, B.; Gong, Y.; Chu, F.; Lei, H. Impact of Nonsteroidal Aromatase Inhibitors on Steroid Profile in a Chinese Population. *Medicine* **2017**, *96*, e7411. [[CrossRef](#)]
423. Bornø, A.; Aachmann-Andersen, N.J.; Munch-Andersen, T.; Hulston, C.J.; Lundby, C. Screening for Recombinant Human Erythropoietin Using [Hb], Reticulocytes, the OFF(Hr Score), OFF(z Score) and Hb(z Score): Status of the Blood Passport. *Eur. J. Appl. Physiol.* **2010**, *109*, 537–543. [[CrossRef](#)] [[PubMed](#)]
424. Sottas, P.; Robinson, N.; Giraud, S.; Taroni, F.; Kamber, M.; Mangin, P.; Saugy, M. Statistical Classification of Abnormal Blood Profiles in Athletes. *Int. J. Biostat.* **2006**, *2*, 1011. [[CrossRef](#)]
425. Mullen, J.; Baekken, L.; Bergström, H.; Björkhem Bergman, L.; Ericsson, M.; Ekström, L. Fluctuations in Hematological Athlete Biological Passport Biomarkers in Relation to the Menstrual Cycle. *Drug Test. Anal.* **2020**, *12*, 1229–1240. [[CrossRef](#)]
426. The Intra-Individual Stability of GH Biomarkers IGF-I and P-III-NP in Relation to GHRH Administration, Menstrual Cycle, and Hematological Parameters—PubMed. Available online: <https://pubmed.ncbi.nlm.nih.gov/33125822/> (accessed on 26 April 2021).
427. Vermersch, P. Describing the Practice of Introspection. *J. Conscious. Stud.* **2009**, *16*, 20–57.
428. Robbins, P.; Aydede, M. (Eds.) *The Cambridge Handbook of Situated Cognition*; Cambridge Handbooks in Psychology; Cambridge University Press: Cambridge, UK, 2008; ISBN 978-0-521-84832-9.
429. Briki, W.; Hartigh, R.J.R.D.; Hauw, D.; Gernigon, C. A Qualitative Exploration of the Psychological Contents and Dynamics of Momentum in Sport. *Int. J. Sport Psychol.* **2012**, *43*, 365–384. [[CrossRef](#)]
430. Hauw, D.; Durand, M. Situated Analysis of Elite Trampolinists’ Problems in Competition Using Retrospective Interviews. *J. Sports Sci.* **2007**, *25*, 173–183. [[CrossRef](#)] [[PubMed](#)]
431. Villemain, A.; Hauw, D. A Situated Analysis of Football Goalkeepers’ Experiences in Critical Game Situations. *Percept. Mot. Ski.* **2014**, *119*, 811–824. [[CrossRef](#)]
432. Krabak, B.J.; Waite, B.; Schiff, M.A. Study of Injury and Illness Rates in Multiday Ultramarathon Runners. *Med. Sci. Sports Exerc.* **2011**, *43*, 2314–2320. [[CrossRef](#)]
433. Baldassarre, R.; Bonifazi, M.; Zamparo, P.; Piacentini, M.F. Characteristics and Challenges of Open-Water Swimming Performance: A Review. *Int. J. Sports Physiol. Perform.* **2017**, *12*, 1275–1284. [[CrossRef](#)]
434. Giorgis-Allemand, L.; Thalabard, J.C.; Rosetta, L.; Siroux, V.; Bouyer, J.; Slama, R. Can Atmospheric Pollutants Influence Menstrual Cycle Function? *Environ. Pollut.* **2020**, *257*, 113605. [[CrossRef](#)] [[PubMed](#)]
435. Merklinger-Gruchala, A.; Jasienska, G.; Kapiszewska, M. Effect of Air Pollution on Menstrual Cycle Length—A Prognostic Factor of Women’s Reproductive Health. *Int. J. Environ. Res. Public Health* **2017**, *14*, 816. [[CrossRef](#)] [[PubMed](#)]
436. Singer, A.B.; Whitworth, K.W.; Haug, L.S.; Sabaredzovic, A.; Impinen, A.; Papadopoulou, E.; Longnecker, M.P. Menstrual Cycle Characteristics as Determinants of Plasma Concentrations of Perfluoroalkyl Substances (PFASs) in the Norwegian Mother and Child Cohort (MoBa Study). *Environ. Res.* **2018**, *166*, 78–85. [[CrossRef](#)] [[PubMed](#)]